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1 INTRODUCTION 
 
As the 21st century unfolds, infectious diseases remain one of the most significant threats to our 
economy, our food animal production systems, animal welfare, and most importantly, the lives of 
people worldwide, regardless of their economic standing (WHO. 1970, 1995, 2000, 2004). The 
potential use of biological threat agents for bioterrorism or bio-warfare further undermines the 
security of our society (CDC. 2000, KONDIRK et al. 2003, TITBALL and WILLIMASON 2001, 2004). 
While the historical records on using biological agents’ for offensive purpose in human history 
goes back to centuries, the intensity of state sponsored research activities to use biological 
products and microbes as weapons in warfare began as the world was ideo-politicaly divided in to 
East-West blocks commonly know us cold war era (CHRISTOPHER et al. 1997, CNS. 2005, CBW. 
1998). Among others, the causative agent of plague (Y. pestis), Glanders (B. Mallei) and Melioidosis 
(B. pseudomallei) belongs to the most intensively studied bacterial pathogens of biological weapon 
(BW) interest in both blocks (ALIBEK. and HADELMAN 1999, DOMARADISKIJ and OREINT 2006). 
Their ubiquitous characteristics, availability, capability of aerosol transmission particularly (Y. 
pestis), the absences of vaccines and stringent control system makes them attractive candidates to 
some of those who has a willingness to use them as BW or bioterrorism. Now we live in an area of 
fear, in which we are faced with different types and degrees of insecurity. Nobody knows from 
where the danger might come. 
There can be no doubt as to the fact that the ideological East-West conflict was one of the central 
problems of the globe of the last century, a period of tension, driven by a complex interplay of 
ideological, political, and economical factors contradictory to one another, which led to shifts 
between cautious cooperation and often better superpower rivalry over decades. The foundation 
was the bipolar military competition between the two superpowers the USA and the USSR and 
their respective allies and developing countries, thus this era was more portrayed as an era of 
“proxy war” because of its global impact on the rest parts of the world (COWDREY. 1984, CAUDLE 
III. 2007, BEECHING et al. 2002, ONISHENKO. 2004). 
 
Due to the relatively independence of the East and West blocks and the closed character of the 
Soviet ideology, there was little reason to speak of any influence of the one on the other. Therefore, 
research activities, for offensive or defensive purposes were mainly, conducted under military 
auspices with high degree of secrecy and controversial testing programs independently. Several 
countries began programs to develop BWs following World War I (WWI) including Britain, 
Belgium, Canada, France, Holland, Italy, Soviet Union and Poland (BELLAMY and FREEDMANN 
2001). Although biological warfare was the subject of detailed examination pursuing WWI, 
However, the most infamous biological weapon program (BWP) was probably that begun by Japan 
in 1932 in occupied Manchuria (HARRIS. 2001) that changed the scopes of research activities on 
highly contagious diseases of military importance dramatically. Thus, establishments of military 
research centres, for aggressive, offensive, and defensive research developments began under high 
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secrecy in both East and West blocs (KLIETMANN et al. 2001, GEISSLER. 1998, FRISCHKNECHT. 
2003). Major research and development programs first emerged in the late 1930s and early 1940s. 
For instance, the development of biological weapons program which involved an extensive lists of 
causative agents of Plague, Glanders, Melioidosis, Anthrax, Tularemia e.t.c., at Camp Detrick, 
Frederick, Maryland USA as the headquarters of the arm’s BW research was implemented in 1943, 
with approximately 3,800 military and 100 civil personnel. Where many of the efforts involved 
military researchers, other from Public Health Service, other Federal Agencies and Civilian 
Research Institutions were also involved (BERSTEIN. 1987, SANDRA. 2000). 
 
During the two decades following the Second World War, laboratories, inclusion of viral, bacteria, 
and toxic mycosis that cause diseases in animals and plants were intensively studied (FRANZ et al. 
2007). Historical records shows that USA, UK, Canada and the former Soviet Union (FSU) justified 
the importance of their program, because they have learned that since 1937, Japan had conducted 
a large biological warfare program, including human test, at its Unit 731 in Manchuria (HARRIS. 
1997), the chemical warfare used the execution of bacterial warfare, in this case B. mallei by 
Germans, in the WWI, with series consequences on animals like Horses and Mules (GEISSER. 1999, 
WHEELIS. 1998, REDOMOND. 1998). The German army was considered, to be the first to use 
weapons of mass destruction, both biological and chemical agents, during WWI followed by Italian 
(FRISCHKNECHT. 2003). The Second World War has also shown similar inputs in FSU as to the 
West after the conquest of Red Army against Japan in Manchuria (DOMARADISKJI and ORENT 
2006). 
 
Although, all military research establishments, in general are covert, the scale of secrecy, intensity 
of research, span of time, area of competence and precedence in specific agents of BWPs interests 
like plague, glanders were much different. In the FSU research activities of these level were 
planned and controlled by state and kept under high secrecy till the collapses’ of the Soviet Union. 
In most case, it is incomparable to that of the research approaches known in Western hemisphere 
(PEARSON and LEE 1985, LESKOV. 1993). For instance, the existence of large-scale production and 
storage capabilities of Plague agent (Y. pestis) and genetically manipulated agent of glanders ( B. 
mallei), to the level of high resistance to chemotherapy and vaccines, among other BW agents were 
some of the factors that distinguishes the Soviet Programs or in area of defence, the development 
of live plague vaccine based on EV76 line NIIEG used for more than 7 decades and continued to be 
used in some member states of FSU (ALIBEK. 1999, HENDERSON. 1999, ZLINISKAS. 2006). 
 
Although state sponsored and institutionalized research activities on plague microbes goes back to 
the Czar period, Its main role were registration of natural foci, controlling endemic outbreaks like 
Typhus, Cholera, Glanders, and exotic diseases like Melioidosis e.t.c., prevention and prophylaxis 
measures. It was in 1928 that the Red Army Military Council made a decision of changes of the 
scopes and directions of the establishments from defensive to offensive research activities, 
recruiting specialized personnel’s (NARKEVICH et al. 1989, 1991). 
Y. pestis, B. mallei and B. pseudomallei were included in the program of all BW research activities 
known in both blocks. According to the Centers for Disease Control and Prevention (CDC), ranking 
3 
system, Y. pestis belongs to category A, similar to the Russian ranking system and B. mallei and B. 
pseudomallei to category B (ROTZ. 2002, CDC. 2000). On the contrary, in Russian ranking System 
both pathogenic Burkholderia species are listed in the second row of the last half six pathogens of 
category A of agents of great concern of potential uses of bioterrorism (KONDRIK et al. 2003). 
 
It was estimated that Y. pestis alone killed over 200 millions of humans throughout history and still 
remains endemic in certain area of the world. Annually over 1000 cases of plague are registered by 
WHO (WHO. 1970, 2000, INGESLSBY. 2000, CASHMAN and BALDOR 2001). Y. pestis has several 
characteristics, like potential for high mortality of aerosol infection, ready dissemination from 
person to person, availability and the capacity to cause public panic, which makes it attractive to 
bioterrorism, and may be used to target humans (SORVILO et al. 2005). So far, there is no vaccine, 
no stringent control measures, no prompt and precise methods of diagnosis and effective 
treatment, that presents us with a dilemma now that enforce the development of vaccine against 
plague agent. 
 
The development of vaccines and immunization is one of the most important medical innovation in 
public health care system. It is acknowledged by the World Health Organization as being ‘among 
the most cost-effective of health investments’. So far vaccination has reduced morbidity and 
mortality from infectious disease more than any other medical intervention. It was a triumph of 
global immunization programmers that enabled the global eradication of Smallpox which was final 
reported by the Global Commission of World Health Organization that Smallpox eradication was 
certified in 1980 Geneva, Switzerland. However there are a number of infection diseases of human 
and animals for which no vaccine is developed yet, like glanders and melioidosis or commercially 
no more available, like in case of plague for human use worldwide save Russia and some member 
states of FSU (FEODEROVA et al. 2007, 2008). 
 
1.1 Peculiarities of the Soviet Microbial Science 
 
The unique characteristics of Soviet microbial science among others can be grouped in: 1) Unique 
establishments - The establishment of the Anti-Plague Institutes (API) in 1920 and 50 years later, 
the “Biopreparat complex” comprised of 52 sites that provide extensive research, development and 
production capacity. Highly qualified scientists and technicians estimated to more than 50,000 
were employed in the last three decades of Soviet Union. (KLEITMANN. 2001, ONISCHENKO. 
2004). During this period the Soviet BW program not only caught up the US BWP, but it became the 
most sophisticated BWP in the world by far. Substantially increased in size and scope. In contrast, 
in this period offensive research activities on BWP in Western hemisphere, like in UK in 1950th and 
USA in 1969 were stopped. Biopreparat complex was closed for foreigners, and what is known 
about it in Western hemisphere first, come from the senior defectors from FSU to the West. If the 
information published by senior defectors, is steadfast one can say the Biopreparat complex was/is 
a gigantic factory of new gene manipulated infectious diseases, which is still secret (ALIBEK. 1999). 
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The API network operated in the whole region of the FSU for more than a century, consequently. It 
has high competence and research experiences of the pathogens in concerns and other highly 
infectious diseases endemic in the region or exotic pathogens and training experts (NARKEVICH et 
al. 1991, ZILINSKAS et al. 2006). No comparable research establishment and networks of the type, 
exists world wide, 2) Research intensity and priorities - Although a number of states were engaged 
in studying these three pathogens for offensive as well as defensive purposes, the significant 
differences between the western research approaches and in the FSU was that research activities 
in FSU were intensive, continuous, and the causative agents of plague, glanders and melioidosis 
belongs to the prior groups of research activities, whereas in the Western hemisphere, research 
activities on these agents were sporadic, with decades of gaps and discontinuities, 3) Availability of 
the pathogens and diversity - In the FSU/CIS, the pathogens in concern, except the causative agent 
of melioidosis are endemic. About 216 millions of hectares (aprox.10 %) of the territories of the 
FSU consists of natural foci with constant and recurring epizootic activities of plague and high 
frequency of intraspecific diversified strains of plague microbe are circulating in the region. These 
strains are unique to the natural foci of the region and are not known outside FSU /CIS (ANISIMOV 
et al. 2004), 4) Differences in Taxonomy:-The Russian API has its own taxonomy of plague microbe 
that differs from what is known in International Code of Nomenclature of Bacteria (ICNB) of 
Yersina pestis taxonomy predominately used in West, which is based on the classifications of very 
limited biochemical characteristics in to three bovars (Antiqua, Medivalis and Oreintalis) 
(NIKOLAEV. 1972, SLUDISKI. 1998, DEVIGNAT.1951). Wheras, in the FSU/CIS, the in 1972, 
standardized taxonomy of Y. pestis based on numerical analysis of 60 phenotypic features is 
currently used in research activities (TIMOFEEVA. 1972, ANISIMOV et al. 2004,). 
 
It is also worthy to note some remarks one at a time to realize the significance of FSU/CIS research 
achievements from the western point of view on this particular subject. For instance, the most 
popularly read Scientist journal edited by GINSBURG. (2005) published on plague an article titled 
as (to fight plague, look to the Russian’s past). Another prominent microbiologist and bioweapon 
experts, ZILINSKAS. (2002) commented, once after having some clues from the FSU/CIS experts 
said, “On the biological side we are far behind, there is a whole history of things we on this planet 
we don’t even know about.” That indicates the significance of research activity of FSU/CIS and 
comprehension to understand the plague pathogen initially and for the development of efficient 
vaccine against plague in the future.  
 
A recent reported cases of glanders outbreak in horses from autonomous region of Chita located in 
South Eastern Siberia in Russia, on the border with China and Mongolia, where more than 100 
infected and positive tested horses were killed indicates the endemicity of B. mallei in the region 
(PROMED. 2007), 5) Area of concentration on the development of vaccines and prophylaxis - Since 
1936, experts in FSU/CIS predominantly concentrated in studies and development of live plague 
vaccine based on Y. pestis EV 76 strain proposed by Girard, and Y. pestis EV 76 line NIIEG is the 
most common derivative strain for human vaccine development. The vaccine was known for its 
prompt, high induction of plague immunity, stability, and effective after administration by different 
routes , including, subcutaneous (s.c.), cutaneous, inhalation, and oral applications (SALTYKOVA 
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and FAIBICH 1975, ANISIMOV et al. 2004, FEODOREVA et al. 2007,). The immunological load 
induced by live dry vaccine in human revealed the higher blood levels of all T lymphocyte 
population on 14 day after vaccination (BOGACHEVA et al. 2009). Currently new candidate strains 
of Y. pestis are under investigation to develop an improved vaccine based on parental strain of 
EV76 line NIIEG and its mutant known as Y. pestis Δ lpxM, one of the promising candidate of 
forthcoming live attenuated plague vaccine development in Russia (FEODOREVA et al. 2007,2008) 
 
In the Western hemisphere, series of whole killed cell vaccine based on different Y. pestis strains 
(USP), were developed. The vaccine based on Y .pestis 195/P strain was the mostly used killed 
plague vaccine in human, mainly in USA . The vaccine is no more available for human use(MEYER. 
1974,WILLIASON. 2001). For the last two decades vaccine research activities  in Western 
hemisphere concentrates on recombinant protein expression technology, investigation of single or 
recombined immunogenic antigens of plague microbe, such as purified Capsule (F1) antigen or 
purified V-antigen. The. Sub-unit vaccine (F1-V), a fusion protein composed of both proteins or 
separately purified F1 and V antigen (Recombinant vaccine) are expected to be licenced in near 
future (WILLIASON. 1995, 2009, TITBALL and WILIAMSON 2001, 2004). 
5) Major records known about plague pathogen - Today the major records mainly known about 
plague, some on glanders and melioidosis are not available in English language publications. They 
are written in Russian language, published in Russian scientific journals, predominantly and most 
of them are rarely known in researches published in English language. In cases where they are 
cited, misunderstandings, or incorrectness are frequent. For instance, plague vaccine research 
review published by JEFFERSON et al. (2008), the cochrane collabration® titled “Vaccines for 
preventing plague (Review)”. 
The Author says under the subtitle of vaccines; 1) Aerosol vaccines (from USSR state 
manufactures), “This is a live attenuated avirulent vaccine, produced in many centers in the former 
USSR, which has been in use since 1908 […]. For example live attenuated vaccines are thought to 
be less effective but have a lower incidence of side effects […] EV76 can be administered as an 
aerosol or subcutaneous.” The statement that says, “Live attenuated vaccines are thought to be less 
effective, but have lower incidence of side effects” is incorrect! It is known for long period that live 
attenuated plague vaccines provided a high degree of protection in comparison to vaccines based 
on whole killed cell, like Haffkine, or USP vaccine series (GIRARD and ROBIC 1936,1963, 
MEYER.1970,SALTYKOVA and FAIBICH 1975, RUSSEL et al.1995), If that was the case as the 
Author argues, that killed plague vaccines provided more protection as live vaccines, then all 
known killed vaccines beginning from Haffikine vaccine to a series of USP vaccine could have been 
not discontinued from production and commercially no more available for human use and the live 
dry plague EV 76 line NIIEG could have never been used for more than 7 decades with its 
international trade name Vaccinum pestosum vivum siccum® produced in Russia and continued to 
be used in the countries of FSU (FEDEROVA. 2007, 2008). 
 
Although the first experimental studies on humans using live attenuated plague vaccine was 
designated "Pest avirulent" by STRONG. (1908), as there is no evidence at this period that the 
vaccine strain was EV76. What is know is that the virulent Y. pestis EV 76 strain was initially 
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isolated in 1926 by Girard and Robic from human case of bubonic plague, Madagascar, attenuated 
by multiple passages in vitro and proposed to be used as vaccine by Girard 1932, where EV stands 
for the initial name of an European child died of plague (GIRARD. 1936, 1963). This strain was 
distributed to various laboratories in the world and there are consistent evidences that showed, it 
can yield several local and systemic reactions, similar to infections induced by wild type, that 
differs from one to other laboratories which makes impossible to be licenced by the neutral bodies 
like WHO in the past.. Studies in FSU specifically on the EV 76 strain in 1936, in NIIEG, Kirov, API 
'Microbe', Saratov, Russia not in 1908 (SALYTKOVA and FAIBICH 1975, FEODEROVA et al. 
2007,2008). It is consistent that live attenuated plague vaccine is known for its efficacy of 
protection, do provide protection against bubonic and pneumonic plague, there is no evidence that 
killed plague vaccine do provide protection against pulmonary infection, but contracted 
pneumonic plague. It is also consistent that live attenuated plague vaccine does provoke both arms 
of the immune system better and consists of all required antigens to induce the immune system the 
the host, which are critical for sterile-immunization against plague microbe. In general, there are 
more inaccurate views on live plague vaccine of (EV 76 line NEIIG) in English language published 
when cited , because it has neither been used, studied nor licenced outside FSU/CIS.  
The main concern of live attenuated vaccine of plague known is its reactogenicity, safety, public 
acceptance and the fear that it might reverts from avirulence to virulence "revertants" (MEYER. 
1970, 1974, RUSSEL. 1995, FEODOREVA et al. 2007), but not that live attenuated plague vaccines 
are less effective than killed plague vaccines. Furthermore there are a number of evidence that 
confirms that the parental vaccine strain EV 76 of line NEIIG showed no signs of alterations in its 
morphological, biochemical characteristics or immunological value studied after three decades of 
storage (SALTYKOVA and FAIBICH et al. 1975). 
Recent evidences showed by KUTYREV VV et al .(2009) who compared several genetic 
characteristics of the vaccine strain EV and its putative "virulent derivatives" obtained after 
passages through highly susceptible animals in order to identify the strains- “revertants” and 
establish their possible origin using PCR and DNA-DNA hybridization allowed to establish that 
virulent "revertants" are not derivatives of the EV vaccine strain, because they do not belong to 
East biovar, do not have ribotype characteristic for EV strain and contain pigmentation area, which 
is absent in vaccine strain, an evidence against possibility of reversion of vaccine EV strain to 
virulent form in organisms of highly susceptible animals, that confirm its stability and safety for 
vaccination.  
The API has a long period of surveillance, unique research records, consistent monitoring activities 
of the natural foci and controlling plague outbreaks and prevention that goes back to 1920th The 
API controlled deadly endemic diseases and prevented the importation of exotic pathogens from 
other countries that could threaten human populations, livestock, and crops in the FSU. It is also 
one of the known achievements of the FSU in its field and Public health services in combating 
disease outbreaks and prevention (NARKEVICH et al. 1991, DOMARADISKIJ and ORENT 2006, 
ZILINSKAS et al. 2006). In area of immunology, consistent research and application of live 
attenuated plague vaccine for more than 7 decades. The development of different forms of plague 
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vaccines like non cellular or synthetic, vaccines also known as “chemical vaccine” proposed to be 
used as booster vaccine (DALVADYANTS. 1997), or an “aerosol vaccine” in combating disease 
outbreaks in case of Bio-attack or Bioterrorism (ALEXANDROV. 1962). These are some of unique 
achievements of FSU, for which no comparable studies are available in Western hemisphere. 
 
Although the research activities of FSU is known as “The enclosed world of secret microbial 
science.” in the past. Today, lack of understanding and integrating the novel achievement, know-
how, resources available to the rest part of the world might led to a bottle-neck for forthcoming 
vaccine development particularly, against plague agent that provides universal protection, have 
global acceptability and global impact.  
 
The current research activities on pathogenic Burkholderia species concentrates on searching for 
immunogenic fragments, virulence determinant factors and mechanisms of pathogenesis. Although 
recent advances have increased in understanding the infection, protective immunity is sorely 
lacking (HARALAND. 2007). 
 
In FSU/CIS, although varies conventional methods of vaccine development, like vaccine based on 
killed cells, Homologous vaccine, Hetrologous vaccines or Recombinant antigens based on other 
intracellular pathogens were conducted in different species of experimental animals, successfully 
clearup of the organisms from the host is not yet obtained (MANZENYUK et al. 1999. ILYUKHIN et 
al 1999,2002) Depending on the species of experimental animals used some forms of vaccine 
showed some low level of protection against virulent Burkholderia infection. Furthermore, There 
are some proposal of the development of vaccine against pathogenic Burkoholderia species based 
on fragments inserted to F. tularensis (ILYUKHIN et al. 1999), vaccine based on avirulent strain of 
B. thilandensis as a prototype in developing new vaccines or vaccine based on surface antigens 
fragments (ILYUKHIN. 2002). Currently there is no vaccine commercially available against agents 
that cause glanders and melioidosis either in clinical trials or licenced form worldwide. 
 
Today more than ever, to fight this kind of war, to develop vaccines against pathogens of BW 
interest is not only the duty of a few researchers or institutions, single, two or three states as it is 
now, rather it needs global approaches for finding global solution. 
 
To better understand the framework of the dissertation, historical backgrounds of the 
development of API, its exceptionality, backgrounds of the establishments and its scientific 
research publications, area of competence which are relevant for this work are thoroughly 
analysed.  
 
It is important to understand where the word “plague” was used broadly to refer to infectious 
diseases causing high morbidity and mortality, where by plague caused by Y. pestis was /is 
endemic in the region, and belongs to the first line of pathogen to be fought by the API. Thus, the 
main core of the work concentrates on research publications on vaccines against plague, glanders 
and melioidosis diseases written in Russian language and published in Russian scientific 
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literatures in comparison  English language publications as the subject coincides. For some unique 
research developments and results for which there are no comparable studies known in English 
language publications, analyses were made according to their relevance to the topic in description 
and future perspectives in developing new or improved vaccines based on the current standard of 
global knowledge. It also endeavours in evaluation of the delicate balances of major immunogenic 
versus virulent antigens which can be included in the development of newer or improved vaccine 
based on the current state of global knowledge on an antigen as single or recombined form, level of 
protection, safety and efficacy required for a new vaccine development in future. 
 
Live plague vaccine of Y. pestis 76 EV derivative of NIIEG line the most known plague vaccine strain 
studied in depth in FSU and now in Russian federation. Thus, this work also thoroughly analyses 
the background of its development, its role in the region and its drawbacks for licencing in global 
level, and impact in future developments of new or improved vaccine against plague. 
 
Problems that are considerably important in developing vaccines, like phenotypic and genotypic 
diversity, their scopes of multidrug resistance, and unique characteristics of the pathogens that 
makes them ideal candidates of vulnerability, availability of the pathogens are taken into 
consideration. 
 
Multidrug resistance is one of the challenging factors in Public Health sector today. Although 
plague microbe is described to be sensitive to first class antibiotics some strains that were isolated 
from a patient died of pneumonic plague and from patients living in natural foci showed high 
resistance to antibiotic (GALIMAND. 1997, EVCHENKO et al. 1997). A dozen of antibiotics 
sensitivity studies done in vitro against a number of Yersinia strains isolated from different natural 
foci showed no efficient protection in experimental animals was reported (SAMOKHODKINA. 
1997). That indicates a wide spread of antibiotic resistance strains of the pathogen and the 
requirement of developing a vaccine as the appropriate steps to the solution. 
 
The alarming spread of antibiotic resistance in B. pseudomallei, exhibits resistance to diverse 
groups of antibiotic including third generation cepahlosporins, penicllins, rifamycins and 
aminoglycosides (HSUEH et al. 2001), resistance to quinolones and macrolids more over limits the 
therapeutic options of melioidosis (CHENG and CURRIE 2005). Furthermore, the organism is 
known for its slow responds to most antibiotics and common relapses after apparently successful 
primary treatment, some expertise call it “silent killer” (CHAOWAGUL et al. 1993), that also 
certainly need vaccine development. Because of its long latent period, melioidosis is known as 
Vietnam's time bomb in USA. 
 
In comparison to human melioidosis, there are very few scientific literatures describing the 
susceptibility of B. mallei to antibiotics in human infection post antibiotic era. It is believed to have 
similar characteristics to the very closely related B. pseudomallei species. One recent reported case 
of laboratory-acquired human infection was a patient who worked with agent. Treatment with 
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cephalexin and cetriaxone did not improve the situation of the patient (SRINIAVASAN. 2001).This 
indicates that B. mallei is capable to relapse despite completing the therapy, that also shows the 
requirements of development of vaccine as the most appropriate solution.  
 
Thus, as a consequence of these major differences of research approaches, experiences with the 
pathogens in concern and the development of vaccines apparently may different correspondingly 
between West and CIS, exact Russia, that consequently may lead to a limited acceptance of one 
form of a vaccine by the other in licencing for global effectiveness as it was in the case of plague 
vaccine in the 20th century such as by a neutral body like WHO. 
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2 CHALLENGING CHARACTERISTICS OF THE AGENTS 
 
2.1 Yersinia pestis 
 
The genus Yersina a member of the family Enterobacteriace consists of 14 species, of which 3 are 
human pathogens, Yersina pestis, the causative agent of the systemic invasive infectious disease 
classically referred to as a plague (DSMZ. 2008, PERRY and FETHERSTON 1997), and the enteric 
food-and water-borne pathogens Y. pseudotuberculosis and Y. entercolitica (BERCOVIER et al. 1980, 
MURRAY et al. 1995). 
 
Yersinia pestis is a gram-negative facultative anaerobe, non-spore-forming, non-motile 
coccobacillus (0,5 to 8 µm in a diameter and 1 to 3 µm long), that exhibits bipolar (“closed safety 
pin”) staining with Giemsa, Wright’s or Wayson staining (BAHMANYAR and CAVANAUGH 1976, 
WHO. 2000, CIDRAP. 2003). Y. pestis is not a fastidious bacterium; It grows well on blood and many 
other enteric media. The organism grows at temperatures from 4 up to ~40 °C (optimum at 28 to 
30 °C); the optimum pH for growth ranges from 7.2 to 7.6; however, extreme of pH 5 to 9.6 are 
tolerated. It is very sensitive to high temperature, drought. At the temperature of 50 °C the 
organism dies within 30-40 minutes, at 70 °C, within 10 min., by boiling in 1 min. Direct sunlight 
kills the organism within 2 to 3 hrs. It is preserved by low temperature. It can survive for 396 days 
under temperature ranges from 0 °C-15 °C in fleas, in mites and ticks up to 509 days. It’s a weak 
concurrent against the coexisting microflora around it (BRUBAKER. 1972, PERRY. 1997, SLUSARI 
et al. 1997). The L-form of Y. pestis could persist in host animals and in carriers such as mites more 
long time (Years) (ZYKIN et al. 1989). Enzootic circulation of Y. pestis in natural plague foci 
requires active infection of host rodents and grows in the fleas, which is essential for the 
maintenance of endemic infection in natural foci (PERRY. 2003). 
 
Y. pestis harbors at least three plasmids one of which is common to the entero-pathogenic species 
Y. pseudotuberculosis and Y. entercolitica (FERBER et al. 1981, PORTNOY et al. 1985). The other 
two plasmids designated pMT1, mostly known as pFra and pPCP1 are unique to Y. pestis 
(BRUBAKER. 1991). Plasminogen activator (pla), the bacteriocin pesticin (pst), and a pesticin 
immunity protein (pim) are encoded on the 9,5 kb pPCP1. The large 100 kb to 110 kbp plasmid 
encodes two potential virulence determinants factors: the Murine Toxin (Ymt) and the Fraction1 
(F1) capsule antigen (CHERPANOV et al. 1991, BEN-GURION and SHAFERMANN 1981, FILIPPOV et 
al. 1990, KUTYREV et al. 1986) 
 
Yet much what is known in English language publications about the genetic and phenotypic 
properties of Y. pestis comes from studies of a limited number of strains commonly found in 
Americas, where there is very restricted genetic diversity (RADNEDGEL et al. 2002, ANISIMOV et 
al. 2004). Thus much of the pathogenic potential of Y. pestis for humans remains largely unknown, 
many of which are found in isolated region of FSU and Asia and not easily accessible to researchers. 
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What is known about the pathogen in this region is predominately written in Russian language and 
Russian scientific journals (TIMOFEEVA.1972, KOKUSHKIN.1994, ANISIMOV et al. 2004). 
 
The first compact summary of Intraspecific diversity of Y. pestis  known in FSU and its significance  
compared to strains known in the Western hemisphere was published in English language by 
ANISIMOV et al. (2004). Not only that about 10 % of  the territory of FSU comprises natural plague 
foci, with its constant and recurring epizootic activities but, also the most diversified, dynamic 
strains of plague pathogen are circulating in the region. A number of strains isolated from the 
region are known to have a high intraspecific diversity, some of them lacks one or two of the 
plasmids Y. pestis harbors and some of them consists  additional cryptic plasmids of different 
molecular masses, whose role is not yet elucidated are know and are equally virulent in 
experimental animals when compared to the wild types (NARKEVICH et al. 1991), 
 
The Russian museum of microbial collection, Institutes and laboratories possess the most highly 
diverse strains of plague bacilli in quantity and quality in the world. Suggesting, that  
understanding these atypical strains only  is even more important, because for one they are rarely 
known, further more there are no specific diagnosis methods and may take an advantage of 
bioterrorism utilization. Thus, It is essential to include in research activities in processes of 
developing vaccine against plague of universal protection and acceptance. 
 
Being one of the oldest identifiable diseases known to man, plague caused by Y. pestis remains 
enzootic and endemic in many natural foci around the world (AMPEl. 1991, WHO. 2000). Until 
now, it is not known what “wakes” them up and leads to periodical outbreaks, so it is possible to 
expect different surprises in a form of swarms of epizootics of plague. What makes the matter even 
worse is that, it is not known from where the danger may erupt if no permanent and stringent 
surveillance is in place (STEPHEN. 1995). One of the most disturbing side-effects of modern life is 
the speed with which diseases can spread around the globe. Decades ago, it was much less likely 
that an outbreak of infectious diseases occurring on one continent could cross-oceans to another. 
Intercontinental air travel now makes it possible for a disease to arrive in other continents before 
signs of the original outbreak have been recognized. The World Health Assembly attributes the 
problem of new emerging or re-emerging diseases such as plague, to the following trends: With the 
increasing global population many are forced to live under conditions of overcrowding, inadequate 
housing, and poor hygiene; more frequent international travel leads to rapid global exchange of 
human pathogens; changes in health technology, food production, as well as its distribution 
(including international trade and handling), climate changes, natural catastrophes, immigrations 
of vectors also known as “amplifiers”, create new opportunity for pathogens; and human 
behavioural changes expose large segments of the global population to disease not previously 
experienced; expanding areas of human habitation expose thousands of people to enzootic 
pathogens previously unknown as causes of human disease; and microbes continue to evolve and 
adapt to their environment, leading to the appearance of new pathogens (WHO. 1995). 
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Furthermore, there is a fear that science of microbiology, genetics could be misused. A fear, that 
microbiological agents can be used as weapons of mass destruction. The belief that the anthrax 
attacks in the year 2001 were carried out by a scientist and that the bacteria came from a US 
laboratory has made microbiologists suspect as well as potential saviours (ATLAS. 2003, CDC. 
2001a,2001b). Recently, The Washington Post (2010) reported:"The Justice Department officially ended its 
eight-year investigation of the 2001 anthrax attacks Friday with the release of hundreds of pages of documents 
that starkly portray the mental unravelling of the deceased Army scientist accused of committing the worst act 
of bioterrorism in U.S. history." That demonstrated the new perils facing the world.  
 
It must be also emphasized that it was the distinguished scientific community who initiated the 
movements to create biological, chemical and nuclear weapons, sponsored by ambitious leaders. Y. 
pestis is classified as level A biothreat agent, characterised as high-priority agent, easily to 
disseminate, with a high mortality rate, with the capacity to cause panic and social disruption and 
requiring specialized public-health responses (INGELSBY et al. 2000, ROTZ et al. 2002, CDC. 2000). 
 
Plague diagnosis may be confused with a number of other infectious diseases depending on the 
clinical manifestation (NEUBAUER et al. 2000). Bubonic plague may be confused with infections 
like streptococcal or staphylococcal lymphadenitis, infectious mononucleosis, tularemia, 
mycobacterial infection, e.t.c, (HULL et al. 1986, CROOK and TEMPEST 1992). Septicemic plague 
may be confused with meningo-coccemia and septicemia caused by other gram-negative bacteria. 
Pneumonic plague may be confused with other causes of acute severe community-acquired 
pneumonia, such as pneumoccal, streptococcus, Haemophilus influenzae infection, anthrax, 
tularemia, legionellosis and viral infections (POLITZER. 1954, HULL. 1987, MARGOLIS et al. 2008). 
 
2.1.1 Differences in Taxonomy and its impact on Vaccine Development 
 
The currently widely used classification of Y. pestis strains in the Western hemisphere is based on 
minor phenotypic and biochemical differences: biovar Antiqua reduces nitrate and ferment 
glycerol whereas biovar Medievals does not reduce nitrate and biovar Orientalis does not ferment 
glycerol (DEVIGNAT. 1951, TUMANSKII. 1957). The fact that Y. pestis is essentially a recently 
introduced pathogen into the Americans, 1900-1904, San Francisco, USA, indicates that the genetic 
and phenotypic diversity of isolates is relatively restricted, particularly compared to those from 
Central and East Asia, where distinct strains are identified in the respective niches  
 
In FSU/CIS the classical subdivision is not directly used as a pre-eminent way of classification of 
plague microbe, because of some drawbacks, for instance, the biovar characterizations are not 
stable and one strain can undergo spontaneous phenotypic variation which would cause it to be 
classified into another biovar (INNOKENTEV. 1969, KOZOLOV. 1979). Strains of different 
biochemical, cultural morphological and virulence characters were realized permanently, even 
within a single species of hosts, which indicates, the plague microbe can maintain broad changes of 
spectrum (MAIKANOV. 1997). 
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The classification of the natural plague foci in FSU were primarily performed based on their 
geographical distribution and then based on primarily infected hosts found in each focus. Various 
strains of Y. pestis isolated from the territory of FSU and Mongolia were classified into “subspecies” 
Yersinia pestis subsp. pestis (sometimes referred to as the “main” subspecies) Y. pestis subsp. 
altaica, Y. pestis subsp. caucasica, Y. pestis subsp. Hissarica, Y. pestis subsp. ulegecia based on the 
numerical analysis of 60 phenotypic features that was standardized in a conference of the experts 
of the APIs of the Soviet Union, Ministry of Health, Ministry of Defence and other governmental 
regulatory agents , Saratov, 1985 resolution. These Taxonomy and Nomenclatures are currently 
used in the works of APIs in Russia and member states of FSU (APARIN et al. 1987). Chinese plague 
experts use their own classification utilizing the term “ecotype” for different Y. pestis subspecies. 
Groups differ in some phenotypic properties from Russian “nonmain subspecies” (TAN et al. 2002). 
However, these systems are not currently included in the International Code of Nomenclature of 
Bacteria (ICNB) at all. Diversity in genotypes and phenotypes is found even among plague isolates 
from the same natural focus. Thus, no system of classification is likely perfect having nearly 100 % 
specificity. Atypical or engineered strains with a variety of unusual characteristics might 
reasonable be expected to be a cause of human infection accidentally or deliberately and is 
warranted to have an impact in treatment, diagnosis and vaccine production (ANISIMOV et al . 
2004). 
 
Y. pestis is closely related to the gastrointestinal pathogen Y. pseudotuberculosis, and it has been 
proposed that Y. pestis is a clone that evolved from Y. pseudotuberculosis probably serotype O.1b 
(SKURNIK et al. 2000) 1,500-20,000 years ago (ACHTMAN et al. 1999) by application of Multi-
locus sequence type (MLST) of house keeping genes. Therefore, Y. pestis seems to have rapidly 
adapted from being a mammalian entero-pathogen widely found in the environment, to a blood-
borne pathogen of mammals that is also able to parasitize insects and has limited capability for 
survival outside the hosts (PARKHILL et al. 2001). Nevertheless, the symptoms of the disease, 
routes of infection, and the scale of virulence, public health care and security caused by the two 
Yersiniae are dramatically different (BRUBAKER. 1991, PERRY and FETHERSTON 1997). The 
enteropathogenic Yersiniae must survive in soil and water and bypass the host gastrointestinal 
mucosa following ingestion, whereas Y. pestis remains within the closed and protected 
environment of its flea vector, thereby ensuring by intradermal injection, a route that requires 
extensive dissemination to achieve favoured visceral niches which support the bulk of replication 
in vivo (PERRY. 2003, HINNEBUSCH, 1997) 
 
The most impressive genetic difference between Y. pestis and the entero-pathogenic species in this 
regard is the presence in most but not all strains of the former of two unique plasmids (FILIPPOV 
et al. 1990), pMT1 (69 to 110kb) encoding (murine toxin and F1) and pPCP1 (9,6kb) encoding 
(plasminogen activator) are important virulence factors (BEN-GURION and SHAFFERMAN. 1981, 
FERBER and BURBEKER 1981, FILIPPOV et al. 1995, KUTYREV. 1986) and some small regions of 
chromosomal DNA (PARKHILL et al. 2001, DENG et al. 2002). Another major difference between Y. 
pestis and the enteropathogenic Yersiniae is the presence of as many as 30 copies of an insertion 
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element termed IS100, both, within the chromosome and on all plasmids (PORTNOY and FALKOW 
1981, RAKIN et al. 1996, BOBROV and FILIPPOV 1997). They also share many additional processes 
that promote disease as reflected by carriage of a common sites in which a large number of genes 
encoding virulence factors such as Yersinia outer proteins (Yop) and the Yop secretory system 
(Yops) are clustered, as well as silent regulatory and anti-inflammatory functions. The generic 
term “low-calcium response,” or Lcr plasmid, has been applied to this plasmid regardless of its 
origin; it is specifically termed pCD in Y. pestis pCad or PIB in Y. pesudotuberculosis and pYV in Y. 
enterocolitica (CORNELIS. 1998, IRIARTE and CORNELIS 1996, PERRY. 1997).  
 
Comparison of the genomic content of this organism to the six published sequences of Y. pestis and 
their Y. pseudotuberculosis ancestor, based on classical glycerol fermentation (+ve) and nitrate 
reduction (+ve) done, showed that Y. pestis Pestoides F is an isolate that belongs to the biovar 
antiqua. This strain is unusual in other characteristics such as the fact that it carries a non-
consensus V antigen (LcrV) sequence, and that unlike other Pla(-) strains, Pestoides F retains 
virulence by the parenteral and aerosol routes. The chromosome of Pestoides F is 4,517,345 bp in 
size comprising some 3,936 predicted coding sequences, while its pCD and pMT plasmids are 
71,507 bp and 137,010 bp in size respectively. Comparison of chromosome-associated genes in 
Pestoides F with those in the other sequenced Y. pestis strains reveals differences ranging from 
strain-specific rearrangements, insertions, deletions, single nucleotide polymorphisms, and a 
unique distribution of insertion sequences. There is a single approximately 7 kb unique region in 
the chromosome not found in any of the completed Y. pestis strains sequenced to date, but which is 
present in the Y. pseudotuberculosis ancestor ( GARCIA et al. 2007). This indicates, that in post 
genomic era, the three frequently used forms of Taxonomy of Y. pestis biovars is aniquated, 
consequently shows the importance of updating the taxonomical classification of Yersina pestis 
based on current global knowledge of the organism and strains known from different natural foci 
worldwide, which are not yet included in the International Code of Nomenclature of Bacteria 
(ICNB).  
 
Further more sequencing of the entire genome of Y. pestis Orientalis strain CO-92 (PARKHILL et al. 
2001) and a Mediaevalis strain KIM+ (DENG et al. 2002) has showed that both strains shared > 98 
% of the genome sequence. In contrast, the two recent sequenced strains of Y. pestis, known as 
Nepal516 (CHAIN et al. 2006) and Y. pestis Pestoides F (GARCIA et al. 2007) showed distinguished 
differences unlike the classical known biochemical and phlogentical division. Y. pestis Nepal516 
strain, isolated from human in Nepal, which has been biochemically characterized to belong to 
biovar Antiqua compared to strain antiqua “classical” antique biovar demonstrated that, there are 
differences between the two biovar antiqua lineage. That indicates grouping Y. pestis strains based 
strictly on the classical definition of biovars (predicted upon two biochemical assay) does not 
accurately reflect the phylogenetic relationships within this species (CHAIN et al. 2006). Y. pestis 
Pestoides F, the first sequenced strain isolated from the former Soviet Union by GARCIA E et al. 
(2007) indicates, unlike the classical Yersinia pestis strains, members of an atypical group of Y. 
pestis from Central Asia, denominated Y. pestis subspecies caucasica (also known as one of several 
pestoides types), are distinguished by a number of characteristics including their ability to ferment 
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rhamnose and melibiose, their lack of the small plasmid encoding the plasminogen activator (pla) 
and pesticin (pst), and their exceptionally large variants of the virulence plasmid pMT- encoding 
murine toxin and capsular antigen (DONG et al. 2001, KOKUSKIN et al. 1994, ANISIMOV. 2004, 
BALAKHONOV. 1991, GRAMOTINA and PROTSENKO 1994). 
 
One important finding of the plague-experts engaged in investigating enzootic strains of Y. pestis in 
FSU is that in some populations the plasmid contents were know to be quite stable,  such as strains 
of Y. pestis subsp. Caucasica isolated from Voles and their fleas in Leninakan and Presvan. Whereas 
in some other populations there were a considerable variation among strains, such as , strains  
isolated from rodents living in close proximity. Strains isolated from Zanzegur-Karabah and 
Dagestan highland natural foci was found that the pPst plasmid that carries the genes for pesticin-
fibrinolysin-coagulase activities was missing (KYTREV et al. 1992). In Mongolia It was found that 
the palsmid content of 894 Y. pestis strains isolated from patients, wild mammals and arthropods 
were divisible in to three distinct populations of strains based on the differences in molecular 
masses of the plasmid the strains harbors (BALAKHONNOV et al.1991, ANISIMOV etal. 2004). In 
China, in Yunnan province 1020 strains were found to carry plasmids of nine different sizes (ZHAO 
et al. 1990). In Brazil, pareaba state, a cryptic plasmid of 14.9 MDa was isolated from 26 strains 
(LEAL et al. 1989). Thus a variation of high plasmid profile, diversity of Y. pestis populations found  
in different region of the world needs further studies in order to understand their role in general 
and for the developments of vaccine specifically. Thus it will be important  to answer the following 
questions:-1) Does the mutation of one plasmid or two major plasmid leads to more virulence or 
avirulence in comparison to the classical strains that harbors all known three plasmids? 2) Which 
role does the additional cryptic plasmids, whose role has not been elucidated can have on vaccine 
development? 3) Does the forthcoming vaccine known as Sub-unit/Recombinant vaccine based on 
two major antigens F1-V or rF+rV respectively of Y. pestis provide efficient protections against 
these isolated from natural foci such as from FSU, Mongolia, China, Brazil or from other natural foci 
found globally  which are yet known but may circulates in natural foci and are virulent? 
 
2.1.2 Multidrug Resistance: Unreliability upon Antibiotics 
 
As the majority of gram negative micro-organism, usually Y. pestis isolates are uniformly 
susceptible to antibiotics, but now new highly resistant strains to first class antibiotics have 
evolved, and are going on reproducing even faster (SMITH et al. 1995). Antimicrobial-drug 
resistance is an increasing important factor and poses a serious international challenge to public 
health in both communities and institutions (WEISE et al. 1998). In spite of the significant role of 
antibiotics in treating bubonic plague, but not pneumonic plague, new multi-drug resistant strains 
of plague bacilli were reported in vitro (FREAN. 1996) isolated from patients (RASOAMUNAN et al. 
1995) and strains mostly isolated from Suslik’s (Citellus citellus), habitats in natural plague foci in 
the CIS (EVCHENKO et al. 1997). Streptomycin, chloramphenicol, and tetracycline, are used to treat 
plague, and sulfonamides are recommended for prophylaxis (BARNES and QUAN 1992). The new 
isolate Y. pestis 19/95 biotype orientalis was isolated in the Ambalavo city of Madagascar from a 16 
16 
-year’s old boy (RASOAMUNAN et al. 1995). It was highly resistant to chloramphenicol, kanamycin, 
streptomycin, sulfonamides, tetracycline, and minocyclin. The resistance genes were carried by a 
plasmid, pIP1202, approximately 150 kbps, that could conjugate to other Y. pestis isolates 
(GALIMAND et al. 1997, DENNIS. 1997) which demonstrates the risks of the spread of resistance in 
Y. pestis, a species previously considered universally susceptible to antibiotics. Resistance to 
ampicillin was due to the production of a beta-lactamase, and resistance to kanamycin was due to 
the synthesis of type I 3’-aminoglycoside phospho-transferase. The strain was also resistant to high 
level of streptomycin as a result of the production of 3’-9’-aminoglycoside adenyltransferase 
(GARROD and WORTH 1962). The second high-level resistant strain to streptomycin (the reference 
antibiotic for plague treatment) due to streptomycin phosphotrasferase activity was named Y. 
pestis 16/95 and isolated in the Ampitana town, Fianarantsoa province, Madagascar from a human 
case of bubonic plague, that is 120 km apart from Ambalavao city , where Y. pestis strain 19/95 was 
isolated (a typical strain of ribotype B). The new strain is described to be a Madagascar-specific 
ribotype Q. The resistance genes were carried by a plasmid pIP1203 that could conjugate at high 
frequencies to other Y. pestis (GUIYOULE et al. 2001). The new multi-drug resistance isolates 
reported by GALIMAND et al. (1997), raises several questions, which are not yet explained: 1) 
where the isolate did acquired its resistance plasmid? 2) do resistant enteric bacteria perhaps 
exists in the rats in the region, while rats mainly live in a fecal contaminated environment (BYRNE 
and SUSAN 1998), with multi-drug resistance human fecal flora? More questions are to be 
answered through systematic, domestic and global surveillance to find appropriate responses 
against multi-drug resistance in plague.  
 
New strains of Y. pestis 19/95 biotype orientalis and Y. pestis 16/95, isolated from patients in 
Madagascar were reported to be resistance to multiple drugs and streptomycin respectively, which 
were carried by plasmids. That demonstrates the risks of the spread of resistance in plague bacilli, 
a species previously considered universally susceptible to antibiotics (GALIMAND. 1997, 
MCCORMICK. 1998, WONG et al. 2000, GUIYOULE et al. 2001, STEWARD et al. 2004).That indicates 
unreliability of treatment upon antibiotic therapy. 
 
The results of studies done on antibiotic susceptibility of Y. pestis strains isolated in the years 
1995-1996 from patients living in three natural foci found in the territory of the republic of 
Chechenia, also indicated that 23 % of the strains isolated from Pre-caspian natural foci were 
moderately resistant to streptomycin, amikacin, cefazolin, kanamycin, and polymixin. Additionally, 
13 strains that belong to the Kavkazian sub-species isolated from the mountain regions of 
Dagestan, were found all, to be resistance to polymixin treatment, 23 % to streptomycin and 
amikacin, 61 % to kanamycin, 61.5 % of the isolates were not or weakly responding to 
ciprofloxacin and 53,8 % the isolates showed resistance to levomycin and cefalotin (EVCHENKO et 
al. 1997). In addition to the strains isolated from patients, resistance to antibiotics was also 
prevailed in strains isolated from nature in the region. 
 
Another similar experimental study focused on antibiotic resistance of Y. pestis demonstrated, that 
an infection caused with non-capsule-forming (F1) strains and simultaneously treated with 
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tetracycline, ß-lactamin antibiotics, and quinoline with in the range of therapeutic dose, showed no 
effect. In contrast to infection caused by capsule forming (F1+) strain of Y. pestis , which expressed 
an effective therapy (SAMOKHODKINA et al. 1997). In vitro investigation of the effectiveness of 14 
antimicrobial agents investigated in 78 strains of Y. pestis showed that, antibiotics like 
streptomycin, tetracycline, chloramphenicol, azithromycin traditionally used for the treatment of 
plague were insufficient to kill the organism in all 78 strains (SMITH. 1995). Resistance of Y. pestis 
to antibiotic is also prevailed in macrophage cell culture, but not in nutrient medium 
(SAMOKHODKINA et al. 1997). A recent know case was reported from California, (MARGOLIS et al. 
2008), where a 79–year old woman A treatment with ceftriaxone followed by scheduled 
ampicilin/sulbactam and levofloxacin, while the patient received a diagnosis of community–
acquired pneumonia initially. As the diagnosis was changed to be a disease caused by Pseudomonas 
aeruginosa, the antibiotic regimen was also changed to meropenem and gentamicin. It was finally 
diagnosed that, it was a septicemic plague and the patient had received 10 day of effective Y. pestis 
covered and had an extended hospital stay, but she was died. MDR in Yersina pestis is not a 
question of if, but it is a question of when, that enforce vaccine development against a plague as the 
most appropriate solution. 
 
2.1.3 Neither Stringent Control System nor Vaccine is currently available 
 
The global availability of the plague pathogen, the capacity for mass production, aerosol 
dissemination, the high fatality rates of pneumonic plague and the potential for secondary spread 
of cases during epidemic, the rapid growing of MDR, the absence of prompt and precise diagnosis 
makes it one of the most serious concerns of ‘critical biological agents’ of category A, that have a 
potential to be used as a biological weapon, which is difficulties to prevent (CDC. 2000, 2001a). 
Several characteristics of biological agents that may make them appealing to bioterrorism are, they 
are relatively inexpensive, readily available, easy to produce in quantity, effective in causing 
damage and confusion, easy to conceal and transport, poses delayed effect, significant economical, 
social  impact and ability to cause panic internationally (HUGHES. 1999). 
 
The epidemiology of plague following its use as a biological weapon would differ substantially from 
that of naturally occurring infection. Intentional dissemination of plague would most probably 
occur via an aerosol of Y. pestis, a mechanism that has been shown to produce disease in non-
human primates and experimental animals (SPECK and WOLOCHOW 1957, WILLIAMSON et al. 
2001. 2001 SMILEY. 2008). A pneumonic plague outbreak would result with symptoms initially 
resembling those of any other severe respiratory illness. The size of the outbreak would depend on 
factors including the quality of biological agent and characteristics of the strain, environmental 
conditions, and methods of aerosolization. The pathogenesis and the clinical manifestation of 
plague following an inhaled aerosolized Y. pestis bacillus would cause primary pneumonic plague 
which would be notified differently than naturally occurring plague. The incubation period to 
aerosolized plague has been found to be 1 to 6 days, in human and non-human primates and most 
often, two to four days (WU. 1926, SPECK et al. 1957, FINGOLD et al. 1968). The first sign of illness 
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would be expected to be fever, with cough, and dyspnoea sometimes with production of bloody, 
watery or less commonly purulent sputum and prominent GIT symptoms including nausea, 
vomiting and chest pain. Abdominal pain and diarrhoea might be present (CDC. 1997). 
 
Currently there is neither stringent control system, nor vaccine is available in the Western 
hemisphere save Russia. Suppose a group of people are armed with it and would commit these acts 
in appropriate time and places, how do the world behave in this situation? Nobody knows. The 
only available vaccine is the live plague vaccine based on the strain of Y. pestis EV76 line NIIEG 
which has been used as human vaccine for more than seven decades and has continued to be used 
in the countries of of Former Soviet Union. Annually more than 100,000 people living and working 
in endemic region are immunized against plague (FEODOROVA et al. 2007, ISTC. 2008). It was 
never used and licenced in Western hemisphere. 
 
2.1.4 Pandemics and Global Distribution 
 
History has accounts of four, some groups it to three, plague pandemics; Egypt in 541 AD, Asian 
Minor in the 14th century, Europe in the 15th, and china in 1860, which were collectively 
responsible for the loss of 200 million human lives (WHO, 2000). 
 
The first pandemic, known as Justinian’s plague, occurred between AD 540-750, causing epidemics 
in Asia, Africa, and Europe. It is estimated to have caused nearly 100 million victims, and was 
followed by various smaller epidemics (DUPLAIX. 1988, MCEVEDY. 1988, WHO. 2000, 
BUCHRIESER et al. 2001). 
 
The second and third plague pandemic is the well-known “Black death” began from Asia Minor in 
14th century and spread to Europe from 15th-16th centuries. This pandemic was the beginning of a 
number of outbreaks of plague, which ravaged Europe and Africa in subsequent centuries, causing 
an estimated 50 million deaths, approximately half of them in Asia and Africa and the other half in 
Europe, where quarter of the population succumbed (MCEVEDY. 1988, SLACK. 1989). It entered 
Europe probably via the trans-Asian Silk Road during the early 14th century. In the year 1346, 
plague arrived in [K]Caffa (Modern Feodesya, Ukraine) at the Criema, It is widely believed as the 
results of biological warfare attack by Mongolian. The unwanted import landed in ports like 
Marseille and Genova and pushed inland. By 1348, plague had already entered Britain at 
Weymouth (BAYLISS. 1980). By the year 1352, 25 million people had died in Europe alone.  
 
The fourth pandemic began in Canton and Hong Kong in 1860 and spread rapidly throughout the 
world, by rats aboard the swifter steamships that replaced slow-moving sailing vessels in 
merchant fleets. Alone, within 10 years (1894-1903) plague entered 77 ports on five continents. In 
India, were over 6 million deaths from 1898 to 1908. Case rate per 10,000 populations was 
registered in India 427; Senegal 269; Hongkong 244; Mauritius 227; Burma 122; Madagascar 116 
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and Uganda 88; to note some of the records of the extension of third pandemics of plague in the 
20th century (WHO. 2000, DUPLAIX. 1988, CDC. 2005). 
 
It was also in this period, precisely in 1894 that Alexandere J. E. Yersin and S. Kitasato 
independently discovered that Y. pestis causes plague. Three years latter W. Haffkine developed a 
heat-killed-vaccine and Simond confirmed that the rats were the vector of plague bacilli, over 200 
species of wild rodents, found to harbor the bacilli. It was believed that, the reservoir of plague 
bacilli in the fleas of the Siberian marmot (tarbagans) was likely responsibly for the death of 
50,000 men in the Manchurian pneumonic plague pandemic in the year 1910-1911. In the year 
1900 the disease officially arrived in North America (RISSE. 1992). In the year 1914 plague arrived 
at the West-African coast, with an outbreak in Senegal, Dakar, where about 35,000 men died in 32 
years. The giant rats, Cricetomys gambiae, which was abundant in the bushes, might be a 
responsible vector in Western Africa as tarbagans were in Manchurian (ECHENBERG. 2001). 
 
Natural foci of plague are situated in all continents except Australia. It covers 6 to 7 % the dry land 
of the Earth, situated in a broad belt in the tropical and subtropical latitudes and the warmer parts 
of the temperate latitudes around the globe between the parallels of 55 degrees North and 40 
degree South (fig. 1). However, with in there limits many areas are free of natural foci of plague, 
such as desert areas with few or no rodents, and the large areas of the continents forest particular 
in the tropics and high glacier-covered mountain. Hence, plague foci are not fixed, and if they can 
change in responses to the shift of the driving factors such as climate, landscape, rodent population 
migration, travel and transportation (DUPLAIX. 1988, PERRY and FETHERSTON 1997, WHO. 
2000). 
 
Cases of human plague have been known from time immemorial, and throughout history, some of 
the authors believe, that oriental rat flea (Xenopsylla cheopis) has been largely responsible for 
spreading bubonic plague (BAYLISS. 1980). In fact, plague is now considered as a re-emerging 
disease (SCHRAG et al. 1995) for at least three reasons; 1) there has been an increase in the 
number of cases reported to the World Health Organization, 2) plague re-appeared in an epidemic 
form in countries, including the Democratic Republic of Congo, Malawi, Mozambique, Zambia, 
Madagascar, India, USA, recently in where it had been silent for two to three decades, 3) the 
number of foci is gradually expanding in certain countries (WHO. 2000, 2003, 2006). 
 
Plague is not an eradicated disease, a curiosity with importance only to medieval history (AMPEL. 
1991). Indeed the official reactions of several countries show that plague remains one of the most 
feared of the infectious diseases. Outbreaks of plague in India in 1994 were notable because no 
cases had been reported in humans there for nearly 30 years. Notification caused global alarm, 
disrupted travel, trade, and resulted in severe economic repercussions with cost of two billion US 
dollars. They also highlighted the lack of preparedness of national and international health 
agencies to deal with plague epidemics. This zoonotic disease, with reservoirs on nearly every 
major continent, exhibits an impressive ability to overcome mammalian host defence (PERRY and 
FETHERSTON 1997, JOHN. 1994). Epidemiological studies in Surat showed that it was an outbreak 
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of pneumonic plague resulted from person-to-person respiratory exposure. The outbreak occurred 
in a setting of high frequency of severe fever. About 75 % of the suspected plague cased in Surat 
were young males. There were no confirmations of bubonic plague (DENNIS. 1994). The recent 
disease outbreak reported to WHO from Democratic Republic of Congo (WHO. 2006), where 100 
cases of suspected plague including 16 deaths in Ituri district were pneumonic, Oriental Province, 
Ituri is known to be the most active “hot-spot” of human plague Worldwide. Recently, in USA a total 
of 13 human plague cases have be reported among residents of four states: New Mexico, Colorado, 
California and Texas (CDC. 2006). The WHO, estimates that there are approximately 3,000 cases of 
plague annually worldwide. The real is believed to be greater than what is registered by World 
Health Organization. In the year 2003 alone nine countries reported 2,118 cases and 182 deaths. 
98.7 % of those cases and 98.7 % of those deaths were reported from Africa. 
 
Today the distribution of plague coincides with the geographical distribution of its natural foci 
(WHO. 2006). Thus, the recent outbreaks of plague in India in the year 1994 remind us once again 
of the need to maintain a core of skills in infectious diseases and the public health infrastructure to 
detect, monitor, and combat a wide range of disease agents, some new, some revisiting and the 
importance of developing vaccines as the most appropriate option. Plague may have retreated over 
the past decades, but it has not gone away (WHO. 1994, DENNIS. 1994). 
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Figure 1. Global Distribution of Plague [cited 2008 Jul] Available from: < http://chppm-
www.apgea.army.mil/documents/FACT/PlagueJusttheFactsOctober2007.pdf> 
 
2.1.4.1 Significance of Plague Distribution in FSU/CIS  
 
 Forty-three natural foci are found in the southern and south-eastern regions of the former Soviet 
Union, which are essentially different in their epizootic as well as epidemic activities. The natural-
foci were strategically located in 11 republics of the former Soviet Union consisted of six Institutes, 
29 regional Anti-Plague stations, (APS), 53 field APSs, and about 200 specialized teams in 
epidemiology. It covers more than 216 million hectares or 9.6 % of the territories of the FSU. 
Analysis of available sources from archives and literatures documented from the year 1875 to 
1997 indicates that there were an incidence of 10,453 human cases of plague in the FSU, whereby 
9,054 (86.6 %) of them died (NARKEVICH et al. 1991, KOKUSHKIN. 1997, ANISIMOV et al 2004). In 
a continental-geographical demarcation, the majority of cases (5,574) were registered in the 
European part and less cases (4,879) in Asian part. Based on the epidemiological surveillance 
1,224 (11.6 %) cases were registered from non-enzootic territories and 9,195 (88.4 %) cases were 
registered from natural foci territories. Investigation done on sources of infection, indicated that 
contacts with contaminated excretes of animals, or contaminated animal products like camel meat, 
as the main sources of infection. Only 34 cases (0.4 %) were reported as laboratory-acquired, 
direct contact in working with the pathogen. Investigations made on location of residence showed 
that, about 85 %, 14% of the cases were recorded from people living in rural area, and urban 
residents respectively (NARKEVICH et al. 1991, KOKUSKIN. 1997). 
The 43 natural foci were classified in 5 regional divisions, the Caucasian region which includes 12 
natural foci, (fig. 2), designated with number [1, 4-13, and 39], North Pre-Caspian region includes 
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number [2, 3, 14-17, and 43], Central Asian Desert region consist of number [18-30 and 42], 
Central Asian Mountain region consist of [31-35 and 40] and the Siberian region that covers 
natural foci [36-38 and 41]. Studies done on the nature of out-breaks indicated that most of the 
epizootic activities of the natural foci were/are recurring. It was also recorded that constant 
epizootic activities were found in Caucasian region [1, 4, and 5] (NIKOLAEV. 1972, BALAKHOHOV. 
1991, KOKUSHKIN. 1997, ANISIMOV et al. 2004). For several decades, hundreds of plague experts 
in the FSU and the neighbouring countries like Mongolia and China were involved in field research 
studies of natural foci. Millions of rodents and fleas habiting in all types of natural foci were 
investigated. From 1920-1989 alone, bacteriological investigation was done on about 30 millions 
of rodents and about 102,095 strains of Y. pestis were isolated. Serological investigation revealed, a 
detection of specific antibodies from 106,349 animals (NARKEVICH et al.1991). 
 
Figure 2. Distribution of natural plague foci in the FSU. 
 
The red line indicate the FSU frontier; green lines indicate frontiers of states of FSU; brown lines indicates 
boundaries of the plague foci; black line indicates frontiers of other countries. Plague foci are yellow (for foci 
containing the main1 Y. pestis subspecies) or, light brown (for foci containing non main2 Y. pestis subspecies). 
(Figure adapted and compiled with permission from Anisimov et al., 2004 refered to (Balkhonov, 2000, 
Kokuskin, 1995, Nikolaev, 1972, Sludiski, 1998). 
1. According to FSU/CIS classification the main subspecies are called Y. pestis pestis   
2. To non main subspecies belongs Y.pestis altaica; Y. pestis Caucasian; Y. pestis hissarica, Y. pestis ulegeica 
(APARIN and GOLUBINISKI, 1989) 
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In order to specify strains isolated from natural foci, studies done on 257 samples of Y. pestis 
strains isolated from 31 natural foci in the FSU and neighbouring countries revealed that 10 % the 
strains obtained additional cryptic plasmids. For instance, strains isolated from Volga-Ural sandy 
focus, showed that 4 % of the isolates lacks pPst; 1.3 % of the isolates lacks pCad; 1 % lacks both 
pCad and pFra; 0.7 % lacks pPst and pCad; 0.3 % lacks pFra from a total of 18 % of the cases 
studied. Additional cryptic plasmids with a molecular weight of 30 MDa, 70 MDa were found in 5.7 
%, 1.4 % of the isolates, respectively (DIMITRYUK et al. 1997, STEPANOV et al. 1975, 1981). 
Similar results were obtained from the Talas, Central-Caucasian, and pre-Balkhash foci, where 
strains isolated from these regions harbored a 20 MDa cryptic plasmid. Suggesting, that plague 
microbes circulating in natural foci of this region are highly diverse in comparison to strains 
known in Western Hemisphere, strains that harbors all three classical plasmids, pFra, pCad and 
pPst (WAKE et al.1983, BRUBAKER. 1991, CHERPANOV. 1991, FILIPPOV. 1990). Another similar 
investigation of 1,020 Y. pestis strains isolated from 44 counties of Yunana in China and the border 
of China-Myanumar were found to carry plasmids of nine different molecular weights, that leads 
the experts in China to classify them in plasmidovars (DONG et al. 2001) rather than biovars which 
is conventionally used in the Western hemisphere. The fact that plague microbes circulating in 
natural foci are surviving according to the law of nature in ecosystem, “survival of the fittest,” they 
are dynamic, diverse, resistance to environmental changes than strains stored in Laboratory, for 
research purposes. Thus, considerations must be taken in processes of developing an efficient, 
universally protective and safe vaccine. Vaccine developed based on single strains stored-freezed 
in laboratories for several decades, must be proofed in providing efficient protection against 
intraspecific diverse strains, which are known as virulent in experimental animal models. Current 
vaccine development against plague in Western hemisphere focus on two major immunogenic 
proteins F1 and V, and the success of new candidate vaccines are majored based on protection 
from challenges with limited strains, with less or no genetical and phenotypical variations and 
mostly the maternal strain from where the antigens are extracted. 
 
2.1.5 Mode of Transmission and Description of Disease 
 
Plague is primarily a zoonotic infection, a disease of rodents and their flies that can infect human 
commonly via bite of an infected flea. It is a very severe disease in people, with case fatality rates of 
50-60 % if left untreated (DENNIS. 1994, WHO. 2000). The most common mode of transmission of 
Y. pestis to human is by bite of infectious fleas. Less frequently, infection is caused by, a) direct 
contact with infectious body fluids or tissue while handling infected animal, b) inhaling infectious 
respiratory droplets or other infectious materials, e.g. laboratory-generated aerosols containing Y. 
pestis (fig.3). The classification of inhalation as less frequent is overlooked. The fact that plague 
outbreak in India (DENNIS. 1994) Madagascar (RATSITORAHINA et al. 2000) and recently 
Democratic Republic of Congo (WHO. 2006) were the pneumonic form, were fatal and the bacilli 
were isolated from cough droplets, which indicates out-coughed bacilli are contagious. Thus, 
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plague is a true respiratory disease and this route of transmission makes it a potential agent of 
biological weapon interest (DOMARADISKIJ. 1998). 
 
 
Figure 3. Y. pestis and its life cycle 
How plague is transmitted. The causative organism, the bacterium Yersinia pestis, has a rodent reservoir. The 
rodents' fleas, such as the oriental rat flea, Xenopsylla cheopis, acquire Y. pestis from a meal of infected blood, 
and transmit the bacterium primarily to other rodents or to humans, causing bubonic plague in people. 
Human-to-human transmission can also take place, through the human flea Pulex irritans. Pneumonic plague 
is less frequent but even more severe; it is transmitted from person to person through respiratory droplets, 
or even by artificially generated aerosols, containing Y. pestis.[cited 2008 Jun 12]. 2001; Data adapted from 
Cole and Buchrieser. Available from:<http://www.nature.com/nature/journal /v413/n6855/fig_tab/ 
413467a0_ F1 html>. 
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There are few reports concerning the possibilities of domestic animals in transmitting the 
infection. All most all of the literature concentrates on rodents. Nevertheless, in the south-western 
USA several human plague cases originated in cats and were transmitted via cat bite, scratch, or 
contact with infected body fluids, such as respiratory droplets (DOLL et al. 1994). Twenty-three 
cases of cat-associated human plague (5 of which where fatal) occurred in 8 western states from 
1977 through 1998 which represents 7.7 % of the total 297 cases reported in that period (GAGE et 
al. 2000). Experimental cats fed on plague-infected rodents and subcutaneous inoculation 
demonstrated that all were ill (WATSON et al. 2001). 3 out 13 reported cases of human plague in 
USA were transmitted by domestic dogs (CDC. 2006). A sudden death of an extended family of 12 
human deaths in March 1998 among the residents of a high-Andean community in Ecuador 
showed evidence of pneumonic plague. The family was believed to have an exposure to sick guinea 
pigs. Five of 14 dogs living in the community were tested seropositive for plague antibody 
providing evidence of a recent epizootic plague in the area (GABASTOU et al. 2000). Pneumonic 
plague outbreaks also played a great role in the Islands of Madagascar; family members of 18 
individuals died within two weeks (RATSITORAHINA et al. 2000). 
 
According to KUNIZA. (1997), analysis of various factors of 470 epidemiological outbreaks of 
plague , and single cases registered in the last 95 years in the territory of the former Soviet Union 
natural foci, showed that, next to the “portal type” of disease transmitted by rats, infected domestic 
camels known as “Utility Camel-type” and consumption of contaminated camel meat were 
responsible for about 81.5 % of the total outbreaks in summer-autumn season in this particularly 
investigated region. The role of domestic animals in transmition or as reservoir for plague microbe 
is not well investigated. 
Plague exists in natural enzootic cycles involving wild rodents and their fleas in certain regions of 
Asia, Africa, the Americas, and extreme south-eastern Europe near the Caspian Sea. The natural 
foci may be in apparent, with no transmission to human or associated with sporadic transmission 
to humans. Epidemic of plague occasionally occurs when the disease spreads from rodents into the 
populations of rats that live in human habitation (ANISIMOV et al. 2004). Because of the high case-
fatality rate and the epidemic potential of this disease, plague is designated a class I notifiable 
disease and thus is subject to International Health Regulations. These regulations require that all 
suspected cases must be reported to and investigated by public authorities and that confirmed 
cases are reported to the World Health Organization in Geneva, Switzerland. Maintenance of 
plague in nature is absolutely dependent upon cyclic transmission between fleas and mammals. It 
was known that, the oriental rat flea (Xenopsylla cheopis) alone, the classic vector for plague can 
ingest from 0.03 to 0.5 µl of blood what at least insures ingestion of 300 Yersinia pestis organism 
(HINNEBUSH and SCHAWA 1993). Based on animals data, at list 100 organisms are estimated to be 
infectious via the respiratory routes. Infection caused through aerosol, such as in case of 
bioterrorism, that causes a primary pneumonic plague, is the most feared and fatal form. In 1970 
the World Health Organization (WHO) analysis suggested that “in the worst-case scenario” The 
release of 50 Kg of Y. pestis as an aerosol over a city with five million inhabitants could results in 
150,000 cases of pneumonic plague, and the 360,000 of those affected would be expected to die. 
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The bacilli would remain viable as an aerosol for one hour for a distance of up to 10 Km. 
Inhabitants trying to flee would spread the disease further. These statements did not take into 
consideration of secondary cases that would occur subsequent person- to- person contacts and 
capability of causing pandemic. 
 
Y. pestis infection in human mainly occurs in one of three primary clinical forms. It can appear in 
human in bubonic (80-90 %), septicemic (10-13 %), and pneumonic (1 %) forms of primary cases 
(fig. 4). Pneumonic plague is the most deadly form of the disease, with an incubation period of 2-4 
days, fatal within 24 hrs if untreated (CHERNIN. 1989, WHO. 1992, 2000, CDC. 1992, DENNIS. 994). 
The classic disease in human bubonic plague, results from flea bite, or direct contamination of an 
open skin lesion by plague-infected material. Following inoculation, a local cutaneous proliferation, 
not usually clinically evident, ensues. In some cases, a vesicle, pustule, or ulcer develops at the 
inoculation site (POLLITZER. 1954, CAMPBELL and DENNIS 1998). The infection spreads via the 
lymphatics to the regional lymph nodes, causing inflammation and swelling in one or several nodes 
(buboes). Buboes may occur in any regional lymph node sites. After an incubation period of 2 to 6 
days, patients typically experience a sudden onset of illness characterized by headache, shaking, 
chills, fever, malaise, and pain in the affected regional lymph nodes and may not be clinically 
enlarged at this stage. Progression of symptoms is usually rapid with regional lymphadenitis 
becoming excruciatingly tender and painful (WHO. 2000, CDC. 2005).When a superficial bubo is 
not found in a patient suspected to be infected with Y. pestis, the primary lymph node involvement 
may be present in deeper areas of the body including mediastinal and intra-abdominal lymph 
nodes. In this latter circumstance, abdominal pain, suggestive of appendicitis, colitis, enteritis or 
cholecystitis may represent the patient’s principal complaint (BUTLER. 1983, HULL et al. 1986, 
1987, VON REYN et al. 1977, WHO. 2000). 
 
Primary septicemic plague is a progressive, overwhelming blood stream infection with Y. pestis in 
the apparent absence of a primary lymphadenopathy. The presence of rapidly replicating gram-
negative bacilli in the bloodstream initiates self-perpetuating immunological cascades typically 
linked to host response to severe injury; in this case, the agent inciting injury is bacterial endotoxin 
(ALBIZO and SURGALLA 1970). The host response may result in a wide spectrum of pathological 
events including disseminated intravascular coagulopathy (DIC), multiple organ failure (MOF), and 
adult respiratory distress syndrome (ARDS) (BUTLER. 1974, CROOK and TEMPEST 1992, WENZEL 
et al. 1996). Disseminated intravascular coagulation can lead to arteriolar thrombosis, hemorrhage 
in the skin, serosal surfaces, and organ parenchyma, and sometimes results in acral cyanosis and 
tissue necrosis (DENNIS et al. 1997). 
 
Primary pneumonic plague follows direct inhalation of aerosolised droplets containing Y. pestis, is 
thus, the infection of the lungs. It is the most fulminating and fatal form of plague. The incubation 
period is usually 1-3 days. Disease onset typically manifests by the sudden onset of chills, fever, 
headache, body pains, weakness, and chest discomfort. Cough, sputum production, increasing chest 
pain, difficulty in breathing, hypoxia and hemoptysis become prominent as the disease rapidly 
progress. Segmental pneumonia may progress to lobar pneumonia and then to bilateral lung 
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involvement and leads to respiratory distress syndrome. Pneumonic plague must be considered 
highly contagious whenever it occurs, person-to-person transmission, is reported in Madagascar, 
where seven male and one female died within 20 days. The source of infection resulted from their 
active participation in the funeral ceremonies and attendance on patients who died from 
pneumonic plague (HEATH. 1998, RATSITORAHINA et al. 2000, PERRY. 1997) 
Plague pharyngitis results from contamination of the oropharynx with the Y. pestis infection 
material, is clinically similar to streptococcal or viral pharyngitis. It is likely that the diagnosis can 
mislead until there is laboratory identification of the Y. pestis in a throat culture (CROOK and 
TEMPEST, 1992). Meningeal plague usually occurs a week or more after the onset of bubonic or 
septicemic plague. It is often associated with delayed, inappropriate, or bacteriostatic antibiotic 
therapy and is more common in patients with axillary buboes (BECKER et al. 1987, CIDRAP 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Plague clinical types: [cited 2007 May 23] Available from: <http://www.kcom.edu/ faculty/ 
chamberlain/website/lectures/lecture/plague.htm> 
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2.1.6 Potential as Biological Weapon 
 
Biological warfare agents are defined as “living organisms, whatever their nature, or infected 
material derived from them, which are used for hostile purposes and intended to cause disease or 
death in man, animals and plants, and which depend for their efforts on the ability to multiply in 
the person, animal or plant attacked” (SPENCER and WILCOX 1993). Many such agents are 
zoonotic and have a considerable impact in Human and Animal health. The plague microbe, Y. 
pestis is one of it, that can cause disease both through endemic exposure and as biological warfare 
agent. Plague has a long history to be used as biological weapon, possibly the first known biological 
agent in human history. Plague is known for its notorious pandemic waves world wide throughout 
human history and transmitted by flea vectors such as deliberate spreading diseases through 
arthropods, the so called the vector effect of biological warfare (WHEELIS. 2002). Its modern 
application in warfare started in 1930s with Japan (INGLESBY et al. 2000). Germany and Soviet 
Union also conducted their investigation in this area around the same time (KIRBY. 2005, 
GEISELLER. 1998). During WWII, a secret branch of Japanese army, Unit 731, is reported to have 
dropped plague-infected fleas over populated areas of China and conducted researches on human 
in occupied Manchuria under the cover of research units named by General Ishrii Shiro (HARRIS. 
1997). One of Ishii’s greatest achievements was his use of the human flea Pulex irritans, as a 
stratagem to simultaneously protect the bacteria and target humans. This flea is resistant to air 
drag, naturally targets, and human flea can infect a local rat population to prolong an epidemic. 
Infected fleas may regurgitate up to 24,000 organisms in a single feeding (KIRBY. 2005). The 
experimental studies of this observation were done on prisoners as a final target to know, how 
effectively, can a human be infected with plague from fleas and pathological investigation, 
autopsies were conducted on some plague victims, even while they were still alive (GAGE and 
KOSOY 2005, KIRBY. 2005). The Japanese apparently used plague as a biological warfare agent in 
China several times during World War II. In any event, in the words of Pentagon analyst Andrew 
Weber quoted by ORENT. (2004), in comparing Japanese activities, it should be remembered that 
the Soviet or USA bioweapons researchers “never killed anybody”. There are degrees in 
bioweapons work as in anything else: none of the Americans or Russians bioweapon scientists can 
be compared to the Japanese who worked on the infamous Units in Manchuria. They worked with 
human subjects on diseases that range from antharx to yellow fever. They researched human 
reactions to plague, typhoid fever, paratyphus A and B, smallpox, tularemia, glanders, tetanus, 
cholera, scarlet fever, tuberculosis, salmonella and other countless diseases that were endemic to 
the communities and surrounding region. No one has been able to catalogue completely all the 
maladies that the various death factories in Manchuria did on human guinea pigs. Testing 
pathogens on humans was only a single chapter, albeit a major one, in Ishii’s BW enterprise, other 
secret research carried out by him and his associates had the two fold purposes of determining: 1) 
methods of culture of biological warfare agents; 2) methods of dissemination of plague, anthrax 
and glanders. They were also engaged with pathogens that kill plants and animals (CAUDLE III. 
2007, BELLAMY and FREEDMAN 2001) and the actual number of people who died in Ishii’s 
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bioweapons attacks and experiments from the year 1931-1945, in different locations will never be 
known, but the toll of the dead may have reached millions interviews and written reports found in 
boxes after Japan surrender contained autopsy reports that cover glanders, plague and anthrax in 
length from 350 pages to more than 800 pages (HARRIS. 1997, GEISSELER. 1998).  
 The Canadian’s worked in ways different from others, developing biological weapons at Canada’sf 
Grosse Ile- a secret germ warfare research facility-labored to produce Anthrax for allies during the 
WWII. The intent was to create a colony of fleas for use in combination of with both plague and 
murine typhus. This concept of using a single vector to spread two different diseases 
simultaneously was an innovative approach, and was titled as “Entomological warfare” 
(USAMIID’S. 2004, KIRBY. 2005).  
 
2.1.6.1 The Soviet Biological Warfare and the Anti-Plague System 
 
The USSR possessed a unique national public health system that included an agency named “Anti-
Plague Institute.” Its mission was to protect the country from highly dangerous diseases of either 
natural or laboratory acquired infections. The predecessors of the Soviet API, called Special 
Commission for the Prevention and fighting against Plague entitled (KOMCHUMA), as well as 
research institutes specializing in the studies of plague and cholera that occurred in various 
regions of the empire, experimental and field laboratories engaged with epidemiological 
surveillance, security, quarantine activities were established during the Tsarist period of Russian 
empire (ONISCHENKO et al. 1999). 
 
The Soviet API has also passed through two eras: the “classical” era (1928-1972) and the “modern” 
era (1973-1991). The USSR, like other nations supported offensive BW programs during this time, 
used the “classical” microbiological techniques of mutation, selection, and propagation to 
weaponize pathogens such as, Y. pestis, B. mallei, B. anthracis, F. tularensis Rickettisia prowazekii, as 
well as viral diseases such as Crimean-Congo haemorrhagic fever by UV light, X-rays or chemical 
agents most efficiently after WWII (OUAGRHAM-GORMLEY 2006, OREINT. 2004, NARKEVICH. 
1991). The main task of the APS in this period was mainly to discover plague natural foci, 
identifying the main carierries classified as primary, secondary and random carriers and 
developments of methodology of epizootics, new treatment and developments of vaccines against 
plague, typhus, cholera, brucellosis, anthrax and tularaemia (WESTERDAHL and NORLANDER 
2006, DOMARADSKIJ and ORENT 2006, FRISCHKNECHT. 2003). 
 
The FSU BW facilities consisted of, a system under military control and the second top-secret 
programmes under civilian cover, called “The Biopreparat complex”, a new network of BWP, began 
in the early 1970 (CNS. 2002). Another group of facilities worked on microbial agents harmful to 
livestock and plants, one of such facilities was, the Scientific Research of Agricultural Institute in 
Kazakhstan (NISKHI) established in 1958. These facilities were administered by the 15th 
Directorate for Biological Protection of the Soviet Ministry of Defense; Fvozrozhdeniye Island in 
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the Aral Sea was the main testing ground for biological agents developed at Ministry of Defense 
(RIMMINGTON. 1996). Leading Bioprepart facilities included the State Scientific Center of Applied 
Microbiology in Obolensk, the Institute of Immunological Studies in Lyubuchany, the State 
Scientific Center of Virology and Biotechnology (known as Vector), to note some of the prominent 
establishments. In addition to the aforementioned centers within the offensive part of the Soviet 
BW program, other facilities were involved mainly in prophylactic and vaccine developments (CNS. 
2002). 
The system of Anti-plague research institutes and field monitoring stations under the authority of 
the Main Directorate of Quarantine Infections of the USSR Ministry of Health include the Microbe 
Scientific Research Anti-Plague Institute in Saratov, the Rostov Anti-Plague Institute, The 
Volgograd Scientific Research Anti-Plague Institute and the Irkutsk Anti-Plague Institute for Siberia 
and the Far East (OUAGRHAM-GORMELY. 2006). The establishments were located in different 
regions of the territory and exchanges of top-ranking specialists between the Anti-plague institutes 
and offensive BW facilities, their participation in some offensive BW program cannot be ruled out 
(ZILINKAS. 2006, ALIBEK. 1999). 
 
Some of the worlds leading experts on pathogens of BW importance in FSU like Igor V. 
Domaradiskij, K. Alibek, L. Melinkov, Sergei Popov, and other prominent scientists of the Soviet 
bioprogram studied plague, anthrax, tularemia, brucellosis, typhus, Q-fever, smallpox, botulinum 
toxin, Venezuelan Equine Encephalitis, and other viral infections their causative agents were 
designated as “the dead list pathogens” in Obolesk, Vector, Saratov, and other similar research 
institutions, located in the territory of FSU (DOMARADSKIJ. 1998, OUAGRHAM-GROMLEY et al. 
2006, ALIBEK. 1999, 2003). The experiments were conducted on horses, monkeys, sheep, and 
donkeys, and on small laboratory animals such white mice, guinea pigs, and hamsters. Lev 
Melinkov, one of the plague expert, in the FSU, who worked at Saratov Microbe Institute quoted by 
ORENTS (2004) said, “The Soviets are born to research on plague”. Indicating a large number of 
highly competent expertise commitment and main concern in plague research at the state level. It 
is also known that, the territory of FSU includes one of the world’s most virulent reservoirs of the 
plague pathogen “hot-spot”, with high intraspecific diversity in quantity and quality in the world 
documented through extensive years of research, monitoring and control of plague disease 
outbreak by API experts including the neighbouring countries like Mongolia (ANISIMOV et al. 
2004, ONISCHENKO et al. 2004). 
 
In the FSU there were two faces of plague work, the plague fighters and the plague engineers, those 
who worked to make plague a weapon and those who combat the endemics in the region. The main 
achievements of the experts in offensive area were, genetical modification of the pathogens, so that 
they will be resistant to vaccine and/or antibiotic treatment and development of vaccines. 
Sometimes these two faces belonged to the some person. Igor Valerianovitch Domoradskij, 
specialized in microbiology, had been deputy director of the Interagency Science and Technology 
Council on Molecular Biology and Genetics, the “brain center” as Domaradiskij puts it–of the entire 
Soviets’ program. The council designed the overall aims and methods of the Soviet bioweapon 
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system. He discovered the methods of detecting plague through plague phages that promotes him 
to be a deputy director (ORENT. 2004, DOMARADSKIJ and ORENT 2006). 
 
In the mid 1960th the Anti-plague Institute at Rostov, where Domaradiskij made his investigations 
was shifted its emphasis from basic research to biodefense under orders from Moscow, the Soviet 
called it problem No.5. He also developed a “dry” plague vaccine using a live strain of Y. pestis. This 
vaccine has an additional property of being able to withstand antibiotics, so that in an emergency it 
could be given concurrently with antibiotics. His team also discovered that in the plague microbe a 
foreign plasmid can be introduced, whereby the bacteria requires a new properties including 
antibiotic-resistance (CBW. 1998). In the year 1979, Domaradskij’s major scientific discovery was 
that Y. pestis not only could accept foreign plasmids, but had three native plasmids of its own. This 
novel discovery was kept as the secret of secrets, which was never published outside the closed 
world of Biopreparat system. The discovery of plasmids was to revolutionize the study of the 
plague, mainly for military purpose. Plasmid as it is known as a working horse molecular 
biotechnology; this discovery was a triumph of high degree for the plague experts (ORENT. 2004, 
DOMARADSKIJ and ORENT 2006). Three years later, FERBER and BRUBAKER (1981), the 
distinguished American plague researcher first published their discovery of plasmids. 
 
The “modern” era of the Soviet BW activities began right after the discovery of DNA technolology, 
which stimulated the Soviet government to increase its own efforts in the field of biotechnology 
including applications of military purposes (ALIBEK and HANDELMAN 1999, ORENT. 2004). Two 
major offensive institutions codenamed “Ferment” and “Ekology” were established. Ferment was 
directed at solving problems related to weaponizing pathogens for the use against human, while 
Ekology was programmed to develop against animals and plants (ZILINISKAS. 2006). Gene 
engineered strains of B. anthracis resistant to tetracyclines and penicillins were also reported in 
Russia (STEPANOV et al. 1996, ALIBEK. 1999). 
 
On 10 April 1972, the Convention on the Prohibition of the Development, Production and 
Stockpiling of Bacteriological (Biological) and Toxin Weapons and on their Destruction was opened 
for signature. It entered into force on 26 March 1975, after the deposit of the instruments of 
ratification by 22 signatory governments, including the governments of the Soviet Union, the 
United Kingdom and the United States as well as seventy-seven countries, which bans the 
development, production, use and stockpiling of BW agents. But research and development 
continued in FSU (MDN. 2004). Three years later Domaradskij and Zhadanov (the famous smallpox 
eradicator) developed a plan levelled the Five Principal Directions, which established the future 
course of biological weapons research. Genetic modifications of existing strains were at the heart 
of this program: viruses and bacteria modified for great virulence, stability, durability in external 
environment, and genetic resistance to vaccines and antibiotics (ORENT. 2004, ONISHENKO et al. 
1999). In particular, they envisioned adding short chains of proteins, or peptides, to bacteria and 
viruses, which create diseases with entirely new and different symptoms, and which would make 
the infections more difficult to diagnose and treat (WESTERDAHL and NORLANDER 2006). They 
planned to divide this work up among many different institutions, some of which would 
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concentrate on basic research, and others which may assign to work directly on highly dangerous 
infections. Head of these laboratories were “Vector” and “Obolensk” (CNS. 2002; ORENT. 2004) 
 
Vector Laboratories, built by convict labor in 1974, is a gigantic complex, dedicated to research on 
viruses, it was the USSR’s principal fiefdom for bio-weapons research on viruses until 1992. 
Obolensk was the chief bacteriological weapon laboratory, which had a close connection with 
Kirov military laboratory, also specialized in highly contagious bacteria (CBW. 1998, WARRICK. 
2002).The Soviet cover was partially blown in 1979 when a massive outbreak of anthrax affected a 
large area around the Ural city of Sverdlovsk where at least 96 people were infected and 66 people 
died. The true figures, no doubt, are higher (MESELSON et al. 1994, CBC. 2004, WILKENING. 2006). 
 
By the late 1970s, the system was composed of 87 facilities engaged in disease surveillance, 
research, production and testing of vaccines and laboratory equipment, and training of civilian and 
military personnel. The system employed a staff of 14,000, including 7,000 scientists whose 
expertise broadened beyond plague to other endemic zoonotic diseases, such as anthrax, 
brucellosis, tularemia, and Congo-Crimean hemorrhagic fever. Most importantly, the Anti-plague 
system stretched beyond Russian borders into Central Asia, the Caucasus, Ukraine, and Moldova, 
with facilities strategically located in 11 republics (OUAGRHAM-GROMELY et al. 2006). 
 
Plague has always been the favourite bacterial weapon of the Soviet military - as Domaradskij puts 
it, after an initial bioweapon attack, “plague spreads from man to man, and further effort on the 
part of military is not necessary”. He found himself in endless, relentless conflict with Urakov. In 
1987, Domaradskij left Obolensk, where he spent twenty-three years in the anti-plague system of 
the Soviet Union (DAMARADISKIJ and OREINT 2006). A year before Domaradiskij left Obolensk 
Sergi Papov, who now works in Virginia, USA, was brought in from Vector at Novosibirisk to do 
genetic engineering experiments on plague and other pathogens. As papov puts it quoted by Orent 
“plague was already a king in Obolensk. Hundreds of scientists studied plague in several of the 
institute’s departments. The microbe was encoded as Agent NO.1 on the secret list of bacteria used 
to make biological weapons”. Papov and his teams, biochemists and virologists, were engaged in 
synthesizing the DNA to produce peptides from various human immuno-chemicals for eight years 
and inserted them in to mouse poxvirus and vaccina virus, stands-ins for smallpox virus, capable of 
regulating production of other proteins in artificial viruses. These were feats of almost 
unimaginable complexity; such experiments showed that, at least in theory, viruses could be 
genetically altered to express new, unexpected, and deadly properties. He also inserted 
synthesized DNA sequences into plasmids that could be delivered directly into the cytoplasm of the 
microbe’s cells, which were designed to yield a variety of effects, including terrifying new forms of 
plague, anthrax, glanders, legionella, and tularemia (OUAGRHAM-GROMMY. 2006, ALIBEK. 1999, 
CBC. 2004, POPOV et al. 1997) 
 
A patient infected with these genetically altered plague strains would first contract what appeared 
to be a typical pneumonic plague infection, immediate treatment with appropriate antibiotics, 
which would cause the plague bacterial cell to break apart. The patient might appear to recover, 
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but within the body, the dying bacteria release their cargo of artificial peptides, which in turn 
would cause paralysis, tachycardia and finally dies from heart stroke or fatal paralysis, which the 
scientists called “Recombinant Plague” (WESTRDAHL and NORLANDER 2006, DOMARADISKJI and 
ORENT 2006). Another scientist, Sergei Netesov, Department director of Vector laboratories, was 
known as the originator of the whole concepts of chimeras: genetically engineered viruses made of 
two component parts – for instance smallpox and Venezuelan equine encephalomyelitis (VEE), 
smallpox and Ebola, that had promoted him to depute director of Vector in Novosibirsk. The name 
of the program he directed was known as ΟΧΟΤΗИК (okhotnik-hunter). He proposed Plague–VEE 
chimera, the object being, a victim of this chimera would be treated for plague with appropriate 
antibiotics, which would kill the plague microbe. But shattering the bacteria cell walls would 
release VEE directly into the lymph node or bloodstream; then straight to the brain, the victim dies 
of encephalitis and the “Okhotnik project was successful” Netesov and Popov quoted by ORENT 
(2004). Papov remained in Obolensk until 1992. Another study was very surprising and far more 
ominous. When they tested their Plague-diphteria chimera on monkeys, they found that it could 
overcome immunity to live plague vaccine. In other words, the new plague chimera was, at least to 
some extent, not only lethal at the lower doses than normal weaponized plague but also vaccine-
resistant. A hyper-lethal, vaccine-resistant, antibiotic-resistant plague weapon would be the most 
powerful biological weapon of all- a veritable Andero-meda Strain, a Black Death for the twenty-
first century. There is no reason to think such a weapon has ever been made. However, the 
technology may now exist to produce it. 
 
In the United States, the main biological weapons threats are considered smallpox and anthrax. 
Nevertheless, the Russians believed that plague is the most dangerous bacterial threat agent. As 
anthrax and plague genomics expert Paul Keim of the Northern Arizona University puts it, the 
Russian and U.S. biodefense programs are like mirror images of each other: we fear anthrax, since 
both lethal and extremely durable in the environment, and they fear plague, for its virulence and 
transmissibility (DOMARADIKJI and ORENT 2004). 
 
Since the mysterious anthrax attacks in late September 2001 in the United States, it was proofed 
anthrax contamination can spread throughout the building, and how difficult it is to decontaminate 
the area to remove the spores. But anthrax does not spread from person-to-person, probably 
because anthrax is not a true pulmonary infection. It can seed in itself in the lungs, but soon it 
moves to the lymph nodes and the chest. You can’t cough it out in a contagious form: coughing 
produces big droplets, which can’t be inhaled, and the bacteria in any event are in the vegetative-
growing-state and are not infectious. Only spores are infectious. Plague is a very different disease 
from anthrax: the chief danger from plague, aside from lethality, is its ability to spread. Unlike 
anthrax, it grows in the lungs; it produces infected sputum; it is coughed out and transmitted from 
person-to-person, lung to lung. Coated in sputum in some manners, as bacteria naturally are, when 
they are coughed out, it becomes more stable in the external environment (not stable as anthrax), 
but stable enough, it can last for weeks on many surfaces under certain conditions and remain 
infectious. Plague in a frozen corpse can remain alive almost indefinitely. 
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The majority of bioweapon publications are concentrated on humans as a target “Anti-livestock” or 
“Anti-agriculture” weapons are less studied and published. But they can wreak economic havoc 
and even undermine a nation’s ability to feed itself. Under the Soviets, as many as six agricultural 
research centers and up to 10,000 scientists and technicians were believed to have been devoted 
to developing them, working under a shroud of secrecy that persists today and complicates efforts 
to keep dangerous materials. This facility is believed to posses more than a dozen viruses, 
including, foot-and mouth-disease (FMD), Newcastle, targeted to livestock and poultry production 
respectively (ONISCHENKO. 2003, ISTC. 2008). 
 
Quiet a few of the best specialists of bioweapon program of the FSU made their way to the west 
and shared their awareness, talked and wrote their memories about the danger of the activities in 
which they were engaged for several decades, with deadly pathogens. To note some of them like, 
Popov defected to UK, Alibek to USA, who was the former first Deputy Director of Biopreparat from 
1988 to 1992, he was famous for his methods of weaponizing anthrax and in his interview said 
“The Soviet Union has two main directorates responsible for developing and manufacturing 
biological weapons were stored at the Minster of defense facilities, for example [the] Kirov facility 
was responsible for storing plague, about 20 tons of plague” (ALIBEK.1999, BARRY. 1993). 
In Todays Russia, the system consists of five research institutes (in Volgograd, Saratov, Stavropol; 
Rostov-on-Don and Irkustisk), 11 stations and 14 units in operation and in natural disease foci 
(ONISCHENKO. 2003). A unique system to control deadly endemic diseases and to prevent the 
importation of exotic pathogens from other countries that could threaten human populations, 
livestock, and crops under the institution designated “Anti-Plague System.” APS is the only one in 
its kind that operated for more than a century, is one of the achievements of the FSU 
(DOMARADISKIJ and ORENT 2006, ZILINSKAS et al. 2006) where the word “plague” was used 
broadly to refer to infectious diseases causing high morbidity and mortality. The threat of BW has 
increased in the last two decades, with a number of countries working on the offensive use of these 
agents. There are more than 10 countries around the world suspected to have offensive biological 
weapon programs (USAMRIID’S. 2004).  
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2.2 Burkholderia mallei  
 
B. mallei, is a gram negative bacteria, that causes glanders, one of the oldest documented infection 
among solipeds recognized since Ancient Greece (LOEFFLER. 1886, BERSTEIN et al. 1909) 
Currently about 41 species of Burkholderia have been identified based on DNA-DNA homology, 
base sequence of the 16S rRNA, and various phenotypic characteristics (YABUUCHI et al. 1992, 
DSMZ. 2008). Although most species of Burkholderia are saprophytes or plant pathogen, two 
species, namely B. pseudomallei and B. mallei, cause serious and fatal diseases (DANCE. 1998), both 
are, nonsporing, bacillus with a “safety-pin” appearance using Methylene Blue or Wright’s stain on 
microscopic examination (ASHDOWN. 1979, HPA. 2003, BOSSI et al. 2004). B. mallei is obligate 
pathogen, strict aerobe, catalase-negative, usually oxydase-positive, non-motile. Primary culture 
isolates require 48 hrs at 37.5 °C under aerobic conditions. In contrast, recent comparative 
genomic sequencing of B. mallei C-5 bacterial culture collection of SRCAM (Russian), originally 
isolated from horse corpse in Mongolia in 1967, and B. pseudomallei–141 isolated from patient in 
Vietnam in 1948 showed a great genome-wide intra- and interspecies variability. At the some time 
this investigation showed a high heterogenity in B. pseudomallei species, a low but detectable 
variability in B. mallei species (FUSHAN et al. 2005). The revealed differences included some 
putative virulence factors, new insertion sequences and a gene cluster of B. mallei that encodes 
proteins involved in the biosynthesis, export and translocation of capsular polysaccharide. The 
capsule has been described as a major virulence factor required for the genesis of glanders in 
animal model (DESHAZER et al. 2001).  
The genome of B. mallei consists of two circular chromosomes and is found to be smaller than that 
of B. pseudomallei, 5.8 Mb and 7.2 Mb, respectively (NIERMAN. 2004). In similar fashion, B. 
pseudomallei has been characterized to be a strong secretor of proteases, lipases and phosoplipalse 
C via the secretory pathway (DESHAZER. 1999) although there role is not well known, whereas B. 
mallei was recently reported poorly secretes these protein, if at all (NIERMAN et al. 2004). 
Most naturally occurring human cases of glanders result from close contact with infected animals 
or the agent itself for instance in laboratory. It may be more communicable than melioidosis. The 
infection dose of both organisms for humans is not known. One reported human case of glanders 
infection described on 5th of May, 2000, was a microbiologist working with pathogen at the 
USAMRID, Baltimore, USA, treatment with ceftiaxone and cephaexin did not improved the 
conditions of the patient. That indicates that B. mallei is capable to resist a number of antibiotics 
and able to relapse despite completing the therapy (CDC. 2000, SRINIVASAN et al. 2001). 
 
For both pathogenic Burkholderia organisms, it is likely that the natural mode of transmission is 
mainly by inoculation into small abrasions. Infection by inhalation also occurs, and is the most 
likely route by which infection will occur following deliberate release, i.e., bioterrorism. There is 
circumstantial evidence that glanders may be acquired by ingestion. This is less convincing for 
melioidosis, although two recent outbreaks in Australia were linked to contaminated potable water 
supplies (INGLIS et al. 2001). 
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Glanders is one of the oldest documented disease of solipeds caused by B. mallei (LOEFFLER. 
1886), but incidental infection also occurring in humans, carnivores and wild animals 
(MCGILVRAY. 1944; ALIBASOGLU et al. 1986). It is still endemic in parts of Africa, the Middle East, 
South and East Asia, Central America, and parts of some of Countries of FSU like in Kazakistan 
(MOTA et al. 2000, WAAG and DESHAZER 2005). 
 
It can cause a subcutaneous infection known as farcy or can disseminate to cause the condition 
known as glanders. In humans, four forms of glanders are seen. The local cutaneous form, if the 
skin was the portal of entry. Pulmonary form, if the organism was inhaled, septicemic form if the 
organism is in circulatory system and the chronic form. The acute infection is characterized by 
necrosis of the trachobronchial tree, pustular skin lesion, and either a febrile pneumonia, or signs 
of sepsis, and multiple abscesses (DIADISCHEV et al. 1997, CDC. 2000; 1992; CFSPH. 2007). The 
generalized symptoms of glanders in humans include fever, muscle aches, chest pains, muscle 
tightness, headache, night sweat, weight loss e.t.c. (SRINIVASAN. 2001). 
 
There have been too few human cases of glanders in the post-antibiotic era to make an accurate 
estimate of case-lethality. Some estimate that glanders is in over 50 % of the cases fatal despite 
antibiotic treatment and other say it may be similar to that of melioidosis, which is indeed 50 % of 
the cases, as well. Without treatment there is a 95 %-100 % fatality rate with all forms of glanders 
(CFSPH. 2007) and can be reduced to 20 %, if appropriate diagnosis is confirmed and treated very 
early (CRAVITZ. 1950, NEUBAUER et al. 1997). 
 
There are several reports that describe in vitro susceptibility of B. mallei to antibiotics (HEINE et 
al. 2001, KENNY et al. 1999, BATMANOV. 1991, RUSSELL et al. 2000). These studies generally 
demonstrate most B. mallei strains exhibit resistance to first class antibiotics. Experimental 
treatment of golden hamster with seven highly effective chemotherapeutic agents against B. mallei 
showed no protection, none of the experimental animals survived (BATMANOV. 2001). Similar 
results were seen, in treatment of golden hamster with four highly effective antibiotics against a 
high dose of aerosol infection with B. mallei that did not protect the animals (ILYUKHIN et al. 
1994). Although, there is little evidence on antibiotic treatments of glanders diseases in Human, 
some authors propose, that B. mallei might have the same characteristic of multi drug-resistant 
(MDR) as its’ very closely related species of B. pseudomallei. B. pesudomallei is well known for its 
MDR and relapses after appropriately successful primary treatment of melioidosis patients and 
MDR in vitro studies are also not uncommon (BATAMANOV. 1997, DANCE et al. 1989a, 
LEELARASAMEE and BOVORNKITTI 1989). 
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2.2.1 Infection, Epidemiology and Transmission 
 
B. mallei is a host-adapted pathogen that does not persist in nature outside its equine host (HOWE. 
1950). It is primarily noted for producing diseases in horses, mules, and donkeys. In the past man 
has seldom been infected, despite frequent and often close contact with infected animals? This may 
be the result of exposure to low concentration of organisms from infected sites in ill animals and 
because strains virulent to equids are often less virulent for man. The clinical courses of glanders 
include fever, rigors, nasal discharges, fatigue, weight loss, decreased appetite, dyspnoea 
(SRINIVASAN et al. 2001, LOPEZ et al. 2003). 
Human cases have occurred primarily in veterinarians, horse and donkey caretakers, and abattoir 
workers. It is also reported as a laboratory-acquired infection in human (CDC. 2000, CHRISTOS and 
ELLIOT 2001). Glanders also has been reported in carnivores that have fed on infected horse 
carcasses. Infection of four lions at Safari park in Napoly, Italy (BATTELLI et al. 1973, GALATI. 
1973) was attributed to ingestion of contaminated meat from imported horses. ALIBASOGLU et al. 
(1986) assumed also that feeding infected raw horsemeat was the cause of an outbreak of glanders 
in lions at Istanbul Zoo. Glanders was an important cause of death among horses at the turn of 20th 
century. The elimination of equine glanders from Western Europe and North America was 
achieved by rigorous slaughter policy and aggressive control measures (FAO. 1997). However, it is 
assumed that it is endemic in many developing countries (KNIGHT. 1972). Glanders is currently 
limited to parts of Asia, Africa, the Middle East, and Asia (specifically Turkey, Syria, Iraq, Iran, 
Pakistan, India, Burma, Indonesia, the Philippines, China, and Mongolia) and possibly the Balkan 
states, former Soviet republics, Mexico, and South America (ARUN et al. 1999, RAY. 1984, STELLE. 
1979, VAID et al. 1981, VERMA. 1981). Cross-reactions with serological tests for B. pseudomallei  
may confound estimates of worldwide distribution.  
 
Human glanders can be acute, leading to a rapid decline in respiratory function, and if untreated, is 
nearly fatal. It is characterized by necrosis of the tracheobronchial tree, pustular skin lesions either 
a febrile pneumonia, if the organism was inhaled, or signs of sepsis and multiple abscesses if the 
skin was the portal of entry (SANFORD. 1991, JENNINGS. 1963). The preclinical stage of the human 
form lasts from 2 to 8 weeks and shows only constitutional symptoms. If it is not properly 
diagnosed in this stage it might mimic tuberculosis or syphilis (nonclinical glanders or “farcy”) that 
can afflict patients throughout their lives (MCGILVARY. 1944, CDC. 2000). Despite the efficiency of 
spread in the laboratory setting, there is no epidemic of human glanders reported. It can spread to 
man by invading the nasal, oral, and conjunctival mucous membranes, by inhalation into the lungs, 
and by invading abraded or lacerated skin. Aerosols from cultures have been observed to be highly 
infectious to laboratory workers (LEVER et al. 2003). Aerosol spread is efficient and there is no 
available vaccine or reliable therapy. 
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Intracellular confinement and persistence of B. mallei or B. pseudomallei cells, and their high 
virulence impede treatment of glanders and melioidosis (JONES. 1996, SHARMA. 2001). A 
comparative assessment of anti-bacterial preparations against experimental melioidosis, found 
that growing recurrence of melioidosis is connected with persistence of B. pseudomallei in the 
bodies of laboratory animals as L-forms, which retain their pathogenic properties and may reverse 
into the initial bacterial strain. It was proven that in case of melioidosis, carriage of L-forms in 
macroorganisms is accompanied with the development of delayed types of hypersensitivity (DTH) 
(BATMANOV et al. 2001), that might be also the case in B. mallei as well. Recently the presence of 
TTS (type three secretion) genes in pathogenic Burkholderia species is suggested to have a link to 
virulence are important to elucidate the contributions of TTS to virulence in these organisms 
(WINSTANLEY. 2000). 
 
2.2.2 Multidrug Resistance 
 
At present information on the effective treatment of human infection due to Burkholderia mallei 
with antibiotic is sparse. It is believed to have similar characteristics to the very closely related B. 
pseudomallei. Humans are accidental hosts of B. mallei. The majority of natural cases have been the 
result of occupational contact with infected animals (stablemen, veterinarians and slaughterhouse 
employees) (STEELE. 1979). One recently reported case of a human infection; a patient who 
worked with the agent was treated with cetriaxone (im). Ten days course of cephalexin did not 
improve the situation of the patient. Then after isolating the agent intravenous application of 
imipenen and doxcycline improved his symptoms rapidly (CDC. 2000, SRINIVASAN et al. 2001). B. 
mallei is regarded as the most dangerous microorganism to handle in the laboratory. Experimental 
treatment of golden hamster with 7 highly effective chemotherapeutic agents, like monocyclin, 
doxycyclin, ciprofolxacin, ofloxacin, biceptol, sulfatan, and rimapcin showed no protection, when 
the animals were infected s.c. with 100 LD50 or aerosol with 160 LD50 with B. mallei C-5 virulent 
strain. None of the experimental animals survived (BATMANOV, 1997). Burkholderia spp. are able 
to survive within phagocytic cells, exhibits mechanisms of resistance against the immune system of 
the host (PRUKSACHA TVUTHI et al. 1990). 
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2.3 Burkholderia pseudomallei 
 
The causative agent of melioidosis, B. pseudomallei was first recognized in 1912 by WHITEMORE 
and KRISHNASWAMI in Rangoogn as a glanders-like disease, motile organism due to its 
multitrichous polar flagellae in contrast to B. mallei, which is nonmotile organism that lacks flagella 
(MILLER et al. 1948, BOSSI et al. 2004), the reason why B. mallei is non-motile is not well studied, 
yet its genome contains numerous flagellar and chemotaxis genes, most of which appear to be 
intact, but recent comparative genomic analysis within three Burkholderia spp. made by NIERMAN 
et al. (2004), showed, that one methyl-accepting chemotaxis gene has a frameshift mutation. In 
addition, a 65-kb insert flanked by IS elements disrupts the filp gene, an essential gene for 
flagellum biogenesis (MALAKOOTI et al. 1994) and a frame shift mutation in the flagellum motor 
motB may the reason for amotility and missing flagellation. The DNA-DNA homology value 
between B. pseudomallei and B. mallei has been reported to be more than 90 %, and the sequences 
of the 16S rRNA of the two species matched completely (BAUERNFEIND et al. 1998). 
B. pseudomallei is a facultative aerobic, opportunistic pathogen, catalase-negative and mostly 
oxidase-positive grows aerobically at an optimal temperature of 37 °C - 42 °C, Cultures have 
earthy/grape odour, which can be detected when the incubator is opened (HPA, 2003). In nature B. 
pesudmallei can survive with in a temperature ranging from 4 °C– 43 °C in water and soil for 
prolonged period without any form of nutrient and is tolerant to range of adverse environmental 
conditions such as low pH. The incubation period of the organism is unclear, but ranges from 2 
days to 26 years are recorded (LEELARASAMEE and BOVORNKITTI 1989). The DNA of B. 
pseudomallei has a higher molar percentage of guanine and cytosine (G+C) residue of 68 % and 
spontaneous transformation has also been found in B. pseuodomallei (HOWE et al. 1971). 
 
An Environmental isolates previously considered to B. pseudomallei have been shown to fall into 
two closely related groups on the basis of there abilities to assimilate arabinose and show 
differences in there DNA macrorestriction patterns and rRNA sequences (BRETT et al. 1997, 1998, 
SMITH, 1997, TRAKULSOMBOON. 1997). Those that can assimilate arabinose (ara+) have been 
assigned a new species, B. thailandensis, and are considered as avirulent, whereas the isolates that 
cannot assimilate arabinose (ara-) and are associated with melioidosis are retained within the 
species B. pseudomallei (BRETT et al. 1997, SMITH. 1997). Although, there are numerous 
correlations between virulence and disease presentation in melioidosis patients, it is not a 
consistent observation. Virulence did not correlate with the origin of isolation (i.e. clinical vs. 
environmental), since numerous ara- environmental isolates were highly virulent. That indicate 
virulence of selected B. pseudomallei isolates is variable, being dependent on environmental factors 
such as iron bioavailability, inoculum size and host risk factors in determining the clinical severity 
of melioidosis (ULETT et al. 2001). The genomic DNA from 22 isolates of B. pseudomallei obtained 
from clinical cases and soil habitats in Malaysia demonstrated high heterogeneity (HASSAN. 2001, 
BULANTSEV and LOZOVAIA 1985) and similar results were also observed in Thailand, in a 
comparative analysis of 371 clinical and 206 soil isolates (SERMSWAN et al. 2001). 
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B. pseudomallei, infects human, domestic and wild animals and is regarded as endemic to the 
southeast Asia and northern Australia, corresponding to the tropical latitudes between 20° N and 
20° S (fig. 5) and currently melioidosis is categorized as an emerging disease. It has only been 
studied in small number of countries i.e., Australia, Thailand, Singapore and Malaysia; but it is 
assumed to be widespread in tropical South East Asia (DANCE. 1991, 2000, 2001, CHENG and 
CURRIE 2005). There is evidence that the disease might be endemic on the Indian subcontinent 
and in some states of Caribbean countries, and there have been reports from South Africa and the 
Middle East. There have been occasional reports of cases of melioidosis in temperate countries, 
including an outbreak in France in 1970 (MOLLARET. 1988) and travellers, military personells 
served in endemic regions and reported cases were imported from tropical areas (ALDHOUS. 
2005).  
 
There are reported instances of person-to-person spread of melioidosis, prenatal transmission 
from mother to child that caused abortion, cases of infection through sexual contact with patient 
among chronic prostatitis (ABBINK et al. 2001). Infection can be acquired in the laboratory 
(MCCORMICK et al. 1975) and Siblings with cystic fibrosis who immigrated from Australia to New 
Zealand were believed to be infected by person-to-person transmission (HOLLAND et al. 2001), 
nevertheless the infection is not highly communicable. 
 
The clinical spectrums of melioidosis are protean, can manifest as disseminated or localized 
disease. In disseminated form, it is characterized by an acute and progressive course with 
septicemia and shock, with acute respiratory failure often develop into adult respiratory distress 
syndrome (ARDS) (MANEECHOTESUMWAN. 1999). In a localized form, it is usually associated with 
lung, liver, spleen lymph nodes, urinary tracts, or muscles (WHITE. 2001). Cases with localized 
cutaneous or subcutaneous abscesses or lymphadenitis can also manifest. Neurological melioidosis 
were also reported in humans and animals (LADDS. 1981, HPA. 2003, CURRIE. 2000). Bacteremic 
melioidosis with pneumonia carries has high mortality. Recent studies showed that, in case of 
pneumonia the mortality rate of melioidosis was 72 % compared to the non-pneumonia group 
(MUKHOPADHYAY et al. 2004). Another similar study reported in Australia showed a mortality 
rate with 67. 3 % (CURRIE et al. 2004). Both results demonstrate that melioidosis is a severe 
disease of public health and security concerns. The overall case-lethality rate of severe bacteremic 
melioidosis might approach 100 % if untreated, but can be reduced to approximately 40 % with 
optimal management. Localised melioidosis has a much lower mortality rate (4-5 %) (CURRIE et al. 
2001). The microorganism can persist in the body for several years before emerging. 
 
Cultural as well as clinical diagnosis of both pathogens is difficult. The infections are often 
misdiagnosed because they trigger multiple symptoms (NEUBAUER et al. 2005) that mimics those 
of other diseases (CDC. 2000). In parts of Asia where B. pseudomallei is endemic, this serial killer 
often commits its crimes without even being identified as a suspect, and portrayed as a “Silent 
killer” (CHENG AND CURRIE 2005). 
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Both B. mallei and B. pseudomallei are included in category B lists of ‘critical biological agents’ of 
the Centers for Disease Control and Prevention, USA (CDC. 2000). However, according to Russians 
ranking system both pathogens are included in group A, potential critical biological agents 
(KONDRIK et al. 2003). They have a number of features that makes them attractive candidates for 
deliberate release. The ability to cause severe, rapidly fatal invasive infections, the ability to initiate 
infections via aerosols, inoculation and possibly ingestion. Its’ intrinsic resistance to many 
antibiotics, to infect a wide range of animals as well as humans, and long term persistence in the 
environment under suitable conditions (B. pseudomallei) (HPA. 2003, ROTZ et al. 2002) and 
currently there is no vaccine commercially available against both pathogen that causes glanders 
and melioidosis Worldwide. 
 
 
 
Figure 5: Global distribution of melioidosis. [cited 2008 Jul 14]. 2005; Data adapted from Currie and 
cheng . Available from: <http://cmr.asm.org/cgi/reprint/18/2/383.pdf> 
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2.3.1 Infection, Epidemiology and Transmission 
 
The facultative intracellular bacterium, B. pseudomallei, that causes melioidosis, is a potentially 
fatal disease of humans in endemic regions, it affects domestic and wild animals, which, like 
humans, acquire the diseases from inhalation or contaminated injuries (BOURRIER. 1978, DANCE. 
2001, CHENG and CURRIE 2005) The infection can range from acute fulminating septics to a 
subclinical form that can be identified only by seroconversion in an infected individual. Although it 
is known that B. pseudomallei is an environmental saprophyte, still little is known about the factor 
that allows to persist, or even proliferate, in some areas and not in others, even though soil 
characteristics and the climate are clearly important (DANCE. 2001, CURRIE. 2003). 
 
Melioidosis is usually a systemic infection, although some patients present with localized 
cutaneous or subcutaneous abscesses or lymphadenitis. Systemic infection is associated with 
abscesses commonly in the lungs, liver, spleen or muscle. Prostatitis and joint infections may also 
occur (WHITE. 2001). Cases of neurological melioidosis “brain stem encephalitis” were also 
reported (HASSELL. 2001). Susceptible individuals have underlying conditions such as diabetes or 
renal disease (CHAOWAGUAL et al. 1989; WOODS et al. 1993). Another risk factors associated with 
melioidosis include alcohol intake and occupational exposure (GUARD et al. 1984, RODE. 1981), 
Kova consumption (CURRIE et al. 2000). Case studies in Northern territories of Australia indicated 
that 85 % of the cases were recorded in “wet” season (ASHE. 2001). 
 
The clinical presentation of melioidosis is similar to that of Gram negative septicemia that misleads 
primary diagnosis. In humans several distinct forms, ranging from subclinical illness to an 
overwhelming septicemia, with a 90 % mortality rate and death within 24-48 h after onset are 
recorded. The disease can reactivate years after primary infection and result in chronic and life-
threatening disease (WALSH et al. 1995). The mean time to detect the growth of B. pseudomallei is 
23.9 h and an increased fatality (73.7 %) was recorded if bacterial growth was positive within 24h 
compared to 40.9 % if the growth was detected beyond 24 h (TIANGPITAYAKON et al. 1999). 
 
The incidence of the disease in many Asian countries is probably greatly under-estimated mainly 
due to the lack of suitable microbiological facilities to allow correct diagnosis and corresponding 
treatment (DANCE. 1991). It has been estimated that the disease incidence in Ubon Ratchathaani in 
northeast Thailand where suitable laboratory facilities and experienced microbiologists are 
available, is approximately 4.4 per 100, 000 per year (SUPUTTAMONGKOL et al. 1994). In this 
province melioidosis is the cause of 20 % of all community-acquired septicemia cases, and 40 % of 
the deaths (CHAOWAGUL et al. 1989). That shows that scarcity of expertise and medication lead, to 
higher mortality. The main endemic foci of melioidosis are in Southeast Asia and northern 
Australia (TAN and GOB 2001, JACUPS and CURRIE 2001, WARNER et al. 2001) where it is a major 
cause of community acquired septicemia and pneumonia, and has a case fatality of up to 70 % 
(CHAOWAGUL et al. 1989, CURRIE et al. 2000). B. pseudomallei is widely distributed in many 
tropical and subtropical regions. Epidemiological studies in Thailand and Australia have confirmed 
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that melioidosis is a disease that presents in rain season in people who have regular contact with 
soil and water, but they have only been able to identify the mode of infection in 5-25 % of the cases 
(DANCE. 2001). A survey of melioidosis in farm animals in northern Queensland showed that 75 
strains of B. pseudomallei were recovered from 30 pigs out of 110; 9 out of 39 sheep; 5 out of 10 
goats; 2 out of 8 native birds; one out of 8 horses and one from tree kangaroo through 5 years of 
investigation (THOMAS. 1981, BOURRIER. 1978). In addition to the livestock species and domestic 
pets, melioidosis was also confirmed from exotic animals in a Wildlife Park in the Northern 
Territories of Australia. These include a spider monkey (Ateles sp.), gibbons (Hylobates lar), a puma 
(Felis concolor) and a cotton-top tamarin (Saguinus oedipus) (MILLAN et al. 2001). For the first 
time melioidosis was also reported among dolphins at an oceanarium (KINOSHITA et al. 2001), 
that indicates B. pseudomallei has a wide ranges of distribution from soil to water and from human 
to domestic and wild animals.  
 
Melioidosis is categorized as an emerging global problem, as defined by the US Institute of 
medicine edited by LEDERBERG et al. (1992). Emerging infections are those whose incidence in 
humans have increased within the past two decades or threaten to increase in near future. 
Incidentally this definition is from a physician point of view that refers to human only it excludes 
the role of farm and wild animals. 
 
The organisms may spread to man by invading the nasal, oral, and conjunctival mucous 
membranes, by inhalation into the lungs, and by invading abraded or lacerated skin. Vertical 
transmission at childbirth and sexual transmissions have also been reported (LUMBIGANON et al. 
1988, 1995, ABBINK et al. 2001). Aerosols from cultures have been observed to be highly 
infectious to laboratory workers and aerosol spread is efficient and there is no available vaccine or 
reliable therapy at present (GREEN and TUFFNEL, 1968, MCCORMICK et al. 1975, CHENG and 
CURRIE 2005) 
 
2.3.2 Multidrug resistance: Unrealiablity up on Antibiotics 
 
The causative agent of melioidosis is characterized to be difficult to treat. The organism is 
intrinsically resistant to most of the antibiotics tested in vitro and in vivo; it is a slow respondent to 
drugs and relapses even to drugs to which it is sensitive in vitro and relapses are common after 
apparently successful primary treatment (TRIBUDDHARAT et al. 2001, CHAOWAGUAL. 2001, 
VORACHT. 2000, KEITH et al. 2001, BURTINICK and WOODS 1999, BURTNICK et al. 2001). B. 
pseudomallei is resistant in vitro to penicillin, amino-penicillin, first and second generation 
cephalosporins, most amino-glycosides, β-lactamas, most macrolides, rifampicin and polymyxins 
(DANCE et al. 1989b, LEELARASAMEE and BOVORNKITTI 1989). Most of the B. pseudomallei 
isolated from 15 patients in Taiwan were intermediate or resistant to ampicillin, flomoxef, 
cefepime, aztreonam, amikacin, and ciprofloxacin (HSUEH et al. 2001). Burkholderia spp. are able 
to survive within phagocytic cells (PRUKSACHATVUTHI et al. 1990, VORACHIT et al. 1995a). They 
can produce glycocalyx, and from microcolonies in infected tissue (VORACHIT et al. 1995b). Since 
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β-lactamas do not penetrate intracellular sites and kill non-multiplying bacteria, treatment with β-
lactamas may not prevent future relapse of melioidosis. β-lactamas with good in vitro activity also 
fail in the treatment of other intracellular infections such as typhoid and legionnaire’s disease 
(MCENIRY et al. 1988). Therefore, the ideal antimicrobial agents for melioidosis therapy should 
have bactericidal effect, should be able to penetrate phagocytic cells, and eliminate or inhibit the 
production of a glycocalyx. 
 
2.3.3 Potential as Biological Weapon 
 
Two pathogenic species of Burkhoderia, B. mallei and B. pseudomallei are studied by different 
states to be used as biological warfare. They belong to category B of the list of ‘Critical biological 
agents’ of the Centers for Disease Control and Prevention, USA (ROTZ et al. 2002). In contrast, to 
CDC, these pathogens are ranked in the lower half of the group A of possible bioterrorist use by 
Russian experts (KONDRIK et al. 2003, VOROBEV. 2001). They have a number of features that 
makes them an attractive candidate for deliberate release including: ability to cause severe, rapidly 
fatal invasive infection, initiate infection via aerosols, inoculation and possibly, ingestion and 
intrinsic resistance to many antibiotics, wide range of natural reservoir (HPA. 2003, CHRISTOPHER 
et al. 2001). Although there no records on B. pseudomallei utility as BW, potential risk of B. 
pseudomallei is uncertain, recently it has been considered an important potential bioweapon, with 
increasing research activities to figure out virulence factors, pathogenesis and to develop vaccine 
(CHENG and CURRIE 2005, SODEMAN. 1994).  
 
During World War I Germany’s programme of biological weapons used the bacteria that cause 
anthrax and glanders, with series of attacks on horses and mules destined in Europe to conduct 
covert operation against the United States and FSU (WHEELIS. 1998, GEISSLER. 1998). The plan 
was to infect large numbers of horses and mules, which should have an effect on troops and supply 
convoys as well as on artillery movement, which were dependent on the animals. The intention 
was both, the destruction of livestock and the transmission of the highly contagious, lethal agent 
from livestock’s to human. Human cases in Russia increased with the infections during WWI. It is 
considered as the first attack with biological weapons in the 20th century (SRINIVASAN et al. 2001). 
The Japans deliberately infected horses, civilians, and prisoners of war with B. mallei at the Pinfang 
(China) Institute during WW II (HARRIS. 1997). The former Soviet Union is believed to have been 
interested in B. mallei as a potential BW agent after WWII. The scientist in Obolensk succeeded 
three key areas: Producing a drug-resistant strain of the glanders bacillus (DOMARADISKIJ. 1998, 
2006, ALIBEK. 1999). The U.S. army studied this agent as a possible Biological Weapon (BW) in 
1943-44 but did not weaponize (USAMRIID’S. 2004). Other countries with a military interest in B. 
pseudomallei included the USA and possibly Egypt (SHOHAM. 1998, HPA. 2003). 
 
The collection of Burkholderia strains in Russia is, said to be one of the most diversified in Europe 
with both endemic strains isolated in Russia and hundreds of strains from South-East Asia and 
Europe (ALEXY et al. 1996). It is one of the most studied pathogen in Russia next to Plague. From 
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the year 1990- 2004 alone, 70 % of the publication of the Anti-Plague Institute focus on 
Burkholderia species, that characterises a remarkable competence on the pathogenic Burkholderia 
species (WESTERDAHL and NORLANDER 2006). 
 
The low transmission rates of B. mallei from animals to humans is exemplified by the fact that in 
China, during World War II, thirty percent of tested horses were positive for glanders, but human 
case from infected horses were rare. B. mallei exists in nature only in infected susceptible hosts and 
is not found in water, soil, or plants as its very closely related species B. pseudomallei (USAMRIID’S. 
2004). 
 
B. pseudomallei holds a significant public health concern due to its ubiquitous nature and morbidity 
and mortality in humans and livestock such as sheep, goats and pigs. In addition, the potential of 
zoonotic transmission from contaminated milk or carcasses has a considerable economic impact. A 
wide range of animals (terrestrial and aquatic mammals, birds and fish) are know to be affected by 
melioidosis with varying severity and clinical manifestations (JODIE et al. 2000). 
 
As human and animals are increasingly transported or moved around the world, there are more 
opportunities for melioidosis to cross state borders and establish new endemic regions. It is even 
possible that soil and water contaminated with B. pseudomallei may be imported from endemic 
areas to non endemic areas (GALIMAND and DODIN 1982, CDC. 2005). 
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3 MATERIALS AND METHODS 
 
 
These pathogens that cause Plague, glanders and melioidosis were considered as the weapons of 
the future—organisms produced in laboratories and unleashed on unwitting populations to 
reproduce, spread, and kill. They are as deadly pathogens , much cheaper to create, and much 
easier to distribute—inside a warhead on an intercontinental missile, in an aerosol can sprayed in 
a crowded building, or by a crop-duster flying over a major city. Exposure occurs without warning. 
Infection from only a few minute particles can mean a ghastly and painful death. The biological 
bioterrorism, the effect of man or natural-caused epidemics are becoming more real. 
 
The FSU was known as “enclosed world of microbial science” in Western hemisphere Research 
publications in Russian language and Russian scientific journals rarely known in English language 
publications. Although the agents that causes plague, glanders and melioidosis were studied for 
biological weapon interest during the cold war area in both East and West blocs, the strength, 
secrecy and intensity of research has  no comparison. As a result, currently what's more known 
about these three pathogens is predominately published in Russian language and Russian scientific 
journals, which are rarely known in English language scientific journal publications. In cases where 
they were/are cited, they are mostly “incorrect”, misinterpretations or misunderstandings are 
frequent. 
 
Thus these dissertation attempts to evaluate, analysis, compares the original Russian language 
published academic journal and the exceptionality of research achievements of former Soviet 
Union and now know as Commonwealth of Independent States. I am privileged in having an 
opportunity to study and work in both Russian and English language that enabled me to take this 
complex hard work, which is not only of Public Health but, also Security, Political, Economical, not 
less Psychological impact at global level. 
To better understand the frameworks, the materials used for deriving the necessary and relevant 
data to reach an argument are based on an extensive searches of published and unpublished 
literatures and academic journals written in Russian language compared to English language at the 
subject coincides. Unique results for which no comparable studies are available, the research 
results are analysed according to its relevance to the subject and its significance for future 
perspectives of developing any types of vaccines against the pathogens in concerns either classical 
forms or recombinante protein basis. The analysed items in this work are accessed in using the 
following forms of methods of information search: 
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1. International Congresses, Conferences, Workshop Handbooks, and Abstracts  
 
In Proceedings of the Scientific and Practical Conference dedicated to the centenary of the Russian 
Anti-Plague service held from 16th - 18th of September 1997, Saratov, Russia. Two volumes of the 
delegate hand books and abstracts were provided from Professor Dr. Dr. Andreas Hensel, the 
president of federal institute for risk assessment, Berlin, Germany, Dr. Heinrich Neubauer, head of 
the institute of bacterial infections and zoonosis, deputy of the president of the Fredrich Loeffler 
Institute, Jena, Germany and Dr. Ernst-J Finke, the head of the institute for microbiology, German 
Federal Armed Forces, Munich, Germany. The conference summed up its meeting with two 
volumes of delegate books and abstracts in Russian language in 466 pages. Volume 1 consists of 
the epidemiological and immunological section of the conference and Volume 2 contains 
microbiology and diagnosis part. As the title of the conference indicates, the Anti-plague system, in 
its kind showed a long year of research activities and achievements in fighting infectious diseases. 
Relevant data related to the topic of the dissertation are thoroughly analysed and cited in this 
work. 
 
The delegate handbook and abstracts of world melioidosis congress incorporating the inaugural 
emerging infectious diseases of Indian Ocean Rim (EIDIOR) workshop, that took place from 26th - 
29th of September 2001, Perth, Western Australia, was kindly posted to us from Dr. David 
DeShazer, bacteriology division, United States Army Research Institute of Infectious Diseases, Fort 
Detrick, Maryland, USA. The first 21 papers presented on September 27th summarise 
epidemiological, clinical, diagnostic, antibiotic resistance and treatment aspects, and 26 papers 
presented on September 28th includes pathogenesis, Veterinary and molecular epidemiological 
aspects of Burkhoderia species. The Handbook consists of 66 pages. 
 
Public workshop on animal models and correlates of protection for plague vaccines, that took place 
on 13th of October 2004 in Gaithersburg, Maryland, USA, was kindly sent to us from Professor 
Andery Pavlovich Anisimov, The director of the Department of Infectious Diseases, State Research 
Center for Applied Microbiology, Obolensk, Russia. The content of the document is compiled in 222 
pages, which describes the current state of knowledge on plague pathogenisis, animal models, new 
vaccine development in western scientific research approaches. 
 
2. Scientific Journal published, Abstracts, Summaries or Titles  
 
An extensive survey of published and unpublished literatures written in English language was 
carried out both through use of multiple search machines, based on electronic database like pub-
med, science, nature and other available life science domains. In case the relevant items are not 
available in electronics form, then traditional paper obtaining, i.e., subscription of the article to 
acquire the copy through library loan procedures, mixed–mode and email contact to the Authors  
were used. 
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In order to obtain items, which were relevant to the topic, the following key words are used to 
identify the articles availability in electronic (Internet) database: Plague, Yersinia pestis, Vaccine, 
Glanders, Burkholderia mallei, Melioidosis, Burkholderia pseudomallei, Immunogenicity, Virulence, 
Genetics, Biological Weapon, Soviet Union, UDSSR, Russia, Anti-Plague Institutes alone, and 
combined as it fits in [MeSH] browser, the National Library of Medicine Database. In addition, “the 
related links” options were used to the identified article accessibility.  
For some relevant historical documents available in electronics form, some fully and some partially 
scanned items like books, reviews, Public-workshops, Congresses-notes, meeting, interviews, 
newspapers, comments, video/ audio data and forums relevant to the topic are used to retrieve the 
data. 
 
3. Scientific Journal articles published in Russian Language 
 
Although Russian language written scientific publications are rarely available in World Wide Web 
search engine to retrieve some of the available documents relevant to the topic the Cryllic 
(Russian) Alphabets and the corresponding Russia terms to the English language were applied as 
keyword, for instance instead of plague The Russian term; “Чума,” and instead of Glanders the 
Russian term; “Сапа,” instead of Melioidosis the Russia term ”Мелиодоз,” instead of Vaccine the 
Russian word for it “Вакцин”, e.t.c. As most of the article published in Russian language, and 
Russian scientific journals were/are not available in electronics form, mixed-mode subscription of 
the article to acquire the copy through library loan and email contact to the Authors and Institute 
Directors of the Anti-Plague Institutes were implemented. These methods were the main and most 
efficient way of obtaining relevant data sources included disclosure forms and official documents 
maintained by the Anti-Plague Institutes in FSU and current state of research activities in Russia on 
the particular pathogens in concern. 
 
4. Books 
Cited books or its parts relevant to the topic were subscribed according to National and 
International Library loan procedures. Cited sections were either copied or thoroughly studied and 
informations were extracted in case the book was at hand. The other options of obtaining were 
books out on loan from Library. 
 
5. Dissertations and Theses 
Dissertations and Theses, titled as [Major criteria of evaluating new vaccine strain of plague 
microbe, enlightenment of Methods] published by the Ministry of Health of Russian Federation 
State Institution of Standardization and control of medical and immunological preparations in the 
name of L.A.Tarasov, Russian research Anti-Plague Institute “Microbe”, Research institute of 
microbiology of the Ministry of Defence of Russian Federation. The document was compiled with 
70 pages, describing all requirements of new vaccine candidates of plague vaccine. And the other 
Theses titled as [Molecular-genetics of Capsule formation and function of Y. pestis] which was 
compiled with 272 pages were kindly sent to us from Professor Andrey Pavlovich Anisimov, Head 
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of the Department of Infectious Diseases, Russian State Research Center for Applied Microbiology, 
Obolensk, Russia. 
 
6. Email contact to Authors 
Personal Email communications were made to obtain relevant documents, which were not 
accessible in other methods described above. These documents were kindly sent to us from 
Professor Piven, Volgograd Sceintific and Research Anti-plague, Volgograd, Russia, publication in 
concerns of glander and melioidosis, and Professor Anisimov, Obolensk, Russia in concerns of 
plague. 
  
The Anti-Plague Institutes of CIS have long period of research activities, resources, experts and 
unique records on plague, glanders and melioidosis diseases. For example, alone from the year 
1985-2004 the Volgograd API has published more than 120 scientific research articles on 
Burkholderia species causing glanders and melioidosis written in Russian language and published 
in Russian scientific journals, which would be thoroughly analysed in this work. 
 
Although the title of the dissertation is self-explanatory for most parts of the work concerning the 
time frame, “the former Soviet Union” it also includes the current state of knowledge of vaccines 
under trail in the region on the pathogens in concerns and the magnitude of gene manipulated 
infectious disease of group 1 BW interests. 
 
The criteria for evaluating the available materials in this work was based on the properties of 
Effective vaccines for prevention of diseases caused by potential bioweapon / terrorism agents like 
plague, glander and melioidosis. A vaccine that can provide universal protection, acceptance to the 
neutral bodies like WHO, UNICEF, and manufacturers and global utilization for the whole ranges of 
population in need. Currently there is no particular position on Plague, glanders and melioidosis 
from WHO, as there are announcements of WHO positions for some other vaccines. Thus, the 
basical requirements for a vaccine against the pathogens in concerns for human use should give, 1) 
life-long immunity, 2) be broadly protective against all variants of an organism, 3) prevent disease 
transmission, such as shedding, 4) induce effective immunity rapidly, 5) be effective in all 
vaccinated subjects, including infants and the elderly, 6) requires few (ideally one) immunizations 
to induce protection 7) be stable (no requirement for cold chain, 8) safe, 9) cheap, 10) sustain 
confidence in people ( WILLIMASON. 2001, BEVERLY. 2002, HASSANI et al. 2004, ANISIMOV et al. 
2004, WHO. 2007, FEODEROVA et al .2007, 2008). 
 
Thus, analyses of research developments on pathogens in concerns were made according to these 
criteria and the extent of vaccine type in fulfilling these requirements, Although few real vaccines 
approach this goal, It is the theoretical aim of any research and development of vaccine to achieve 
these goals in using modern molecular tools from which development of vaccines may possibly 
profit. The strength and weakness of vaccines studied, single or recombined protective antigens 
are thoroughly analysed according to the above-described properties of the vaccine type and the 
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current state of knowledge of vaccine in one side and the immunology of the host and host–
pathogen interaction on the other side. 
 
Documents found from data base archives, describing the backgrounds of varies research 
approaches made to develop vaccines against, Y. pesits, B. mallei and B. pseudomallei are briefly 
described according to their stages of developmental chronicles, their efficiency, and their role in 
the past and impact on the future studies in attempts to develop new or improved vaccines based  
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4 DEVELOPMENT OF VACCINES 
 
Indeed, vaccines are considered among the most, if not the most, cost-effective and successful 
approach in medical development to prevent infectious diseases, because they have successfully 
eliminated an entire wild type disease from the planet Smallpox, (WHO. 1979) with a second 
disease about to eradicated (Poliomyelitis) and control of several different infectious diseases 
including measles, mumps, rubella, tetanus, diphtheria, pertussis, Haemophilus infleuenzae type B 
disease e.t.c. (WHO. 2004). The secret behind this success lies to a large extent in the ability of the 
vaccines to teach the body to respond to the wild pathogen, rather than directly treating the 
disease, as therapeutics such as antibiotics do. Mortality and morbidity due to several infectious 
disease have been dramatically affected by wide spread use of immunization (WHO,199, 2000). Yet 
there are dangerous pathogens like Yersina pestis renowned for being the agents of the Black Death 
and is one of the most potent bacterial pathogens feared that can infect human for no vaccine is 
available in western hemisphere or the agents of glanders and melioidosis for not yet developed. 
The availability of these pathogens around the world, manifestation of multidrug resistance 
strains, capacity for mass production and aerosol dissemination, difficulty in preventing high 
fatality rate of aerogenic infection and potential for secondary spread of cases during an epidemic 
in case of plague, and the potential use of these pathogens as a biological weapon enforces the 
development of an effective vaccine as the most appropriate and beneficial measure to combat 
against these pathogens that have a great Public health and security concerns (STEPHEN,1995, 
GALIMAND. 1997,RASOMAMUNA, et al.1995, EVECHENKO et al. 1997,INGLESBY et al. 2000, 
AMPEL.1991). 
 
Although our knowledge of understanding the pathogens to genomic level, host-pathogen 
interaction, efficiency of the protections and virulence of expressed single or recombined antigens 
and to some extent their mechanisms and induction of the Immune systems mediated in the host in 
the past two decades, currently, there are some significant roadblocks to the development and 
licensing of improved or new vaccines, that includes biological and technological issues, but to the 
large extent, the major challenges are the difficulty in preparing a 100% safe, efficient product, for 
universal application and the high cost of testing and almost unavoidable consequences of the 
occasional, no matter how frequent and how minor adverse events are reported (ROSEENTAL and 
ZIMMERMAN 2006). 
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4.1 Plague Vaccines Licenced for Human use 
 
4.1.1 Killed Whole Cell Vaccines  
 
The first plague vaccine was named after Haffkine. It was developed from a heat–killed, old 
boullion culture in 1897, three years after Yersin identified the causative agent of plague. It was 
widely used to fight against plague in endemic regions of the world such as in India, Egypt, Uganda, 
Kenya, Madagascar, Java, Senegal and in some natural plague foci regions at that period (DESMIDT. 
1929, ECHENBERG. 2002, ISUPOV. 2002). It was administered subcutaneuosly in a dose ranging 
from 2.5 to 12 ml per inoculation varying in methods of its production (TAYLOR. 1933). Such as, 
vaccines produced in Nairobi, Kenya; by methods of Haffkine was inoculated subcutaneous in a 
dose of 2 ml. In the year 1914, alone in Senegalese epidemic outbreaks, about 62,776 persons were 
immunized with Haffkine vaccine. The injection was invariably given subcutaneously on the arms 
of the patients. When abdominal injection was attempted, not only did the patient object, but also it 
was found that belts rubbed against the mark produced painful abscesses. Later on, it was 
observed that the vaccine produced a wide variety of side effects ranging from more soreness at 
the point of inoculation and low level of fever to painful swellings of the lymphnodes in groin or 
armpit, where some of them where persisting for a month or more (ECHENBERG. 2001). Breast-
fed children were found to have vomited the night following the inoculation of their mother. 
Furthermore deaths of immunized individuals was recorded, that led to the rejection of further 
vaccination by the population. Similar problems were observed in Kenya, Hawaii where Haffkine 
vaccine was used against plague epidemy (DESMIDT. 1929). In addition to the vaccine, Haffkine 
also worked on methods of preparations of anti-plague serum, gained from horses and used as 
prevention and treatment of individuals living in natural foci regions and for those who had 
contact with patients voluntarily (HAFFKINE. 1897). 
 
At the beginning of 1930s epidemiological investigation of the regions where Haffkine and other 
similarly killed-vaccines used, were proofed to be of risk to prevent from the epidemy of plague, 
especially in areas where they were applied earlier, like in Madagascar, Java and others (WILLIAMS 
et al. 1980, MEYER. 1974). This phenomenon was explained differently: some argued that it is the 
result of the denaturation of the immunogen part of the plague microbes, the bacterial protein that 
induces antibody and other authors argued that the killed vaccine lacks the V-antigen, one of the 
major immunogenic proteins of the pathogen. That being the general view of that period, today it is 
known that Y. pestis harbors in addition to the two known major immunogenic antigens, the F1 
(Fraction 1) and LcrV (Low cacium response Virulon), additional groups of highly conserved 
proteins designated as YOPs, which are essential virulence factors of the pathogen, and some of 
them are also known to be immunogenic (CORENEILS. 2000, TROSKY et al. 2008, VIBOUD and 
BLISKA. 2005). Y. pestis also harbors an antigen called Pesticin (BEN-GURION and HERTMAN 1958, 
BEN-GURION and SCHAFFE RMAN 1981). 
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During the decade preceding World War II, research on killed plague vaccines was at low ebb. In 
the United States, however, studies on killed vaccines continued in the laboratories of the Hopper 
Foundation, University of California which was known as United States Army Vaccine (USP), a 
formaldehyde-killed preparation of the highly virulent strains like Shasta, Yerka and 195/P strain 
of Y. pestis that replaced the Haffkine vaccine (MEYEER. 1964, MARSHALL et al. 1974). Although 
preliminary experimental results established in animal models, differs from authors to authors in 
its level of protection, such as killed plague vaccine afforded more than 90 % of protections for 
guinea pigs against s.c. infection dose of 1.8 x 1010 CFU of Y. pestis was reported by MEYER (1970), 
and in contrast CHEN et al. (1974) experimental studies found that killed plague vaccine showed 
only 40-75 % protection of guinea pigs against 106 and 103 cfu challenged s.c. with virulent Y. pestis 
strain 195/P.  
 
In case of the clinical responses of the vaccine in humans showed an alarming effect: fever, malaise, 
myaligia, dizziness', gastrointestinal symptoms, insomnia, persisting for weeks. Based on long 
years observation, October 1941 the subcommittee on Tropical Diseases, National Research 
Council committee on Medical Research, USA, passed the following resolution on plague 
immunization: 
“Resolved that, even the available knowledge does not seem to afford definite evidence of the benefit 
of the use of plague vaccine, it is considered advisable to vaccinate with killed plague bacilli of an 
approved strain all military or naval personnel under serious threats of exposure to bubonic plague.” 
 
Based on this recommendation, vaccination with killed plague vaccine was initiated in the armed 
forces. There were varies modified batches of USP vaccine, designated as Vaccine A, produced 
between 1942-1945, based on Shasta strain of Y. pestis culture, consisting of 3.6-4.0 x 109 cfu, 
Vaccine B produced from 1950-1967 based on Yerka strain of Y. pestis containing 2.0 x 109 cfu, and 
vaccine C which was produced since 1967 to 1999 based on Y. pestis 195/P consisting of 2.0 x109 
cfu. in USA. All these vaccines were used in immunization of human and thoroughly studied by 
MEYER and MARSHALL et al. (1974). Generally, all of them (A B C) showed general and systemic 
adverse reactions, no evidences of protection for pneumonic plague (RUSELL. 1995, 
WILLAMSON.2009).  
 
Summing up all kinds of killed plague used in human in the past, beginning from Haffkine vaccine 
to USP vaccines , basically, they all consists of heat or chemical killed bacterial cell cultures of  
different  virulent strains of Y. pestis. Even though methods of killing and immunization schedules 
are slightly different between them and there are various bits of evidences that killed whole cell 
vaccines do protect against bubonic plague. But, conversely there is no evidence of protection 
against pneumonic plague. There are numbers of evidences that showed experimental animals 
immunized with killed vaccine developed pneumonic plague. Similar cases, where people have 
been immunized with killed whole cell vaccines have contracted and developed pneumonic 
plague.(DOLL et al. 1994, TITBALL and WILLIAMSON 2001, 2004, WILLIAMSOM .200). There is 
also no evidence of protection caused by virulent atypical strains of Yersina pestis which are 
isolated from natural foci and know to be virulent (ANISIMOV et al 2004).  
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The other issue of concern with killed vaccines were/are their reactogenicity, side effects following 
immunization, short term protection, that frequent revaccination, (3 booster immunization per 
year), 
requires multiple immunizing doses and short period of protection. Vaccine production needs 
especial containment, they are all expensive and have low public-confidence. There is no evidence 
of protection against infection caused by atypical strains known and isolated from natural foci 
regions. Killed Plague vaccines are unable to induce all desired types of immunity to clear up the 
pathogen. and do not fulfil the current standard of vaccinology, immunology, biotechnology and 
the requirements which the authorities like WHO, UNICEF, or any vaccine producing manufacture 
(Tab.1) needs to produce licence the vaccine for human for global application. From immunological 
point of view, the main drawback of killed vaccine is that it cannot mimic the steps and processes 
elicited during the establishment of the natural immunity which is ultimately controlled by cell-
mediated-immunity that requires a robust and protective T-cell memory response to clear up the 
pathogens  from the host organism, as Yersina pestis is a facultative intracelluar (CORNELIS. 2000, 
SMILEY. 2007, WILLIMASON,2009). 
 
The KWCV is not more available for human uses, the manufacturer discontinued producing it in 
1999. Currently, the only killed whole cell vaccine, which is available, is the vaccine produced by 
the Commonwealth Serum Laboratories in Australia (CORNELIS. 2000), and is reported to be for 
research purpose.  
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Table 1. USP Vaccine compared to Ideal (Effective) plague vaccine 
Descriptions USP Ideal(Effective) vaccine 
Protection Only Bubonic Must protect all forms 
Duration Short term Life-long protection (Ideal) 
Universality limited Must protect from all variants 
Side effect High (MSD 12%) Zero tolerance (Ideal) 
No immunization Short term 3 booster 
inoculation 
One inoculation, induce effective 
immunity rapidly 
Stability (Cold chain) Stable, but requires 
cold chain 
Stable no requirements of cold-
chain 
Safety/Handling/production Special containment Not needed 
Cost Expensive Must be cheap 
Public confidence Negative Must sustain confidence 
Induced Immune system  Humoral Humoral and cellular 
Immunesystem 
 
USP- United States Army Plague Vaccine, MSD-Mean standard Deviation, Data adapted and compiled from 
(Rusell et al. 1995, Myron. 2000, Meyer. 1974, Marshall. 1974, WHO. 2008, Beverly. 2002,WHO,2005). 
 
 
4.1.2 Live Attenuated Vaccines 
 
 
Historically the first trail of live attenuated vaccine was Yersin himself. He was quite interested in 
determining which species most closely reflected human. Therefore, he isolated a live attenuated 
vaccine strain, which he found virulent in rats but not in five species of macaques and injected 
himself. Luckily, he survived (YERSIN. 1900). 
 
The first experimental studies on humans demonstrated by STRONG. (1908) that live attenuated 
vaccine was evidently superior to others like heat or formalin killed vaccines. They provided a 
great degree of protection. He observed that the experimental animals obtained higher immunity 
as when they were immunized with live attenuated vaccines. For instance, monkeys which had 
been immunized against plague by live attenuated vaccines were immune against multiple 
subcutaneous inoculations of lethal doses of virulent strains of Y. Pestis. Further strain like Y. pestis 
Tjiwidej were also tested in humans, and were considered to have been highly effective in reducing 
plague morbidity on the islands of Madagascar and Java. It was expected to be 90 % effective in 
areas where it was used (GIRARD. 1963). Vaccines derived from live attenuated organisms are 
known for inducing cellular immunity efficiently that provides protection against intracellular 
organisms like Y. pestis, however mild allergic reactions of local form in 4.2 % of the cases and 3.7 
% general reaction were reported following subcutaneous inoculation of 109 organisms, and 
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similar results were achieved during mass vaccination in South Africa (GRASSET. 1942, 1946) and 
Senegal (ROTMAN. 1945). Another live attenuated plague vaccine of EV strains initially isolated in 
1926 from human cases of bubonic plague in Madagascar and then attenuated by continuous in 
vitro passages on nutrient medium at the room temperature (18 °C-25 ° C) for 6 years were used 
(GIRARD. 1936). Different lines or subcultures of the EV strains were used as live attenuated 
vaccine to combat plague worldwide (GIRARD. 1963, MEYER. 1970). One of the most frequently 
used derivatives of the EV strain is the Y. pestis EV76 live vaccine. 
 
In the former Soviet Union studies on EV 76 live vaccine strain proposed by Girard and Robic for 
vaccine production against plague began in 1936 and the most common derivatives frequently 
used for human vaccine is Y. pestis EV line NIIEG (designated based on the Russian abbreviation of 
the Scientific- Research Institute for Epidemiology and Hygiene, Kirov, Russian Federation) where 
the vaccine was maintained for long period of time. Also, in both NIIEG and the Russian State Anti-
plague Research Institute ’Microbe` Saratov, Russia. The major protective and immunobiological 
properties were studied, methods of optimizations and techniques of lyophilization in special dry 
nutrient medium were developed (FAIBICH et al. 1947, CHALISOV. 1947). After initial vaccination 
of more than seventy thousand volunteers the vaccine showed relatively low frequency of adverse 
effects and high protective efficiency, thus it was recognized for live plague vaccine production and 
immunization for human(GIRARD.1935, SALTYKOVA and FAIBICH 1975]. 
 
The drawbacks of formaldehyde, heat killed vaccines or fractions of plague microbe (F1) in 
experimental animals were intensively studied in the FSU (KOROVKOVA. 1955, 1957, 1962) that 
led to find another methods of attenuation, such as heating, vaccine strains, like the Yersina pestis 
of EV 76 cell culture grown on Hottinger agar medium in the presence of highly concentrated 
Saccharose solution was developed. This method was expected to reduce the intensity of the 
denaturation of immunogenic substance of the vaccine strain. The first lot of vaccine produced 
intended for human in this method was known as AD-Vaccine. The vaccine was used from the, 
during the campaign of eradication of plague in Volga-Ural natural foci in Gureiv region year 1941-
1942, where 40,143 people living in the region were immunized. Although the vaccine better 
protection was seen when compared heat or formalin killed vaccines used prior, it was not 
produced and used in human further. In 1943, it was replaced by the live attenuated EV 76 strain 
line NIIEG (OSOLINKER. 1960, ISUPOV and LEDVANOV 1997, 2002, SALYTKOV and FAIBICH 
1975). 
 
In 1940, the institute of “Microbe” organized and performed a production of a vaccine in a liquid 
form. Correspondingly, the NIIEG studied major morphological, biochemical characteristic, 
stability of the vaccine strain, developed methods of optimizations, lyophilization techniques in 
special dry nutrient medium of more stable form of live-dried plague vaccine that retains its 
activity for not less than 1 year  (FAIBICH et al. 1947, CHALISOV. 1947) . Relatively low post 
vaccine adverse reactions were seen in immunization studies made on more than 66,000 people 
(KOPILOV et al. 1947). Furthermore epidemiological efficacy of the vaccine was also studied during 
an eradication programme of epidemic outbreaks as a consequence of Japanese bioweapon 
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experiments during World War II in Manchuria in the year 1945-1946 (SALTYKOVA and FABICH. 
1975, FEODOROVA et al. 2007, 2008). Millions of Soviet Red Army personnel’s were immunized 
during this period under physically difficult conditions and there was no single case of infection 
reported from the vaccinated personnel’s, where there was high infection rate in the region and 
the inhabitants (DOMARADISKIJ and OREINT 2006). 
 
Different lines of subcultures of EV76 strain were employed as live plague vaccines world wide, 
resulting in considerable reduction of mortality and morbidity of human plague (FEDEROVA et al 
2007). However, there were reports from different laboratories, that EV76 vaccine strain might 
posses residual virulence in mice and other animals species (MEYER 1970, RUSSELL et al. 1995, 
TITBALL and WILLAMSON 2004, HALLET et al.1973), raising a question of “residual virulence“ 
which might occasional cause disease in human post vaccination and its widespread use might be 
precluded by practical constraints such as manufacturing and safety concerns. Live attenuated 
vaccines needs systematic investigation of the vaccine strains, beginning from its quality, stability, 
biochemical and morphological characteristics, immunogenicity, reactogenicity, fluctuation during 
processing, production, storage, and in courses of immunization. Variation of a strain in one of 
these characters from one to the next generation usually leads to “Saprophytization”, results to 
deterioration or a loss of its immunological values indicating the disqualification of the candidate 
strain for further investigation for vaccine production. Thus, special experimental investigation 
were conducted to prove the stability of the EV76 line NIIEG in comparing to various EV 76 
cultures donated from Institue of “Microbe”, Irkutiskaya Anti-Plague Institute, Robert Koch 
Institute Berlin, Germany and Institute of Hygiene Dairen, China form 1942-1947 [Saltykova. 1947] 
cited by [SALTYKOVA and FAIBICH 1975]. 
 
Immunological investigations were carried out in guinea pigs. A single subcutaneous Immunization 
of animals with different EV culture from various institutes followed by infection with highly 
virulent strains of Y. pestis culture were compared for 30 days. These studies confirmed that a 
culture of EV strain preserved in the museum of NIIEG, showed to be highly resistant against the 
impacts of various biochemical and physical factors imposed on the strain during the experiment 
and retained its minimal immunization doses in the limit of 1x 105 cfu, capable of inducing higher 
expression of immunogenicity. Higher immunogen expression was observed from animals 
immunized with Y. pestis EV 76 strain line NIIEG, which was attenuated in 10 % saccharose 
solution and stored in an ampule at 8°C in a vacuum for five years (CHALISOV et al. 1947, 
AKIMOVICH et al. 1964,)Alteration of growth on nutrient media, which indicates the reduction of 
immunogenicity, was observed only after 100 serial passages of the strains through nutrient broth, 
application of special phages, or UV-radiation (SALTYKOVA and FAIBICH 1975).  
 
Although there were no essential cultural-morphological differences observed between different 
culture of EV strains compared, and none of them killed guinea pigs and mice challenged 
subcutaneously with a dose of up to 2x109 cfu but, significant differences were obtained in their 
level of protection. Cultures received from Institute of “Microbe“, Irkutsk Anti-plague Research 
Institute, Berlin and Dairen showed definitely less protection. Even the highest doses of 
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immunization (1 x109 cfu) followed by infection of virulent strains protected less than 50 % of the 
animals. According to the Russian state standard, requirements for plague vaccine, a minimal 
immunization dose consisting of the lowest cell concentration must be able to provide not less than 
80 % protection of guinea pigs against challenges with 200 DCl 21-days after immunization 
(ANISOMOV. 2002).  
 
The high immunogenicity of the live attenuated strain of EV 76 line NIIEG was accompanied with 
its high survival rate in inoculated animals such as in guinea pigs, that raises the question of 
Infectiousness, the possibility of uprising of “residual virulence” This question was addressed in a 
series of experiments conducted in guinea pigs, mice and fleas that showed no signs of reversion or 
changes of the stability of the vaccine (SALTYKOVA and FAIBICH 1975). As a result, In 1947, It was 
concluded to be produced as a “Etalon” (National standards of reference) strain for plague vaccine 
production and to be used as a quality measure to evaluate other candidate strains and cultures to 
develop new or improved plague vaccine. 
 
The live-dried plague vaccine consisted cells of Y. pestis EV 76 line NIIEG ;a culture grown on 
Hottinger agar medium, washed off with 10 % saccharose solution and lyophilized according to 
NIIEG methods and stored in ampules at 8 °C under vacuum as “series No 303”. It was used to 
produce a vaccine against plague until 1953 (CHALISOV et al. 1947). 
 
From the year, 1953-1959 a “bivalent” dry-plague vaccine from EV strain designated No1 proposed 
from the Institute of “Microbe“, and strain No 17 from Irkutsk Anti-Plague Research Institute were 
released as a recombinant vaccine known as vaccine №1-17 and 93,289 people living in Volga–Ural 
natural plague focus were immunized with it, where the recurring epizootic activity of plague were 
occurred from 1954-1956 (OSOLINKER. 1960). 
 
Experimental investigation of the new vaccine strain No 1-17 was thoroughly studied by KOZLOV 
et al. (1960) that includes, clinical healthy volunteers of, 136 females and 155 males with an age 
between 25-35 years, intracutaneously immunized with similar doses of the some serie prepared 
at the Irkutsk Anti-Plague Research Institute with in two days. The study indicated that the vaccine 
showed high reactogenicity as well as cultural-morphological and biochemical instability, risks of 
alteration that can led to virulence. Thus, the drawbacks of vaccine strain № 1-17 were confirmed 
at the end of 1950s and was not more produced.  
 
Since 1960, the vaccine strain of EV 76 line NIIEG line and its subcultures are used in producing the 
live-dried-plague vaccine for different routes of administration such as inhalation or oral 
application (LEBEDINISKII. 1971).  
 
In the year 1971 the WHO committee of expertise recommended to produce live-plague-vaccines 
to those States who wishes to develop plague vaccine from “Its’ original approved maternal strain 
of EV, preserved its’ properties without any alteration”. Although the EV vaccine strain was the 
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strain of choice that fulfilled necessary requirements for vaccine production at that period, no 
plague vaccine is licenced by WHO yet. 
 
In August 1979 a resolution was ratified by the Ministry of Health of USSR on a national criteria for 
plague-vaccine testing and in the year 2002 updated by Federal Centre of State Epedemic 
Surveillance of Ministry of Health of Russian Federation, Moscow, is currently applicable and is 
known as, Russian national criteria for plague vaccine-testing (the main requirements for 
evaluating of new vaccine strains of the plague pathogen): Methodological Guidelines MI 
3.3.1.1113-02". It consists of 15 headings, subheading and 7 appendices with exact description in 
69 pages. Although each line of the statement in this particular document is equally important and 
one procedure can not executed without the success of the other, here the general regulations and 
criteria required for candidate strain  for the developments of improved or new vaccine compared 
to the standard vaccine used in FSU/Russia are briefly described. 
 
The introductory part of the document in the 1st heading briefly describes the characteristic of 
plague microbe and the deployment of live vaccine against plague prophylaxis in Russia. The 
quaility of attenuated strain of vaccine candidate of choice must be compared to the Etalon 
(reference) EV line NEIIG strain obtained from State Research Institute of Standardization and 
Control of Medical Biological Preparations named after L.A. Tarasevich. The 2nd heading describes, 
norms, references and regulatory authorities, institutions e.t.c. in concern. The 3rd heading 
describes the general position for the strain of choice for live vaccine production, its stability in 
losing its' virulence in human, but retains its' residual virulence in mice and higher doses in guinea 
pigs, investigations must be of bio-safety group III categories. It also determines the number of 
cells (10 Units= 1.109 cfu) to be used, generation (2nd) of culture grow on agar media. The 4th 
heading describes the identity of the strain of choice requirements at species level, i.e a candidate 
strain must be lyse by the L-413C plague phage, must show typical cultural-morphological and 
biochemical properties', must harbour three DNA plasmids pFra (60 MD), pCad (47 MD) and pPst 
(9 MD) with corresponding molecular masses. 
The 5th heading determines the non-toxic character and the extent of residual virulence of the 
candidate strain, extents of dissimilation, survival of the bacterial cell in the tissue and organs or of 
guinea pigs, methods and reference standards of the procedure. It also explains the importance of 
residual virulence of the strain, ability to multiply in the organism, as a result an effective immune 
system of the host is induced. The strain of choice must be able to replicate and survive in the body 
of inoculated animal with in 3-15 days, activates the construction of immune system of the host. 
After 30 days, as a rule the animal is free of bacteria cell. The 6th heading briefly describes similar 
parameters as heading 5 but in white rats. 
The 7th heading describes the extent of the candidate strain in losing it virulence and methods 
applied. A cell cultured after 10 s.c. serial passages of the candidate strain through the organism of 
guinea pigs must not show residual virulence, must not alter its' cultural-morphological, and 
biochemical properties; plasmid profiles.  
The 8th heading illustrate methods and norms of determining the reactogenicity of the candidate 
strain in guinea pigs challenged s.c. Highly immunogenic vaccine strains of plague microbe must be 
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able to induce acceptable local and systemic reactions related to the concentration of bacterial cell 
acceptable ranges of body weight lost, mean body temperature raised in the group of animals.  
The 9th heading describes morphological indications of strain of choice in guinea pigs following s.c. 
challenges. The extent of morphological as histological changes of regional lymph nodes, and 
internal organs (liver, spleen, kidney) of the animal as a results of residual virulence and 
corresponding method to be applied. This section also illustrate dose, duration, organ related 
changes and standard references that the strain of choice must fulfil. 
The 10th heading describes the reactogenicity of the candidate strain after aerosol (inhalational) 
immunization in the guinea pigs and methods applied. It determines the time-organ related 
numbers of bacterial cell accepted when recovered form different organ-homogenate. For instance 
isolation of  single cell from lung, form 1-14 days and regional lymph nodes is acceptable only at 
this time range. Reactogenicity is evaluated in relation to the average body weight the animal lost 
in group after inoculation, thus with in 7 days lose of weight (> 5%) and body temperature raised 
(> 1.5 °C) is not accepted. It also determines types of morphological and histological changes in 
tissue and organs, which are or not accepted. 
The 11th heading briefly describes  reactogenicity of the vaccine strain in guinea pigs under stress 
condition and methods applied. The 12th heading describes the impact of the strain of choice on the 
immune system of guinea pigs and the methods used. It express that a 1.105 cfu s.c. challenges 
choice must not have a suppressive effect on humoral and cellular immune system; rather must be 
able to increase the quality of lymphocytes found in S+G2+M phases of cell cycle from 1.5- 2.0 folds. 
The 13th heading describes immunogenic activity of candidate strain. Plague vaccine strain must 
protect guinea pigs against  s.c. and aerosol infection with virulent strain, and white mice from s.c. 
infection. Thus the strain of choice must efficiently provoke the formation of immunity in the host  
and durable. It describes the ID50 in guinea pigs (< 1.103 cfu) and white mice  (<1.104 cfu).The 
minimal vaccine dose (5.103 cfu: standard reference) must provide not less than 80% and 50 %the 
animals challenged with 200 DCL of virulent strain 21 and 7 days post vaccination respectively. 
An aerosol immunization dose of 2-8. 106 cfu of  standard vaccine or candidate strain must protect 
8 out 10 guinea pigs against plague microbe. 
The 14th heading describes the stability of strain in processing and production and the final 
heading describes a dry plague vaccine trails in human, regulatory norms and authorities 
(BURGASOV et al. 1979, ANISIMOV et al. 2002). 
 
It was estimated that more than 10 million people living in different states of the world including 
former Soviet Union were immunized with live-attenuated EV 76 line NIIEG against plague. A 
vaccine was used as the best prophylactic measure in combating varies endemic outbreaks in the 
FSU. Furthermore it was also known, that during the war more than 70,000 people were 
immunized under physically difficult conditions in the USSR alone (KOPILOV et al. 1947). 
 
Based on the proposal of the API experts on the vaccine, in case of a great epizootic outbreak in the 
population living in natural foci territories of CIS, mass vaccination were necessarily organized. 
Such as, massive immunization project conducted in 17 endemic regions, where constant epizootic 
outbreak activities were emerged. There were also additional evidences that confirms, the efficacy 
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of the live attenuated vaccine of EV-NIIEG line, such as, the investigation that included 7 rural 
villages, where 33,675 people lived, where there were 2,127 cases of human infection registered 
through epidemiological surveillances before massive immunization took place and 223 cases 
were proofed to conduct a disease (SVISTUNOV. 1997). 
 
Another immunization program with the vaccine name known as serial No 22, OБK No 229 of 
Stavropol Anti-Plague Research Institute, was also used in human. The program was accomplished 
within 25 days, which covered 2,524 individuals including children. Children with an age under 6 
were immunized with 1x108 cfu and an age of 7 and upward, with 2x108 cfu. As the epidemic broke 
out, 37 individuals showed sign of infection, where 10 of the patients were not immunized, 1 
patient died of “primary septicemic plague,” 7 of the patients conducted “bubonic-septicemic 
plague” and 2 patients presented bubonic plague. 27 cases of the patients who conducted infection 
belonged to the vaccinate groups (SVISTUNOV. 1997). The reason why the immunized individuals 
conducted infection is not further explained. 
 
Inhalation and oral vaccine were thoroughly investigated by ALEXANDROV’S and associates’ 
(1962) as a dry dust (aerosol) plague vaccine based on EV strain line NIIEG, which was inhaled to 
543 healthy volunteers of an age ranging from 18-25- year- old males that consisted of 1.5-2 x 106 
cfu, followed by medical observations like regular control of body temperature haematology and x-
ray imaging. These unique experimental investigation in its form was reported, that aerosol 
immunization with dust plague vaccine based on EV line NIIEG vaccine caused no distinct post 
vaccine reactions in comparison to s.c. and cutaneous immunization. The author found that s.c 
immunized 100 healthy males with an age of 18-25- year- old with standard live EV vaccine 
showed general post vaccine reaction in almost all vaccinees ranging from significant rise of body 
temperature above 38,5 °C to the slightest elevation and local reactions in the form of hyperemia, 
swelling and tenderness, sometimes accompanied by lymphadenities. Nevertheless, cutaneous 
immunized 5,600 healthy young males with an age of 18-25 years-old  did not show any systematic 
post vaccination reactions. However, mild and simple reactions were observed in 2.1 %, and in 1.7 
%) of vaccinees. Local inflammatory reaction in the location of inoculation and responses of 
regional lymphadenitis was observed in 96 % of the cases, which disappeared or significantly 
reduced within 7-8 days later.  
 
The author also found that aerosol immunization with the dust plague vaccine, using the EV76 of 
line NIIEG vaccine strain showed prompt and high level of Immunity without no distinct post 
vaccine clinical reactions. however the author found that the vaccine instigated changes in the 
peripheral blood. It was also confirmed that the methods of immunization in field trails was quite 
simple in comparison to other known route of administrations of live or dead vaccines. This 
vaccine allows mass immunization to be carried out against plague with in a short period of time, 
which leads to be the best option of herd-immunization to protect a population in case of 
deliberate release of plague pathogen in densely populated locations or in case of epidemic 
outbreak of plague in endemic regions or unintended release of plague pathogen. Another 
experimental investigation done on monkeys also confirmed, that even low doses of aerosol 
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vaccine immunized twice through inhalation protected 50 % of the animals challenged in the some 
route with virulent strain of plague pathogen. 
 
In contrast to killed vaccines, live attenuated EV vaccines protect quite well against aerosol 
challenge, but its has never been licenced and used in Western hemisphere. Furthermore there is 
also a scarcity of research publication that compares the live attenuated EV 76 vaccine with USP 
Vaccine in experimental animals or human trails (RUSSELL et al. 1995), likewise particularly EV 76 
line NEIIG vaccine.  
 
For the extent of 25 to 30 years of intensive investigations, experts in CIS concluded that, the Y. 
pestis EV 76 line NEIIG strain as the most effective prophylactic preparation against plague until 
now that retained its whole immunological value and stability through decades (SALTYKOVA and 
FAIBICH 1975) and the most intensively studied, used plague vaccine in CIS for more than 7 
decades and currently, it is the only available vaccine against plague for human (FEDEROVA et al. 
2007, 2008). The vaccine was found to be effective after administration by different routes 
including subcoutaneous (s.c), cutaneous inhalation and intramasucular (i.m) routes of injection 
and has been continued to be used in the countries of FSU. The life-dry plague vaccine, based on 
Y.pestis EV NIIEG line, is known with a trade name –Vaccinum pestosum vivum siccum ad usum 
oralem registeration number 93/160/21 is available and produced only in the Russian Federation 
(NIIEG. 2008). 
 
Although these being the strength of this particular vaccine at the moment, there are also some 
concerns on live attenuated vaccines in general, that there is a fear, that the strain can reverse from 
avirulence to virulence, can cause a series of side effects such as reactogenicity (adverse local and 
systemic reactions), expression of allergic reactions, short term protection, costy, difficult in 
Heandling e.t.c. (tab. 2) less protection to pneumonic forms of the diseases and unable to protect 
from disease caused by atypical virulent strains of Yersinia pestis, more over, less public acceptance 
(WHO. 2008), that limited its global acceptance (RUSSELL et al. 1995, ALEXEEVA et al. 1997). 
 
Live attenuated vaccines allow for infection of host cells and efficient MHC class I presentation of 
antigens that can stimulate strong and persistent CD8+ T cells responses, which is required for 
efficent protection. It mimics the natural infection and induce both arms of immune system. The 
central question that remains for the vaccine against disease requiring effector CD8 + T cells is 
whether persistent or periodic antigen (booster immunization) will be required to sustain a pool of 
circulating effector–memory CD8+ T cells that would be important in providing protection 
(BEVERLEY. 2002). Thus newly constructed live attenuated vaccines like the derivative of Y. 
pestis∆lpxM, or mutants like Y. pestis CO92 yop∆ H with their improved characteristics can be a 
potential candidates of vaccine which can provide a universal protection against diversified strains 
of plague pathogens available in different regions of the World. 
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Table 2. Live attenuated EV76 line NIIEG compaired to Ideal (Effective ) plague vaccine 
Descriptions EV76 NIIEG Ideal (Effective Vaccine) 
Protection Bubonic, Pneumonic, septicemic, 
etc. against atypical strains (?) 
Must protect all forms of 
infection 
Duration Short term ca.1Year Life-long protection (Ideal) 
Universality Limited  Must protect from all 
variants 
Side effect High (MSD 5 %) Zero tolerance (Ideal) 
No immunization 3 booster inoculation/Year One inoculation, induce 
effective immunity rapidly 
Stability (Cold chain) Stable ±, but requires cold chain Stable no requirements of 
cold-chain 
Safety/Handling/production Special containment Not needed 
Cost Expensive Must be cheap 
Public confidence Acceptable (in Russia) Must sustain confidence  
Induced Immune system Humoral and cellular Humoral and cellular 
 
EV76 NIIEG- Live vaccine Y. pestis EV76 line NIIEG, Data compiled from: Salytkova et al. 1975, Anisimov et al. 
2004, Federova, et al. 2007, 2008, NIIEG. 2008, WHO. 2008, Beverly. 2002. 
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4.1.3  Plague Vaccine trails in Humans 
 
4.1.3.1 Subunit / Recombinant Vaccines  
 
In recent years, research efforts appear to have focused on the use of recombinant technology to 
design a new vaccine candidate for immunization against plague. The principal attention being 
focused on subunit vaccines containing recombination of two major immunogenic antigens, the 
Fraction 1 (F1) and Low-calcium response V antigen(LcrV). 
 
In the United States, the subunit vaccine containing the rF1 and rLcrV as fusion protein (rF1-rLcrV) 
constructed in pET19b consists of the F1 protein fused at its carboxyl terminus to the amino 
terminus of the entire V antigen is under development (HEATH et al. 1998, JONES et al. 2003). In 
UK similar proteins but equal concentration of both components (rF1 + rLcrV) is under 
development. Both vaccines provided efficient protection against bubonic and pneumonic plague 
in murine animal models against F1- and F+ strains of Y. pestis and it was also reported to be well 
tolerable in Human trials phase 1 (TITBALL and WILLIAMSON 2001, 2004, ANDERSON. 1996, 
WILLIMSAON. 1999, WILLIASON et al. 2001, 2005). 
Better protection was observed when it was given as a subunit/ fusion protein (rF1-rLcrV) to the 
mice as either F1 or V alone against s.c. challenged with F1+ Y. pestis CO92 strain (HEATH et al. 
1998). Better protection by antibody directed against both, F1 and V antigens might occur by 
counteracting both the antiphagocytic activity associated with F1 (BURROWS. 1963) and the 
virulence enhancing activity associated with secreted V antigen (NAKAJIMA et al. 1995). 
 
Similar results were also achieved when it was given as recombinant/ equi-molar concentration of 
both antigens ( rF1+ rLcrV) that provided a protection of BALB/C mice against a subsequent s.c. 
challenged of 106 LD50 Y. pestis strain GB, while in contrast control mice challenged with similar 
doses of Y. pestis developed disease and animals died at day 5 post infection (GRIFFIN et al 2005). 
The predominant IgG subclass raised to both F1 and V antigen was IG g1, that correlates with 
protection against plague in the mouse model was reported (WILLIAMSON et al. 1999). But guinea 
pigs immunized with (rF1+LcrV) vaccine on the contrary were protective only against low dose of 
of Y. pestis GB strain. As the doses increased there was a loss of protection and only 50 % of the 
animals survived, where all mice were protected against s.c. challenge with the same doses. All of 
the immunized guinea pigs were seen to have buboes including the lowest challenged group and in 
almost all cases, under the right forelimbs. Bacteriological analysis confirmed Y. pestis isolates in 
the liver, spleen and lungs. More significantly, the levels of Ig1 class antibodies were notably 
variable against both proteins (JONES et al. 2003). 
 
In concerns to guinea pigs, according to the Russian national standard of plague vaccine resolution 
steadfast, that the potential efficacy of plague vaccine strain requires that at least 50% of guinea 
pigs should be protected against s.c. challenge with 200 MLD (2000 cfu) of virulent strain 
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(ANISIMOV et al. 2002) and guinea pigs belongs to one of the multispecies notably included in 
Plague research in CIS (ANISIMOV. 1999, 2004, ANISIMOV et al. 2002, FEODOROVA. 2007, 2008). 
 
In addition to the two major imunogenic antigens of Y. pestis, studied in depth, there are also a 
number of proteins known as Yops and Pla in eliciting antibodies and some of them provides 
partial protection (YoD) from s.c infection in mice model (ANDREWS et al. 1999). Recent studies 
made by LI et al. (2008), showed that 10 other novel antigens that provided an experimental 
evidences for immunogenicity in using an antigen microarry containing more than 140 Y.pestis 
virulent associated proteins in detecting antibody responses in plague patients. 
Although LcrV protein belongs to one of the major immunogenic protein, it was also reported that 
LcrV triggers the release of interleukin-10 (IL-10) by host immune cells and supresses 
proinflammatory cytokines such as TNFα and TNFγ as well as innate defense mechanisms required 
to combat the pathogenesis of plague which may preclude the use of LcrV as a human vaccine 
(NAKAJIMA. 1993). Y. pestis can bypass protective antibodies to LcrV and activation with IFN-
gamma to survive and induce apoptosis in murine macrophages (NOEL et al. 2009). The three 
human pathogenic Yersinia species all harbors a 70 kb virulence plasmid LcrV (FILIPOVA. 1990, 
BURBAKER. 1991, CHERPANOV. 1991). DNA sequencing of the LcrV antigen revealed that two 
evolutionarily distinct types of V antigen exist in Yersinia spp. One type is expressed by Y. 
enterocolitica serotype O:8 (designated LcrV-YenO8 or V-O:8), and the other type is expressed by Y. 
pestis, Y. pseudotuberculosis, and Y. enterocolitica serotypes O:3, O:9, and O:5,27 (LcrV-Yps or V-
O:3). More recently, it has been suggested that Y. pestis strains possess their own V-antigen type, V-
Yp (ANISIMOV et al. 2004). The Antisera from two LcrV variants did not show cross-protection. 
Protection was observed in mice if the immunizing LcrV antigen was from the same type as LcrV 
antigen by the infective strains (ROGGENKAMPF et al. 1997). It appears that they are at least , 
potentially interchangeable LcrV antigen variants and it is possible that in the diverse population 
of Y. pestis circulating in Asia there are more variants (ANISIMOV et al. 2004). Thus this peculiarity 
of only self recognizing characteristics of LcrV might deter in active immunization and in providing 
universal protection against highly interchangeable variants which might be found in the diverse 
dynamic populations of Y. pestis circulating in natural foci found around the world. 
 
Individually, the F1 and V recombinant proteins are immunogenic and protective against 
challenges. In combination, they provide protection against very high challenge levels with virulent 
plague in small animal models. The predominant animal model used in most of the research 
activities, achievement were/ are based on mice (WILLIAMASON et al. 1997, 2001), where guinea 
pigs are categorized as bad model to study plague pathogenesis, immunology and vaccine 
developments in USA and UK (WORSHAM. 2004). It is also known that mice and guinea pigs 
respond differently to the plague pathogen and that LD50 of 10 cfu of the poorest virulent strain of 
Y. pestis can kill guinea pigs, thus while research results depend on the animal used, it make 
difficult to translate from different animal models to human use. Translation of experimental 
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results of vaccine based on single animal species model might rise a questions of acceptability, 
where it is known that a number of rodents are infected and are sensitive to the plague microbe. 
 
In Russian the major focus of plague vaccine research approaches concentrates on the 
development and investigation of live plague vaccine as improved or new vaccine (FEDEROVA et 
al. 2007). Currently a dozen of strains of Y. pestis which fulfils the Russian national standards of 
major requirements of qualification for new or improved vaccine development compared to the 
“Etalon” reference vaccine strain of live EV 76 line NIIEG (ANISIMOV et al. 2002, FEODOROVA et al. 
2007, 2008). One of the current candidate, the Y. pestis∆lpxM, has shown, as new improved vaccine 
with better efficacy, more protection and less toxicity in all three animal models in comparison to 
the live EV76 line NIIEG against infection induced with virulent wild-type 231 strain of Yersinia 
pestis (FEDEROVA et al, 2007,2008). 
 
In contrast to the above analysed vaccine candidates in USA and UK, the Russian national criteria 
for plague vaccine-testing and candidate strains for new or improved plague vaccine developments 
is currently applicable for the development of new or improved vaccine against plague pathogen in 
Russia ( ANISIMOV et al, 2002, FEODEROVA, 2007, 2008). In contrast to the west, the live 
attenuated vaccine of EV 76 NIIEG line is the most thoroughly studied plague vaccine in FSU/ CIS 
since 1936. It was constantly proofed to be the best effective, stable prophylactic preparation 
against plague, with its constant cultural morphological-biochemical characteristics and 
immunogenicity that was proved through an investigation done on the strain after 30 years of 
storage. Although the EV 76 strains used as a vaccine showed various results depending on the 
laboratories (RUSSEL et al.1995), EV76 NIIEG line was proofed to be stable. All important 
immunological, biochemical and morphological characteristics analysed were consistent, showed 
no signs of alteration was seen after 3 decades of storage (SALYTKOVA et al. 2000, ISUPOV and 
LEDVANOV 2004). It is also important to note that each year, over 100,000 CIS citizens get anti-
plague vaccine based on the Live EV 76 NIIEG line, mostly geologists, cattle breeders, and live-stock 
expertise (Veterinarian, Animal nutritionist, Zoologists, e.t.c.) most likely to be in contact with 
plague-infected animals. The vaccination is valid for at least 6 months (DOMARADISIJ and ORENT 
2006, FEODEROV. 2007, 2008, ISTC. 2008). 
 
In most of the cases protective efficiency of new vaccine candidates researchers, developments and 
success in UK or USA are mostly compared F1+V or F/V fusion vaccines with killed USP vaccine. 
There is no comparative study made between the live attenuated EV strain of NEIIG line and F1/V 
or rF + rV yet. Thus, it was reported that, the benefit of a vaccine containing both F1 and V is, that 
F1 should protect against variant strains of Y. pestis, which might be altered in the amount, or 
composition of V antigen, in a manner analogous to that by which V antigen protects against F ¯ 
strains. As another potential advantage reported for an F1/V multi-component vaccine would be to 
protect individuals who may be non-responders to one component of a vaccine. 
A number of studies have clearly demonstrated that flagellin is a potent adjuvant that promotes 
robust immune responses when it is given with a protein antigen. MIZEL et al. (2009) evaluated the 
efficacy of a recombinant protein vaccine composed of a single fusion protein containing flagellin 
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and  two protective antigens of Yersinia pestis (F1 and V) in eliciting protection against respiratory 
challenge with Y. pestis. It was reported that, the fusion protein (Flagellin-F1-V) retained full Toll-
like receptor 5-stimulating activity in vitro. Using a prime-boost immunization protocol, they found 
that flagellin-F1-V elicits robust antigen-specific humoral immunity in mice and two species of 
nonhuman primates an immune mice were fully protected against intranasal challenge with 150 
mean tolerated doses of Y. pestis CO92. In immune mice, the bacteria were completely cleared 
within 3 days after challenge. Flagellin-F1-V exhibited full stability for at least 297 days at 4°C and 
at least 168 days at 25°C. At between 29 and 84 days at 37°C, the protein exhibited a loss of 
biological activity that appeared to be associated with a substantial change in protein diameter, 
possibly due to oligomerization. 
 
Not less important, is also, that a number of atypical strains, with intraspecific diversity of Y. pestis 
isolated from different natural foci, which are not yet known in Western hemisphere, but persist on 
all continent save Australia, has never been included in sort of vaccine studies yet. Most of the 
research results in west are based on strains which are genetically identical to over 98 % and 
stored in the laboratories for long period of time, like strains of Y. pestis CO92, Y. pestis KIM, Y. 
pestis GB, unlikely which differ with the strains found in natural foci known in CIS and other 
regions of the world, that narrows the shield of protection of vaccine based recombinant of F1 and 
V antigens  (PARKHILL et al. 2001, DENG et al. 2002). Plague microbe population inhabiting in 
varies ecosystems are dynamic and responsible for sporadic out breaks which are consistently 
reported to the WHO. Thus, it is essentially needed to gain full knowledge of them in order to 
develop an effective, stable, efficient, tolerable, prophylactic measures against plague for global use 
and has a universal protection and acceptability and the subunit/recombinant vaccine must be 
proofed for fulfilling these requirements.  
 
4.1.3.2 Non-cellular (Synthetic) Vaccines 
 
Techniques have been developed for locating and defining epitopes on bacterial or viral proteins 
and the possibility to synthesize peptides chemically corresponding to these antigenic 
determinants. They are designed to overcome the drawbacks of classical vaccines like, safety, 
difficulties in processing, reversibility, genetical variations of microbes within themselves, 
multiplicity of the microbes and more over post-immunization side effects, like toxicity and 
stability (ARNON. 1997, HARARI et al. 1997, MULLER. 1982). 
In the beginning of the 70th PITROV et al. [quoted by ALEXEEVA. 1997] showed for the first time, 
that series of synthetic polyelectrolyte's, substances that does not have natural analogue, were able 
to express an immunomodulating effects. This observation was based on the facts that 
immunization with the given polymer complex enhanced specific types of immunogenicity, that 
were able to substitute the function of helper T (TH) cells. This experimental evidence may give a 
new opportunity to produce vaccines based on non-immunogenic or weak immunogenic 
substances. It might overcome the problems of phenotypical corrections of genetically controlled 
immune responses and might provide protection to all vaccine contingents independent of the 
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genotype of the immunized subject. Experimental investigation of the conjugates obtained from 
capsule antigen designated as F1 and F1A, based on the methods of extraction was reported that, 
mice immunized with the combination of polymers, monomers or tetramers of non immunogenic 
polysacchride (PS) and synthetic polyelectrolytes of cationic nature called “sopolymer 4-
vinylpyridin and 4-vinil-N-ethylpyridinbromid” or (ME-3) complex enhanced the survival rate and 
immune responses complex against plague infection (ALEXEEVA et al. 1997). The combined 
vaccine was designated as Chemical plague vaccine (CPV). It was also reported that significant 
improvement in expressions of 1st and 2nd cellular immunity responses to F1A, and prolonged 2ry 
humoral responses was observed (ALEXEEVA et al. 1997). That indicates an alternative option of 
constructing a vaccine against plague based on capsule antigen and polyssacharides with les or 
non immunogenic substances. 
 
DALVADYANTS et al. (1997) studied the experimental model of CPV (F1A-PS-ME3) described, as a 
soluble substance that stored its immunogenicity for a longer period, significantly less toxic and 
less allergic in comparison to live attenuated EV NIIEG line vaccine or killed whole cell vaccine 
(USP). The observation was based on experimental studies made on animals and human 
volunteers. It also showed an efficient protection against virulent strain of Y. pestis, when it was 
used as revaccination (booster-vaccine) than as primary vaccination. Thus, the vaccine was 
described to be even superior to live attenuated EV NIIEG vaccine in specific situations, in that it 
was more stable and can stores its specificity for 15 years and it can be used with external 
prophylactic substances like antibiotics or immuno-modulators. His experimental studies on 
laboratory animals (mice, guinea pigs, primates) and clinical investigations of volunteers done lead 
to suggest, that the CPV has such a good quality to be implemented as a revaccination (effective 
booster quality) with minimal clinical adverse post-vaccine reactions was reported and it was also 
reported that it reactivates the immune system better than live plague vaccine (LPV) and USP 
vaccine. Specific antibody titers was observed in a range of (1:2-1:32) to the F1 antigen in 36 % of 
volunteers inoculated in the transition period to revaccination. 30 days after booster immunization 
the titer rose to 96 % to F1 antigen, ranging from 1:64-1:4096 in 54.13 % of the case. Whereas, 
revaccination with LPV increased the titers in only 10 % of the volunteers, with maximum 
antibody titers less than 1:64 in 20 % of the participants. Indirect analytical methods used to 
indicate the efficiency of revaccination of volunteers with live and chemical plague vaccines 
showed specific immune stimulating substances of the CPV which were preserved for 3 to 6 
months. In 84 % of the volunteers, specific antibodies to F1 were detected during the period with 
titers ranging 1:6-1:512 in 27.4 % cases. 
 
Recent report what is known about the CPV was an investigation made by DALVADYANTS et al. 
(2005). He used the biocomponent of capsule antigen (F1) and OSA from Russian word (Osnovnoi 
Somatichiskii Antigen [main somatic antigen]), i.e. an antigen isolated from experimental animals 
like white mice, guinea pigs, hamadryas pavian, and from human in clinical trials for immunization. 
The study consisted of 100 healthy human volunteers, with an age of 18-30 years old, gender not 
specified. Volunteers were immunized s.c. with live plague vaccine serie 66, № 559; 3x 108 cfu 
initially and were randomly selected and grouped in to three. Group 1 consisted of 52 individuals, 
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group 2 consisted of 16 and group 3 consisted of 14. Group 1 were revaccinated s.c. with CPV of 12 
μg concentration in a volume of 0,5 ml in 0.9 % saline solution /head. The second group were  
revaccinated with LVP vaccine serie 66 with the some dose as the primary immunization per-head 
and group 3 were placebo (control) groups. This study compared the efficiency of CPV to LPV and 
included control group (placebo). It investigated the frequency of general reaction of the 
volunteers revaccinated with CPV or LPV like, body temperature, depression, general feelings, 
headache, vomiting, weakness. Significant differences of physiological parameters between CPV 
and LPV vaccineetes were not observed. Further, the indicators of local reaction in hrs like pain, 
hyperemia, oedema were also examined. Pain were observed in 90 %, 93% of the CPV and LPV 
vaccineets respectively in the first 24 hrs. Further observations showed that after 72 hrs 11 %, 25 
% of CPV and LPV Vaccinates respectively feel pain. Whole blood and serological investigation was 
also done in order to elucidate the dynamicity of antibodies against the CPV and F1 antigen and for 
the exclusion of toxicity of the vaccine. It was shown that CPV was less reactogenic, while protein 
products produced under stress conditions were not detected. CPV is easy of handling, well 
acceptable. Serum antibody measured 6 months after revaccination were detected in 85 % of the 
vaccinates inoculated with CPV used as booster vaccine and in 64 %, of individuals injected with 
LPV used as revaccination, that indicates CPV is more active and efficient in inducing antibodies. In 
addition serum antibody measured against F1 antigen, 30 days post booster injection with CPV and 
LVP were detected in 94 %, 47 % of the cases respectively. Thus, the Authors proposes the 
importance of including the CPV vaccine as booster vaccine in cases of combating against plague 
outbreak or in plague control and prevention. No experimental studies are available on CPV as 
“standalone” which a vaccine against plague is supposed to be. 
 
Despite the fact that synthetic vaccines may have several advantages in comparison and have been 
shown to elicit neutralizing antibodies in certain viruses of animal pathogens, like Foot- and mouth 
disease, rabies virus, there are also a number of disadvantages, which needs consideration and 
further investigations. Synthetic peptide vaccines are poorly immunogenic, needs adjuvants, they 
are linear, lack any tertiary or quaternary conformation while epitopes are not composed of linear 
arrays, of contiguous aminoacids, but rather three-dimensional shapes in its native form. Most B 
cells epitopes are nonlinear (discontinuous) and therefore not reproduced by peptides. Short 
linear peptides can be recognized by T-Cells, when bound to MHC protein. May be to narrowly 
specific, not protecting against natural variants. Single-epitope vaccine may readily select mutants 
in the field (HARARI. 1997). In order to produce vaccines based on synthetic vaccine these merits 
must get solutions. There is no licenced purely synthetic vaccine for human use yet. 
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4.1.4 Plague Vaccine studies in Animal Models  
 
4.1.4.1 Live Attenuated Vaccines 
 
Recently new improved vaccine like, the Y. pestis EV NIIEG derivatives with deletion-insertion in 
lpxM gene (hexa-acylated-lipid A) are under experimental levelin animal models . The lpxM 
mutants vaccine construction was reported to be, less reactogenic in comparison to its parental 
strain and provided better protection in three species of experimental animals against s.c. 
challenged virulent strain of Y. pestis 231 (FEODOROVA et al. 2007). It was also reported that, no 
bacterial cells were detected from organ speciemen cultured from animals’ immunized with Y. 
pestis∆lpxM vaccine. That suggests, there are no signs of residual virulence related to the new 
improved vaccine. 
 
Comparative studies done by FEODOROVA et al. (2007), in regards to the efficacy of protection 
between Y. pestis∆lpxM, the new improved vaccine and the parental EV76 NIIEG line vaccine in all 
three animal models tested showed that Y. pestis∆lpxM provided a significant level of protection 
against challenge doses of 1.2 x104 to 2 x104 cfu (LD50 = 1,2-2,0 x 103 cfu) of wild-type 231 strain. 
In contrast, immunized animals with parental vaccine were not protected was reported. Also a 
protection of 57-86 % was provided in outbred mice immunized with Y. pestis∆lpxM vaccine 
depending on the concentration of doses of immunization. It was observed that immunzation doses 
with higher concentration of bacterial cell significantly showed more protection as low 
concentration. For instance a vaccine with 109 cfu of Y. pestis∆lpxM was capable of protecting 
85,7%, where as vaccine with a concentration doses of 105 cfu protected only 14 % of the outbred 
mice and no differences were seen with regard to the parental vaccine, that both high or lower 
concentration did not provide any protection. 
 
Furthermore, it was reported that, the Y. pestis∆lpxM elicited modest protection (no more than 
40% of survivals) in Balb/C mice whereas, Y. pestis EV NIIEG do not show any protection; all 
immunized animals did not survive. It was reported that, among guinea pigs, a marked protective 
efficacy against challenge with 1,2 x104 cfu of wild–type was achieved following a single dose of the 
Y. pestis∆lpxM strain between 107 and 1,5 x1010 cfu/ animal. No protection of guinea pigs was seen 
following immunization with the Y. pestis NEIIG regardless of the level of concentration even after 
higer doses of 1010 cfu immunization (FEODOROVA et al. 2007).  
 
In similar studies it was reported, that highly attenuated phenotype of Y. pestis CO92 yop∆ H 
(YopH- a protein tyrosine phosphatase mutant), provided higher protection against s.c. or 
intranasal (i.n.) challenged out bred CD1 mice that corresponds to bubonic and pneumonic models 
of plague respectively (BUBECK and DUBE, 2007). Further observation was made, that vaccination 
with live attenuated Y. pestis CO92 yop∆ H, i.n. with dose of 107 cfu provided 100 % protection 
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against the some route of challenge with ~105 cfu of Y. pestis CO92 virulent strain, and s.c. 
immunization showed 70 % of protection against i.n. infection. Interestingly it was found that  mice 
vaccinated i.n was 100 % protected against s.c. challenges with virulent strain of Y. pestis CO92 
(BUBECK and DUBE 2007). 
 
Thus, the current challenge is to develop safe, universally effective vaccine against the deadly form 
of plague, the pneumonic plague, and the most likely way of disease transmission in bioterrorism. 
Toady, it is a constant observation that vaccines targeting intracellular pathogens like Yersina must 
induce both arms of immune system. Although immunity towards intracellular pathogens is often 
depend upon the generation of CD8+ memory T cells, for long-lasting and effective protection, the 
humoral part of immune system plays its main role in the effective activation of the antigen-
specific immune response, in antigen-uptake, and antigen presentation (ISUPOV and LEDVANOV 
2002, FEODOROVA et al. 2007, SMILEY. 2008). Thus, any forms of plague vaccine development 
must be able to fulfil the drawbacks known by killed vaccines. 
 
Live attenuated vaccines allow for infection of host cells and efficient MHC class I presentation of 
antigens that can stimulate strong and persistent CD8+ T cells responses, which is required for 
efficient protection. It mimics the natural infection and induce both arms of immune system. The 
central question that remains for the vaccine against disease requiring effector CD8 + T cells is 
whether persistent or periodic antigen (booster immunization) will be required to sustain a pool of 
circulating effector–memory CD8+ T cells that would be important in providing protection 
(BEVERLEY. 2002). Thus newly constructed live attenuated vaccines like the derivative of Y. 
pestis∆lpxM, or mutants like Y. pestis CO92 yop∆ H with their improved characteristics can be 
potential candidates of vaccine which can provide a universal protection against diversified strains 
of plague pathogens available in different regions of the World. 
 
4.1.4.2 Heterologous Vaccines 
 
A vaccine that confers protective immunity against a pathogen that shares cross-reacting antigens 
with the microorganisms in the vaccine and provides cross-protection is hetrologous vaccine. Ideal 
vaccine must be able to protection from both infectious agents simultaneously by utilizing a single 
vaccine so to say “kill two birds with one stone”. Studies on microorganisms of the same family and 
genera were given priorities based on their cultural, morphological, biochemical and common 
antigens, if they are capable of protecting from one or both agents (EBLÉ et al. 2006). 
 
Recent observation on the genome plasticity in Y. pestis led to the proposal that Y. pestis is a recent 
clone of Y. pseudotuberculosis that arose between 1,500 and 20,000 years ago and more than 95% 
of genetic identity (ACHTMAN et al. 1999). In spite of what they have in common, the causative 
agent of pseudotuberculosis lacks F1 and Murine toxin, which plays an important role in inducing 
immunity and toxicity in Y. pestis. 
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One of the first trials of immunization of animals against the plague microbe with Yersinia 
pseudotuberculosis was carried out by ZLATOGOROFF (1904, 1918) [cit. by DOMARADISKIJ. 1998], 
unfortunately there was no positive result. In contrast, MACCONKEY (1908) and ROWLAND (1912) 
[cit. BY DOMARADISKIJ. 1998] inoculated animals with live and killed cell cultures and achieved a 
clear expression of immunity against plague. BOY (1932, 1933) [cit. by POLLITZER. 1954] used a 
formalin killed Y. pseudotuberculosis cells in experimental trails as a vaccination for human in 
Madagascar against plague was not unsuccessful. In further studies THAL, (1955, 1956) [cited by 
DOMARADISKIJ. 1998] showed that a single inoculation of guinea pigs with liveY. 
pseudotuberculosis serotype IV boullion (avirulent strain 32) induced a stable immunity. Another 
similar study reported by SIMONET et al. (1985), indicates that specific immune response to Y. 
pestis was induced when mice were immunized with viable bacteria from a virulence plasmid 
cured strain of Y. pseudotuberculosis. Also, this antigenic stimulation generated specific protection 
against virulence-plasmid-harboring Y. pseudotuberculosis. Recently it was reported that two oral 
immunization of live attenuated vaccine based on Y. pseudotuberculosis IP32680 provided a 
protection of 88 % of mice against subcutaneous challenged Y. pestis  CO92 (BLISNICK et al. 2008). 
In spite of the capability of Y. pseudotuberculosis in inducing immunity against bubonic plague, 
several questions remain unanswered. For example, the question concerning the mechanism of 
immunity against plague as a result of an inoculation of Y. pseudotuberculosis or, which antigens of 
this microbe are necessary for the development of immunity or the level of protection? If it does 
protect against pneumonic plague, the most feasible route of infection in case of intentional spread 
of the pathogen? Or plague caused by a number of atypical strains available in nature around the 
world and are know to be virulent for human? 
 
Immunization with Y. pseudotuberculosis carrying the recombinant plasmid signified as KM100 
containing, the major protective antigen of the Y. pestis, capsule antigen (F1) and attenuated 
auxotrophic strain of Y. pseudotuberculosis KM99 were reported to show some low level of 
protective in mice and guinea pigs challenged s.c. with virulent strains of Y. pestis and Y. 
pseudotuberculosis (DARMOV et al. (1997). 
 
Studies made by TAYLOR et al. (2005) showed that oral immunization of BALB/C mice with a dam 
(gene encoding DNA adenine methylase) mutant of Y. pseudotuberculosis strain IP32953, protected 
against a s.c. challenge with 100 MLDs of Y. pestis strain GB and an intravenous challenge with 300 
MLDs of Y. pseudotuberculosis IP32953. It was also reported that no bacteria were detected in 
spleen homogenates in both cases, where as naive mice challenged s.c. with 100 cfu. Y. pestis of GB 
died within 10 days. Although mice immunized either by oral or i.v route showed protection 
against Yersinia pestis challenge, immunization with Dam-deficet Y. pseudotuberculosis offered the 
highest levels of protection with complete protection seen if the dose of 106 cfu or greater was 
reported. That indicate the possibility of developing a bivalent vaccine. 
 
Thus, uses of pathogens that naturally infect mucosal surfaces are of interest as vaccine vectors for 
the delivery of foreign antigens to the immune system to stimulate both systemic and mucosal 
immune responses, which may protect against bubonic and pneumonic plague. They can also be 
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administered orally. Therefore, Salmonella based vaccines are attractive as carriers of protective 
antigen like F1, V-antigen YOP e.t.c. Intragastrically and intravenously application of the 
recombinant vaccine that consisted of an attenuated S. typhimurium aroA- strain, which expressed 
the F1, capsular antigen of Y. pestis protected mice against the virulent strain Y. pestis GB (OYSTON 
et al. 1995, TITBALL et al. 1997). It was also reported that the protection was correlated with the 
induction of high titers of immunoglobulin G in serum samples and T-cell response Attenuated S. 
enterica serovar typhimurium SL3261 (aroA-) expressing the Y. pestis V-antigen immunization was 
shown a protection (30 %), when mice were challenged s.c. with 97 cfu of Y. pestis GB (GARMORY 
et al. 2003). V-antigen specific IgG was detected in the serum of all mice. However, the 
concentration of specific antibody induced in mice which survived the plague challenge were not 
significantly different to some antibody concentrations induced in dead animals. 
 
Similar studies done by ANDREWS et al. (1996) also showed that, Fraction 1 capsular Antigen (F1) 
purified from Y. pestis CO92 and from an E. coli HB101 /F1 recombinant strain protected 70 to 100 
% of the mice challenged s.c. with 100 LD50 of wild-type of Y. pestis CO92 where as the licenced 
killed-whole-cell (USP) plague vaccine protected 50 % of the mice. After aerosol challenges with 
the same doses 65 to 84 % of the mice immunized with recombinant vaccine were survived, where 
as the plague vaccine protected only 1 mouse of 9 mice. 
 
Oral immunization with attenuated S. enterica serovar Typhimurium vaccine strains in mice has 
generally constituted a model for oral immunization with attenuated S. enterica serovar Typhi 
vaccines in humans, since S. enterica serovar Typhi is not known to be virulent in any animal model 
by the oral route of infection. A recombinant strain of attenuated S. enterica serovar Typhi surface-
expressing Y. pestis F1 generated by transforming strain BRD1116 (aroA- aroC- htrA-) (LOWE et al. 
1999) with plasmid pAH34L encoding the Y. pestis caf operon, protected 65 % of intranasally 
immunized mice, (twice with a dose of 1X 108 cfu) 13 out of 20 from lethal challenges with Y. pestis 
(GRIFFIN et al. 2005). Immunogenic antigens of Y. pestis like F1 or V encoded in closely related 
species of Y. pseudotuberculosis strains or other enteropathogenic species like, Salmonella and 
Escherichia showed that there is a possibility of developing a bi-or multi-valent vaccine, but that 
needs further investigation. Multivalent vaccines can have great disadvantage such as, the 
increasing complexity of antigen mixture may make of vaccine associated adverse events and may 
also have advantage like, they will induce immune responses different from those engendered by 
single antigens or single organism products. 
In addition various forms of vaccine trials, such vaccines based on non-cellular extracts 
(synthetic/chemical), vaccines based on recombinant antigens of other closely or distantly related 
bacteria, i.e. Y. peudotubreculosis (DARMOV et al. 1997), S. typhmurium  (OYSTON et al. 1995; 
TITBALL et al. 1997) E. coli (ANASIMOV. 1999) were also studied. Some of these vaccines 
demonstrated some level of protection, in experimental animals and few human volunteers in 
specific situations. 
 
ANISIMOV’S. (1999) investigations, including 42 strains of Y. pestis, 1 strain of Y. enetercolitica, 41 
strains of E. coli, in which the major capsule antigen (F1) gene were introduced by plasmids 
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showed that, a recombinant capsule antigen (F1) of Y. pestis expressed by E. coli expressed high 
protection against the infection of virulent “wild” strains of Y. pestis to guinea pigs and mice for the 
first time. Serological studies of recombinant antigen of F1 based on 42 strains of Yersina, induced 
1,000-10,000 times higher antibody titers than the reference vaccine strain of Y. pestis EV NIIEG 
line. Recombinant antigen based on 10 strains of Salmonella spp. showed, that recombination 
based on S. minnesota protected the animals to the same level of the live EV 76 vaccine of NIIEG 
line. Most of what is known about recombinant vaccines based on other organisms are targeted to 
s.c. infection, and less is known about aerosol or atypical caused plague infection. 
 
4.1.4.3 DNA Vaccines 
 
The first report to the successful expression of naked plasmid DNA in mouse muscle tissue was by 
WOLFF et al. (1990). Three years later the potential for the development of new vaccines against 
infectious organisms was demonstrated when DNA encoding the nucleoprotein of influenza virus, 
pseudorabies virus were shown to induce antibody, specific T-cell responses, and protective 
immunity against viral challenge (ULMER et al. 1993, CHANG. 1998). Since then, DNA vaccine has 
been prepared and tested against a wide range of infectious disease initially against infections 
caused by viral diseases (WANGE et al. 1998, BOYLE et al. 1999). 
 
The DNA vaccines are the simple rings of DNA containing a gene encoding an antigen and a 
promotor/terminator to make the genes express in mammalian cells. They are promising new 
approaches for generating all types of desired immunity: cytolytic T lymphocytes (CTL), T helper 
cell antibodies (SMILEY. 2008), Whilst being a technology that has a potential for global usage in 
terms of manufacturing ease, broad population administration and safety (FYNANA, et al. 1993). 
There are few studies reported on the use of DNA vaccine against bacterial infections, although the 
potential has been demonstrated for Mycobacterium tuberculosis (HEWINSON. 2005) Clostridium 
tetani, Corynebacterium pseudotuberculosis in sheep (CHAPLIN et al. 1999), Chlamydia psittaci 
(VANROMPAY et al. 1999), Bacillus anthracis (STEPANOV et al. 1996) and some intracelluar 
infections.  
One of the impediments to successful vaccination against the aforementioned infectious agents like 
plague, glanders and melioidosis, are likely they require a cellular as well as humoral immune 
response for protection (ROBERT et al. 2000, MICHELLE et al. 2005). In this regard, although killed 
vaccine like USP in plague is efficient at inducing antibody responses which alone is not sufficient 
to provide complete protection, only vaccines based on live attenuated organisms be able to induce 
cellular immunity efficiently, which is crucial for intracellualr pathogens like Yersian pestis. It 
should be noted, however, that wide spread use of life attenuated vaccine might be precluded by 
practical constraints such as manufacturing, post-immunization adverse reaction, safety concerns 
or short term protection and needs of multiple booster immunizations. Thus, it was demonstration 
over the last decade that plasmid DNA vaccines can induce both humoral and cellular immune 
responses in a variety of murine and primate disease models and might overcomes the drawbacks 
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of killed or attenuated vaccines known yet. This has engendered considerable excitement in the 
vaccine community. 
 
The historical basis for DNA vaccines rests on the observation that direct in vitro and in vivo gene 
transfer of recombinant DNA by a variety of techniques resulted in the expression of proteins that 
is able to elicit protective immunity (ULMER et al. 1993). DNA vaccines provide prolonged antigen 
expression leading to amplification of the immune response and appear to offer certain advantages 
such as ease of construction, low costs of mass production, high levels of temperature stability and 
the ability to elicit both humoral and cell-mediated immune response (GURUNATHAN et al. 2000).  
  
The endogenous expression of antigen from DNA introduced into host cells lead to peptide 
presentation with the major histocompatibility complex class I (MHC-I) which is ideal for induction 
of cytotoxic T-cell response. Therefore, DNA vaccines have been primarily considered for use 
against intracellular pathogens such as viruses (GREGERSEN 2001, SAIKH et al. 1998). 
Nevertheless, the observe ability of DNA vaccines to elicit both cell-mediate and humoral immune 
responses paved the way for their assessment as expressers of soluble, secreted bacterial antigens 
conferring immunity presumably by eliciting the classical MHC-II mediate humoral response 
(FELTQUATE et al. 1997). It was also known that the efficacy of such DNA vaccines was found to 
vary from case to case and depends on the nature of the individual antigen, on the vaccination 
mode and on the subcellular location in which the antigen was expressed (BOYLE et al. 1997, 
TORRES et al. 1999). It has been also suggested that the use of DNA vaccine may be complicated by 
fundamental differences between prokaryotes and eukaryotic genes (e. g. codon usage, and gene 
products due to different cellular machinery), leading to the poor expression of a proteins correctly 
folded. 
 
It was reported by HAIM et al. (2003), that DNA vaccine against plague, based on plasmids 
expressing derivatives of Y. pestis capsular antigen F1, devoid of its putative signal peptide (deF1) 
induced an effective antibody response and conferred protection against high dose of infective 
virulent Y. pestis strain of Kimberley53 (HAIM et al. 2003) and intramuscular (im) and intra-
dermal (id) immunization of different mice strains, out-bred and inbred mice challenged with 50 
LD50 s of Y. pestis 3 weeks post immunization provided practically fully (98,4 %) protection, 
independent of the mouse strain or the mode of vaccination and the GMTs (geometric mean titer) 
of specific anti-F1 antibodies in this various groups ranged from 4,000 to 19,000. 
 
Another study reported by WILLIMASON et al. (2002) demonstrated, that co-immunization with 
plasmid DNA cocktails primes mice against anthrax and plague. It was demonstrated, that the 
protective antigen PA of B. anthracis and V antigen of Y. pestis are potent immunogens and 
candidate vaccine subunits. Mice primed with a combination of each plasmid and boosted with a 
combination of the recombinant proteins were fully protected against challenges with Yersina 
pestis whereas mice immunized with plasmid DNA encoding V antigen and boosted with rV were 
only partially protected (50%) against the same challenge dose. This indicates that, DNA 
immunization can be an effective strategy against plague as recombinant proteins, both PA and V 
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antigen, are potent immunogens inducing high titres of circulating IgG in the mouse model. 
Attempts to understand the advantage in combining plasmid DNA constructs encoding, rPA and rV 
respectively into a single immunization and its efficacy to protect from single or both infectious 
disease needs further investigations. 
 
The possibility of combing a number of plasmids in a cocktail to create a multivalent vaccine could 
be very attractive as well as conceptual and logistical advantages can be expected. There could be 
practical advantages in that, that one plasmid may act as an adjuvant for a co-administered 
plasmid. WANG et al. (2004) studies, demonstrated that a novel DNA vaccine expressing a modified 
V antigen (LcrV) of Y. pestis, with a human tissue plasminologen activator (tPA) signal elicited 
strong V specific antibody responses and the tPA/V DNA vaccine protected mice from intranasal 
challenge with lethal doses of Y. pestis (KIM strain). 
 
DNA vaccination might provide several important advantages over current vaccines: 1) DNA 
vaccines mimic the effects of live attenuated vaccines in their ability to induce major 
histocompatibility complex (MHC) class I-restricted CD+ T-Cell responses, which may be 
advantageous compared with conventional protein-based vaccines, 2) DNA vaccines can be 
manufactured in a relatively cost-effective manner and stored with relatively ease, eliminating the 
need for a “cold chain” (the series of refrigerators) required to maintain the stability of vaccines 
during distribution, 3) Induces both, humoral and cellular immune responses which are necessary 
to protect from intracellular pathogens like Y. pesti, 4) Unable to reverse to virulent. 
These being the advantages of DNA vaccine theoretically, there are also some area of concerns such 
as, possible integration into chromosomal DNA, leading to insertional mutagenesis or oncogenicity, 
the possibility of the vector plasmid in transforming the microflora of the host to antibiotic 
resistance and possibility of germline transmission, induction of autoimmune disease including 
anti DNA-Antibodies (MURPHY. et al. 1999, GLENTING and WESSELS 2005). Worldwide, there are 
no licenced vaccines based on DNA against bacterial infection yet. 
 
Currently, there are a number of novel approaches to design a vaccine, molecular-biotechnical 
methods like, identifying essential immongenic proteins as well as virulence factors of the 
pathogen, single or recombined to develop a vaccine (WILLIAMSON. 2001), sequencing different 
strains of Yersina or Burkholderia species to understand their relationships, the role which each or 
groups of genes do paly (PARKHILL et al. 2001, DENG et al. 2002, CHAIN et al. 2006, GARCIA et al. 
2007). Furthermore, the availability of cross checking technologies of purity, stability, safety, 
durability e.t.c., of vaccine components (WHO. 2007, CORNEILS. 1989, 2002, GRANDI. 2001), or 
deleting the immune suppressive and reactogenic encoding genes (FOEODROVA et al. 2007,2008, 
BUBECK and DUBE 2007, PALMER et al. 1999). 
 
The advances in our understanding of the basis of immunology of the host on one hand and the 
host-pathogen interaction on the other hand facilitates the development of new vaccines which are 
based on a rational choice of pathogen-derived immunogenic sequences in order to induce 
effective, long-term protection with less, ideal with no toxicity (ROSENTHAL and ZIMMERMANN 
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2006, FEODEROVA et al. 2007, 2008), that will all lead us to the new era of vaccine production 
against pathogen that causes plague, glanders and melioidosis, which are relevant to public health 
and security concerns. 
 
The ease of manipulation of gene sequences, isolation of the target gene, cloning, expression and 
investigation of the role of specific protein in vivo and in vitro and novel delivery systems are 
emerging which can activate specific pathway of immunity. New vaccine developments directed 
against intracellular microorganisms like Yersinia pestis must induce both arms of immunsystem, 
the humoral and cellular immune responses must be provoked. The Vaccine must be able to 
activate especially cytotoxic T-cell responses, which have been difficult to induce with some other 
forms of vaccines like killed vaccines. New or improved vaccines must provide universal protection 
against virulent atypical strains which are available worldwide (ISUPOV and LEDVANOV 2002, 
HEALEY et al. 2005, KALACHEV et al. 1997, KETHEESAN et al. 2001). 
 
4.1.4.4 B Antigen and BaSoAn 
 
B antigen and Basic Somatic Antigen (BaSoAn) are thought to be the major components of the 
water-insoluble “residual” antigen (DALVADYANTS. 1997) initiating a classical T-cell-modulating 
state of immunity that has been protective for guinea pigs (BRUBAKER. 1972, BURROWS. 1963). 
BaSoAn can be obtained from Y. pestis and Y. pseudotuberculosis grown under a wide range of 
cultural conditions and the extraction lacks endotoxic activities (GRIBOEDOV. 1985). The B-
antigen is known to be a macromolecule complex of polysaccharide, tightly bound to protein and 
non-toxic lipid localized on the outer coat of the virulent strains of plague pathogens. The 
biosynthesis of B-antigen is determined by chromosomal DNA and the optimal extraction of the 
antigen takes place at an incubation of temperature 27 ± 1 °C and 37± 1 °C in cultures grown on 
solid medium or broth commonly used in microbial laboratory. B antigen is also produced in vivo 
by Y. pestis (BYVALOV et al. 1997). 
 
Subcutaneous immunized guinea pigs with B antigen were shown to be protected against similar 
routes of challenges with virulent Y. pestis in a dose of 100 LD50, whereby the Id50 was signified as 
14:1.47 mg of antigen. It also initiated a classical T-cell-modulated state of the immune system 
(BYVALOV et al. 1997). In analogical conditions of studies, immunization of guinea pigs with 0,34 
mg protected more than 80 % of the animals against aerosol infection of virulent strains with a 
dose ranging from 10 to 15 cfu LD50. In contrast to guinea pigs, B-antigen does not protect white 
mice (BYVALOV et al. 1997, ANISIMOV et al. 2004). Serological studies of a serum collected 21 days 
after immunization with F1 (Fraction-1) and B-antigen showed that there is a direct strong 
correlation between the level of antibody titers and survival rate of the animals, mice, guinea pig 
and non-human primates immunized with recombinant antigens of F1+BaSoAn were protected 
against challenged wild type strain of Y. pestis. (GRIBOEDOV. 1985). 
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Summing up, the native vaccines used against plague in the 20th century, killed or live attenuated 
and the forthcoming vaccines, based on major immunogenic antigen (F1/V) of plague microbe, 
known as subunit /recombinate, differences in the level of protection was observed when mice and 
the guinea pigs challenged by various routes. The forthcoming vaccines against plague, F1+V 
antigen or F1/V do protect mice but not guinea pigs  and non human-primates (tab. 4) only 
modestly against the strains from where they were derived (TITBALL and WILLIAMSON 2001, 
2004, LEARY et al. 1995). They are likely much less genetical and phenotypical diversity when 
compared to strains from other parts of the world, particularly FSU . Whether these vaccines 
protect against them is not known. Further investigation of their protection against strains isolated 
from various natural foci with intraspecise diversity is crucial for the qualification of any vaccine 
candidate against plague for global acceptance and implementation, above all in case of intentional 
use of the pathogen. 
 
Although there is no comparative study between vaccines based on subunit antigens and live 
attenuated vaccine such as EV 76 NEIIG, it is constant that the live EV NIIEG strain provides 
protection for both species of experimental animals, suggesting live attenuated EV NIIEG has the 
advantage over the rest of the vaccine forms yet. The recombinant F1+B antigen also protect both 
species against bubonic plague caused by wild types and not known if it does against pneumonic 
plague. The recombinant antigen of F1 + BaSoAn is known only in protecting bubonic plague (tab. 
4) caused by wild types (ANISIMOV et al. 2004). Further studies are essential for the forthcoming 
vaccine candidates to resolve the relevant characteristics that are not yet known. 
 
  
  
 
Table 3. Relevant characteristics of the current and forthcoming plague vaccines in mice and guinea pigs 
Protection of: 
                                                Mice from: Guinea pigs from: Nonhuman primates from: 
 w.t. F1- w.t. F1- w.t F1- 
Vaccine 
pre
par
ati
ons 
Bubonic 
plague 
Pneumonic 
plague 
Bubonic 
plague 
Pneumonic 
plague 
Bubonic 
plague 
Pneumonic 
plague 
Bubonic 
plague 
Pneumonic 
plague 
Bubonic 
plague 
Pneumonic  
plague 
Bubonic 
plague 
Pneumonic  
plague 
Live (EV) + + ± ? + + + ? + + ± ± 
Killed USP + - - - + ? ? ? + - - - 
F1/V or F1+V + + + + ? ? ? ? + + + + 
F1+B + ? ? ? + + ? ? + + ? ? 
F1-BaSoAn + ? ? ? + ? ? ? + + ? ? 
Y. pestis∆IpxM + ? ? ? + ? ? ? ? ? ? ? 
Y. pestis yop∆H + + ? ? ? ? ? ? ? ? ? ? 
 
F1- : challenged with Fraction 1 negative strains, B : B. antigen, F1-BaSoAn: Fraction 1-Basic Somatic Antigens, Y. pestis∆IpxM- hexa-acylated lipid A mutant, Y.pestis yop∆H- 
Protein tyrosine phosphates mutant, +: Protective, ?: not known, - : not protective . Data compiled with permission from Anisimov et al. 2004, Feoderova et al. 2007, 2008, 
Bubeck and Dube 2007.  
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4.1.5 The role of major Proteins : Immunogenicity versus Virulence  
 
The major three proteins encoded by the plasmids, pFra, pCad, pPst, of Y. pestis are well studied as 
single purified protein or as recombinant /subunits in order to eluicdate their role as virulence 
factor or protective antigens (BRUBAKER. 1991, CHERPANOV. 1991, FILIPPOVA. 1990). 
By definition the ability of a biological product to stimulate an immune systems response in the 
body, promoting the formations of antibody is called immunogenicity, which is a desirable 
characteristics of an antigen for vaccine. But induction of antibody alone doesn’t make an antigen 
to be a good vaccine candidate. It is more important to know, which antigen/ or antigens are 
promising, are in a position to fulfil the requirement which is necessarily needed to develop a 
vaccine, enable in provoking all required arms of the immune system and appropriate antibodies 
that must protect the vast majority of the experimental animals in the first line and finally humans 
from the most virulent strains of the species and have no adverse reaction, furthermore must 
provide universal protection against infection caused by atypical strains and retains a global 
acceptance (STEPANOV et al. 1997, WHO. 2004, 2007). 
 
There are different views on the definitions of Y. pestis virulence determinant factors. PERRY et al. 
(1997) defined virulence determinant factors of Y. pestis as a factors that promote bacterial 
survival, growth, and/or transmission by directly affecting the host through adherence, thwarting 
host defence responses, disrupting cellular metabolism, or acquiring essential nutrients from the 
host. Thus, we would not classify purine biosynthetic enzymes or other metabolic enzymes as 
virulence determinants although they are required for virulence of Y. pestis, while they are 
common to all three human pathogen yersinae. In the contrary, BURROWS. (1957, 1960) and 
DOMARADISKIJ. (1998) describe that the virulence properties of Y. pestis as, follows: 1) the 
capability to form a capsule by fraction1 (F1), 2) capability of purine synthesis and, 3) formation of 
“pigmented” colonies on nutritional media that contain hemin. 
 
The extreme virulence of Y. pestis can be attributed to its ability to efficiently invade and subvert 
the mammalian innate immune system resulting in an overwhelming infection. The capacity of Y. 
pestis to disarm the innate immune system is determined by numerous virulence factors encoded 
on its chromosome and three plasmids pFra, pCad, pPst. (WAKE et al.1983, BRUBAKER. 1991, 
CHERPANOV. 1991, FILIPPOV. 1990), which are contained by the majority of the Y. pestis isolates 
regardless of biotypes or origin has also several chromosomal associated factors that are essential 
to its virulence and survival in mammalian hosts and flea vectors (STRALEY and BRUBAKER 1982). 
Strains isolated from natural foci which lack one or two of the three plasmids are also known to be 
virulent by aerosols (WORSHAM and ROY 2003). The extreme virulence of Y. pestis to large extent, 
from its ability to impair innate immune system, the mechanism that enables to overwhelm the 
host defense, paramount among these is the plasmid, pLcrV that encodes a type III secretion 
system and effectors (HESSEMANN 2006, VIBOUD and BLISKA 2005). This system produces 
‘injectisome’, that translocates Yersina outer proteins (Yops) to the neighbouring host cells, where  
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they disrupt signalling pathways, prevent cytoskeletal rearrangements, suppress cytokine, 
production and promote apoptosis (RUCKDESCHEL et al. 1997, HEDERSON and NATARO 2001, 
SMILEY. 2008, TROSKY. 2008), that indicates the system inhibits the antibacterial defense 
mechanism of phagocytes. 
 
Views on virulence determinant factors of Y. pestis are very complex and vary. It is difficult to put a 
demarcation for some of the antigens of Y. pestis if they are very essential or not for the survival 
and invasions of the pathogen. One likely indicator of potential virulence for humans is an 
indication of high level of virulence in experimental animals. The guinea pig has been the animals 
of choice for virulence and immunogenicity studies in the FSU; whereas in USA or UK guinea pigs 
are categorized as bad model for studies of Y. pestis and they prefer mice as a model to study 
plague in general (WORSHAM. 2004). Thus different results can be achieved based on the animal 
species used for experimental studies and more difficult to translate results to human use. 
Additionally most of the studies made on the plague pathogen in the Western hemisphere are 
mostly based on very few strains which are very closely related with each other. Whereas, in the 
FSU/CIS, there are a number of strain isolates with high intraspecific diversity and equal know as 
virulent, but not yet known by experts outside CIS (APARIN et al. 1987, ANISIMOV. 2002). 
 
When virulence is measured in the context of animal infection, the intensity and manifestations of 
pathogenicity of individual microbial strain are dependent on many conditions like animal species 
used for studies, immune status of the host, route of infection, infection dose, and conditions of 
animals care feeding (ANASIMOV. 2002, PERRY and FETHERSTON  1997). 
 
Heterogeneity within the strains, intraspecific virulence, host specificity, biochemical and 
physiological traits were observed in strains isolated in FSU, Asia, and in different natural foci in 
Africa (MARTIN EVSKII. 1979, ANISIMOV et al. 2004). That indicates significant variability in their 
characteristics and virulence for mice and guinea pigs. Strain heterogeneity in Y. pestis can 
obviously have a major impact on virulence and vaccine studies. Since any studies of plague 
pathogenesis, focused on strains isolated in the Americas like Y. pestis Strain CO92, that displaying 
much less genetic diversity than strains found in FSU and Asia the conclusions from this studies 
may not be entirely applicable across the board for all strains of Y. pestis with high virulence for 
humans (ANISIMOV et al . 2004). 
 
The FSU classification used in determining virulence differs from subspecies to subspecies. For 
instance Y. pestis subspecies pestis strains are lethal, whereas strains of subspecies altaica, 
caucasica, hissarica, ulegica and talassica as a rule exhibit dramatic reductions in virulence or even 
the complete absence of virulence for animals (APARIN and GOLUBINISKII. 1989, TIMOFEEVA. 
1972). It is still not known which particular set of genetic and phenotypic traits are indicative for 
virulence in laboratory animals. At the moment, there is no one definite criterion for stating that a 
given strain of Y. pestis has high or low pathogenic potential for humans, but virulence in guinea 
pig and rhamnose fermentation are the two likely virulence indicators for human (ANISIMOV et al. 
2004). 
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4.1.5.1 Iron Utilization and Pigmentation: Hms System 
 
Y. pestis grows in fleas before being transmitted to the mammalian host, part of a cycle essential for 
plague’s persistence. A number of proteins may contribute to the maintenance of Y. pestis in fleas. 
Among them two well-established determinant factors that play a important role for survival of the 
bacteria in fleas have been identified. The hemin storage (hms) system and the Yersina murine 
toxin (Ymt) (JAKSON and BURROWS 1956). The chromosomally borne hms locus was initially 
identified as being responsible for pigmentation of Y. pesits when cultured in vitro on agar 
containing hemin and Congo Red dye (PERRY. 1990, 2003). It is required for Y. pestis cells to 
colonize and block the proventriculus of the fleas. In addition in Y. pestis, five iron acquisition 
systems have been characterized (Yfe, Yfu, Ybt, Hmu and Has) and all of them are controlled by the 
Fur protein (THOMPSON et al. 1999, CORNIEL. 2000, GONG et al. 2001, ROSSI et al. 2001, 
SCUBERT. 2004). At least two (Ybt and Yfe) of them have proven to be required for the virulence of 
Y. pestis (BEARDEN et al.1998, BERDAN and PERRY 1999). One of the distinct features of Yersinia 
pathogenesis is the ability to scavenge iron from the host via siderophore called yersinabactin 
(Ybt). The genes of Ybt are chromosomally encoded and clustered on a highpathogenicity island 
(HPI). It was identified that eleven genes contained within an unstable 102-kb chromosomal region 
termed the pgm (“pigmentation segement”). Pgm is important for biosynthesis (BEARDEN and 
FETHERSTON 1997). It also includes the hms (hemin storage) locus (LILLARD et al. 1997), which 
confers a pigmented phenotype (greenish-brown or red) on Congo Red agar dyes plated at 26 °C 
but not at 37 °C. It was shown that this locus is important for transmission of Y. pestis by the flea 
vector (HINNEBUSCH et al. 1996, KUTYREV et al. 1992). Both parts are important either for 
virulence (Ybt) or for disease transmission (hms locus). Loss of virulence, linked to the loss of the 
capability of forming pigmented colonies on nutrient medium containing hemin, indicated a 
reverse and full recovery, if a pgm- strain (with another virulence determinant factor) is inoculated 
to a mice with non-toxic doses of hemin or iron salts. But experiments in guinea pigs showed only 
weak effect. Replacement of iron salt with another metal was not successful. Iron did not turn a 
pigmented avirulent strain to virulent strain, for instance pgm+/ F1+ /VW-, and its non-pigmented 
mutant pgm- /F1+ /VW- (BURROWS and BACON 1956, 1958). 
 
Speaking about the significance of iron ions for the virulence of plague bacilli, it is also necessary to 
pay attention to one circumstance, namely the capacity of all Yersiniae to produce new 
polypeptides, in an iron deficient environment. Two of them consist of high molecular weight 
proteins (HMWPs), synthesised de novo, only by highly virulent strains and are contained in the 
outer membrane fraction. An interesting peculiarity of HMWPs is that, all of them have a common 
epitops (CARNIEL et al. 1989). The essential conditions of HMWPs synthesis can be found in all 
organisms of humans and animals. The production of HMWPs is correlated with signs of pigment 
formation of plague bacilli, and deletion of HMWPs inhibits the production of macrophages to 
produce oxygen (O2) radicals (DOMARADISKIJ. 1998). A chromosomal locus responsible for the 
pigmentation phenotype, iron-inducing proteins and iron uptake is necessary for virulence from 
peripheral routes of inoculation (BRUBAKER. 1991). Most of vaccine strains used as live 
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attenuated vaccines were pigmentation deficient (pgm-), usually due to the spontaneous deletion of 
102 kb chromosomal fragment encoding iron binding and transport functions. For instance, the 
live vaccine based on Y. pestis EV 76 NIIEG line, is attenuated due to the deletion of the pgm locus, 
which includes the hms locus responsible for the ability to store hemin and a cluster of genes 
needed for production of the siderophore-based yersiniabactin biosynthetic/ transport system 
(FETHERSON and PERRY 1994, FEDEROV et al. 2007). 
 
Live vaccines of pgm- strains were often more immunogenic than killed vaccines in animals, but 
they some times cause local and systemic reactions (HALLET et al. 1973, MEYER et al. 1974). 
Reactogenicity varied with the host animals and the route of inoculation. For instance, such strains 
are virulent for mice by the intra-venous (iv) route but attenuated by peripherial routes of 
infection (UNE and BRUBAKER 1984), and several species of non-human primates are significantly 
more sensitive to pgm– Y. pestis than are guinea pigs (MEYER et al. 1974). Experimental studies 
done to examine the virulence of the Y. pestis C092 pgm– strain in Swiss Webster mice showed that, 
the strain was lethal at high s.c. dose only, with a LD50 of 107 cfu. A dose of 106 cfu (0.1 LD50) of the 
strain given subcutaneously was generally nonlethal. The virulence of C092 pgm– strains by the 
aerosol route in experimental studies showed, that after exposure of 16 African green monkeys to 
an inhaled doses ranging from 1.1 x104 to 8.1 x107cfu, eight died and eight survived, non- survivors 
and survivors did not differ in weight. The death was not related to the dose (WELKOS et al. 2002). 
Except the patho-morphological and bacteriological findings, there is no explanation to the 
question why half of them died while the other half survived. 
 
4.1.5.2 Murine Toxin 
 
The large 100 kb to 110 kbp plasmid encodes two potential virulence determinants factors: the 
Murine Toxin (Ymt) and the Fraction1 (F1) capsule antigen (CHERPANOV et al. 1991, BEN-GURION 
and SHAFERMANN. 1981, FILIPPOV et al. 1990, KUTYREV et al. 1986). Murine toxin was 
characterized as a protein fraction of the Y. pestis in the 1950’s, and later shown to have -
adrenergic blocking ability that relates toxicity to mice and rats which is manifested by 
hypotension and vascular collapse when Ymt is released from lysing bacteria at the terminal stage 
of septicemic plague (BROWN and MONTE. 1977). But Ymt is less active in other animals such as 
guinea pigs, rabbits, dogs and monkeys. This suggested that Ymt contributes to the very low 
infection doses in mice, from where its name is derived (CHERPANOV et al. 2000). The pMT1-
encoded murine toxin has two conserved motifs that are similar to human phosophliase D, that has 
shown to be located on a gene for pohospholipase D activity (RUDOLPH et al. 1999, HINNEBUSCH 
et al. 2000). It is localised in the cytoplasm and expressed better if Y. pestis is grown under room 
temperature. Ymt differs from other exotoxin, like diphteria, and anthrax toxin in: 1) there is no a 
latent period, 2) there is no direct relation between virulence and toxicity of the culture 
(DOMARADISKIJ. 1998). If not the major element, Ymt plays an important pathogenic role during 
the processes of infection of plague bacilli (EVESTIGNEEV et al. 1981). Ymt was shown to be 
required for survival of Y. pestis in the mid-gut of its principal vector, the rat flea Xenopsylla cheopis 
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and intra-cellular PLD activity appeared to protect Y. pestis from cytotoxic digestion a product of 
blood plasma in the flea gut (HINNEBUSH et al. 2002). When fleas were infected with Ymt+ or Ymt- 
Y. pestis cells, only Ymt+ cells, multiplied in the mid-gut to form cohesive aggregates and some flea 
was eventually blocked whereas, Ymt- Y. pestis cells in the flea mid-gut, did not survived (PERRY. 
2003). Suggesting that Ymt acts from intracellular location to confer resistance to the antibacterial 
activity present in the flea mid-gut, which is the prerequisite for Y. pestis to form a blockage in flea. 
HINNEBUSH et al. (2002), demonstrated that E. coli and Y. pseudotuberculosis introduced into 
midgut of flea were rapidly eliminated or reduced in number. However, when either of these two 
species was transformed with recombinant Ymt gene, survival capacity in fleas dramatically 
increased. Therefore, Ymt is essential for the maintenance and survival and multiplication of Y. 
pestis in flea. 
 
Recent observation by VASILEVA et al. (2005) indicate that Mouse toxin (MT) was found to have a 
pronounced apoptogenic action with respect to the phagocytic cells of mice, but not guinea pigs. 
Macrophages were affected by this action stronger than neutrophils, and in both cases this effect 
was dose dependent. As the dose of MT decreased to 0.01 µg/ ml, the proportion of cells dying as 
the result of apoptosis increased, the necrotic type of damage was almost absent. On the contrary, 
as MT concentration rose to 1.0 microg/ ml and over, the proportion of phagocytes dying due to 
necrosis increased with a decrease in the number of cells in which the process of apoptosis started. 
The results of the study are indicative of the fact that the mechanisms programming the death of 
cells under the action of MT on macrophages and neutrophils took part in the process, which, in its 
turn, determined their role in the pathogenesis of plague. 
To determine the protective efficacy of Ymt as it was included in the production of chemical 
vaccine, a 100 to 500 µg purified Ymt per se with incomplete Freund’s adjuvant or aluminium 
hydroxide did not protect against sc inoculation guinea pigs and mice against LD100. There were no 
sign of development of antibacterial immunity (EVESTIGNEEV et al. 1981). These factors make Ymt 
a weak candidate to be used as a recombinant antigen or chemical vaccine production against 
plague. 
 
4.1.5.3 Fraction I 
 
BAKER et al. purified the specific capsular like antigen of Y. pestis, Fraction 1 (F1), in 1952. It is the 
major component of the surface of the plague bacilli that is expressed at 37°C on nutrient media. 
However, not at a temperature of 26 °C-28 °C (optimal growth temperature of Y. pestis) where, the 
F1 is not expressed or weakly expressed (FEODOROVA and DEVADARIANI 2001).  
 
The genetical control of F1 synthesis is encoded by a unique 100 -110 kbp large plasmid called 
(pFra). Its molecular weight ranges from 60 to 65 mDa. F1 forms a large gel-like capsule containing 
multimeric aggregates (BENNETT and TONABENE 1974). Production of the 15,5-kDa F1 subunit is 
encoded by the caf1, caf1M gene (GALYOV et al. 1990, 1991) and the calfA (KARLYSHEV et al. 
1992) genes that encode, respectively, a chaperone which allows export of the F1 antigen subunit 
to the surface and a anchors protein which the F1 antigen into the outer membrane. The essential 
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carbohydrate component of mature FI antigen was suggested to be encoded by chromosomal 
genes, which were not specific for Y. pestis, but were found also in all Yersinia spp. and some other 
bacteria (FEODOROVA and DEVADARIANI 2001). 
 
Experimental investigation of pFra mutant strains of Y. pestis from the Year 1991-1996 found, that 
fra- (mutants) which were unable to synthesise the chaperone caf1M were capable of forming a 
capsule, which was different from the wildtype and had different virulence, level of protection, 
biochemical characteristics like hydrophobicity and isoeletrical potential (IS). Caf1M– mutants of 
virulent strains of Y. pestis were able to cause an infection that was similar to the “classical” plague 
infection clinically and histopathologicaly. But it was unable to protect, against homologous strains 
(ANISIMOV et al. 1997). 
 
Y. pestis M493 isolated from a natural focus and stored as “Fra±” (strains which were observed in 
producing F1 only in destructed cells but not in nutrient medium) for several years in the museum 
of „Microbe“ showed atypical capsule formation, i.e it was unable to form a capsule (PROZENKO et 
al. 1983, BAKANURSKAJA and NEKRASIVA 1997). This indicates the possibility of essential 
structural changes in the area of the caf-gene. Analysis of the clon of lyophylized and culture grown 
on hottinger agar showed in 10-30 % of cases lost pFra and in 8-25 % of the cases the clon 
increased molecular mass of pFra in comparison to “wild “type strains (SHEREMET et al. 1987, 
BAKANURSKAJA. 1997, ANISIMOV. 1999). Serial passages of heterogen culture through organs of 
white mice resulted in deletion of atypical clon population from the plague microbe. Atypical 
strains were characterised, strains with identical morphological and biochemical properties to the 
“classical” capsule forming strains but differ in immunological tests. In experimental model of 
white mice (Balb/C) infection with atypical strains showed resistance against immunization with 
live attenuated EV vaccine NIIEG line, suggests that pFra mutation does not directly result in 
avirulence (ANISIMOV and MARKOV 1997). This is an indication for mutation that took place 
through long period of storage, or for new essential antigenic variation. The F1 subunit is thought 
to be assembled on the surface of the bacterium to form the capsule, where its production is 
temperature regulated by the product of the caf1R gene (KARLYSHEV et al. 1992). A plasmid with 
molecular weight of 13 mDa, which is found uniquely in the strains of Yerka might take part of F1 
synthesis (TSUKANO et al. 1986). In addition, four more extra plasmids were expressed by this 
specific strain (TSUKANO. 1989, ZHAO et al. 1990) this indicates that F1 synthesis is controlled by 
chromosome and it is responsible for protection. The F1 gene was found to code for 17,5-kDa 
polypeptide carrying a putative secretion signal (GALYOV et al. 1990). It is considered to be an 
important but not essential virulence factor unique to Y. pestis (DAVIS et al. 1996, WELKOS et al. 
1995). Deletion of the F1 gene does not abolish virulence but leads to delay in onset of the disease 
in animal model. Oral infection of 98 outbred mice with virulent Y. pestis strain 358 (pFra–) showed 
reduced virulence to 100 folds as in compared to its isogenic variant that harbors all three types of 
plasmids known in plague microbe (KOKYSHKIN. 1997). It is even possible to propose, that the 
product of the virulence determinate factor of plasmid pFra is necessary to realize the pathogenic 
process of plague infection caused via alimentary tract. F1 appears to have a role in blocking 
uptake by macrophages (ROSQUVIST and FORSBERG 2002), it also prevents the association with 
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phagocytes preventing uptake by interfering at the level of receptor presumably adhesin-receptor 
interactions in the phagocytosis. Thus, F1 antigen inhibits phagocytosis (DU et al. 2002). 
At the moment any discussion of plague vaccines would be in complete with out consideration of 
Fraction 1 (F1). The specific capsular antigen of Y. pestis is highly immunogenic in both, animals 
and humans, and is widely used in serological tests for detection of specific antibody to Y. pestis. F1 
is the principal immunogen in killed or live attenuated vaccines which were widely used in 
different epidemic regions of the world, which showed efficient protection against bubonic plague. 
However, it is less active against the pneumonic form (BARTELLONI et al. 1973). Although some 
adverse clinical reactions were observed when F1 is used as a vaccine alone, it is one of the best 
antigen candidates in order to develop vaccines against the plague microbe in any possible form of 
construction. 
 
4.1.5.4 V-Antigen 
 
The Low-calcium response Virulon or Stimulon (termed pLcrV, pCad, pVW or pYV) is a 68 to 75 kb 
plasmid that encodes a major groups of defined virulence proteins. V-antigen of Y. pestis encodes 
the leading virulence factors , the type III secretion system (T3SS) complex (CORNELIS et al. 1998, 
PETTERSON et al. 1999, FIELDS et al. 1999) and effectors known as Yops Yersina outer proteins 
(PERRY and FETHERSTON 1997, GHOSH. 2004). Host-pathogen interaction result in expression 
changes within both the host and the pathogen. Although pathogenic Yersina species are 
predominately an extracellualr, they can translocate heterologus antigens from extracellulaur 
location to the cytosol of the APC with their type three secretion system (T3SS) which are critical 
for virulence to evade the host. To overcome host defense mechanisms, yersiniae translocates a set 
of Yops into immune cells to inhibit the innate and the adaptive immune system. At list four Yops 
(YopH, YopE,  YopT and YopO/YpkA) are involved in inhibiting phagocytosis of yersiniae by 
disrupting the cytoskeleton of PMNs and macrophages (ROSQVIST et al. 1990, 1991, SCHESSER et 
al. 1998, BLISK. 2004, ZHOU. 2006). 
 
A comparative analysis of the structure of the pYV from 14 strains of Y. pestis  and Y. 
pseudotuberculosis showed that they possess identical BamHI- (B) and HindIII-sites (H) in the LCR-
region, which proofed that they are highly conserved and homologous in two other pathogenic 
species, Y. psedotuberculosis and Y. enrtercolitica as well (BOBROV and FILIPPOV 1997, BÖLIN et al. 
1982). The plasmid of Y. pseudotuberculosis (pYV) differs from that of Y. pestis in that, it lacks one 
or two B-sites in the YopkA/YpO gene region, and an integrative mobile elements, IS100 which is 
found only in pCad of Y. pestis and IS285 which is found in pcad of Y. pseudotuberculosis, 
predominantly (BOBROV and FILIPPOV 1997). These might be the product of mutations in the 
process of evolution and a reflection of phylogenetical relation of the plasmids. Maximum 
expression of the V-antigen and YOPs occurs in vitro at 37 °C in the absence of calcium or low-
calcium-media (STRALEY et al. 1993) or after an intimate contact of the bacteria with the plasma 
membrane of eucaryotic target cells (ROSQVIST et al. 1991, SORY et al. 1995). 
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Antibodies rose against purified preparations of V-antigen provided protection against plague in 
mice and polyclonal antibodies rose against highly purified LcrV as well as monoclonal antibody 
that recognize the central domain of LcrV conferred passive protection against experimental 
infections with Y. pestis and Y. pseudotuberculosis (LAWTON et al. 1963, UNE and BRUBAKER 1984, 
MOTIN et al. 1994, HILL et al. 1997). It has been established that active immunization using LcrV as 
an antigen can provide high level of protection against up to 107 cfu lethal doses in experimental 
bubonic and pneumonic plague (LEARY et al. 1995). Similar results were observed during studies 
done on immune responses of mice survived from pneumonic plague. Over 90 % of mice 
immunized with V antigen showed an immuno-globulin (IgG) titers with an average of 1:9,000 
measured by ELISA and immunoblotting methods (ANDREWS et al. 1999). Recombinant V (rV) 
antigen vaccine adsorbed in to aluminium hydroxide protected mice against 7.4 x 105 LD50 F1+ as 
well as F1- strains of Y. pestis (ANDERSON et al. 1996). 
 
Comparative sequencing of the V antigen gene from different geographical origins showed that the 
very majority of the strains posses’ identical nucleotide sequences. The lack of lcrV differences 
among these strains suggested that little evolutionary distance separates them from a common 
ancestor, with only few exceptions such as the Angola strain (PRICE et al. 1989). This fact is of 
major concern in considering rV-antigen as candidate for vaccine. If that is also the case in strains 
isolated from natural foci in FSU, Mongolia and China is not yet known. There are strains isolated 
in FSU, with different sizes of pCad, strains with additional cryptical plasmids isolated in different 
regions of the world. 
 
Previous studies by SATO et al. (1991) and LAWTON. (1963) demonstrated a clear role of 
antibodies to the V antigen in passive protection, though the mechanism by which the V antibody 
prevents fatal disease is not yet clearly explained. A good IgG antibody response to the rV antigen 
developed as early as 13 days post immunization and its titers continued to rise up to the time of 
challenge was observed on day 58 post immunization. This can be the bases of its efficacy. The 
predominant IgG subtype was shown to be IgG1, followed by IgG2a and IgG2b when aluminium 
hydroxide is used as adjuvant (GEORGE et al. 1996). The ability of rV to prevent death and the 
establishment of a chronic infection in the majority of the surviving mice challenged subcutaneous 
or by aerosol indicates the value of this immunogen as a part of any subunit vaccine against plague.  
However, it has also been proposed that LcrV acts by suppressing the inflammatory responses 
early during infection, suppress the innate immune response, alters cytokine profiles during 
Yersinia infection, which may contribute to immune system subversion (BRUBAKER. 1991, 
NAKAJIMA et al. 1993, 1995, NEDIALKOV, et al .1997). This is supported by experiments in which 
the injection of LcrV in mice suppressed the expression of TNF-  and IFN-  and promoted the 
survival of LcrV-negative Y. pestis (NAKAJIMA et al. 1995). LcrV inhibits neutrophil chemotaxis in 
vitro as well as in vivo (WELKOS et al. 1998). In addition to its effect on host V protein is involved in 
the regulation of the low calcium response of Y. pestis (BERGMAN et al. 1991, PRICE et al. 1989, 
1991, SKRZPEK and STRALEY. 1995). This limitation could damper the ability of a vaccine using a 
combination of recombinant LcrV and F1 subunit (WILLIAMSON et al. 2001) separate or as a 
fusion protein (HEATH. 1998). In addition to that, it is also not known, how the recombinant 
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vaccine formulation responds to strains with various plasmid contents and strains isolated from 
natural foci, which lack the LcrVantigen (DMITRYUK et al. 1997). Nevertheless, experiments 
performed with mice illustrated the efficacy of the V antigen as a vaccine against lethal 
subcutaneous and aerosol infections with F1+ and F1- Y. pestis strains (ANDERSON et al. 1996, 
HEATH et al. 1997, LEARY et al. 1995, MOTIN et al. 1996, WILLIAMSON et al. 1995). Althugh, the V 
antigen of the Y. pestis has been described to the potent suppressor of TNF production, the pro-
inflammatory cytokine which is a mediator of inflammation and plays a major role in host 
responses to microbial infections (VASSALLI. 1992). TNF is predominantly produced by activated 
macrophages, although other cell types, e. g. T cells, NK cells and the mast cells have been 
recognized as sources for TNF. Locally, TNF acts as a stimulator for the expressions of cytokines 
including IL-1 and IL-6, and chemokines such as IL-8 and monocyte chemotactic protein-1MCP-1 
(LI, 1993, SCHULTE et al. 1996). TNF also induces the expression of adhesion molecules E-selectin, 
vascular cell adhesion molecule-1 and stimulates macrophages to produce large quantities of nitric 
oxide, which is thought to contribute to killing of bacteria (EVANS. 1995). Comparatively, little is 
know about countermeasures of the TNF responses.  
 
The V antigen is also characterized as suppressor of TNF and IF-γ levels in sera and spleens of mice 
infected with virulent Y. pestis when compared to control mice (ANNET et al. 1999). That indicatres 
that V-antigen is an interesting protein, because once it is not only required for the translocation 
process, but it has also been detected in the cytoplasm of the host cells and the extracellular milieu 
of the infected cell (BLISKA. 2004). It is also known as one of the major immungenic component of 
Y. pestis, a candidate for new vaccine development and on the other side it is also proofed as 
immune suppressive protein, it counteracts cytokine production that might cause toxicity after 
immunization. Currently attempts to neutralise the suppresive effect of V- antigen are under 
studies. However V antigen is the next strong candidate protein in development of plague vaccine 
to F1 in any form of vaccine design.  
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4.1.5.5 Pesticin 
 
Pesticin was first isolated from plague bacilli by BEN-GURION and HERTMAN in 1958. Three years 
later, BRUBAKER and SURGALLA reported that the plague microbe possesses additional pesticin, 
and then they named it P1 and P2, respectively. The majority of plague microbes posses P1, but not 
Y. pseudotuberculosis. P2 is characteristically produced by both, Y. pestis and Y. pseudotuberculosis. 
The principal difference between them is, that the production of P2 is coded on the chromosome, 
whereas a gene of p1 ”pst” is localized on the plasmid P (pst), it is also known as (pPCP1) with 
molecular weight of 9.5 kb, the smallest plasmid harbored by Y. pestis (DOMARADISKIJ. 1998). 
 
Pesticin (P1) of Y. pestis is determined by the pesticin activity gene (pst), [40 kDa] and the 
immunity gene (pim) [16 kDa] found in periplasma (PILSL et al. 1996). The genes are tandemly 
arranged on small plasmids and transcribed in opposite orientation, which is typical for pore-
forming colicins, as opposed to the colicins with nuclease activity (BRAUN et al. 1994, JAMES. 
1996). Both pesticins neutralize antiplague serum and virulent strains of Y. pseudotuberculosis. 
Pesticin was considered as a N-acetyl-glycosaminidase previously, and apparently kills by 
degrading cell walls leading to osmotic instability and lysis (FERBER and BRUBAKER 1979). 
VOLLMER et al. (1997) indicated that pesticin is a muramidase and not a N-acetyl-glucosamini-
dase, that converts cells into stable spheroplasts by slowly degrading murein. Pesticin 1 was 
reported to be essential for the virulence of plague bacilli previously, as variants of Y. pestis lacking 
pesticin (pst-) were avirulent in comparison to strains that possess pesticin 1 in white mice and 
guinea pigs challenged subcutaneously. But intraperitoneal challenge reduced its virulence to 4-5 
folds, and both pst1- and pst1+ strains were similar in intravenous inoculation. Further 
investigation of the mutants showed that they lack coagulase and fibrinolytic activities 
(BRUBAKER et al. 1965). In contrast, GREBTSOV et al. (1991) reported that pesticin do not play an 
essential role in expressing virulence and immunogenicity, but it is possible, that a vaccine strain of 
Y. pestis circulating in the organism can induce antibodies and can contribute to protection of the 
animals from infection. Similar investigation also showed that all mutants of plague microbes, that 
lost the capability for P1 production, were avirulent, although some of avirulent strains produce P1 
(DOMARADISKIJ. 1998). 
 
Guinea pigs infected with Y. pestis strain 358 that harbor pPst+ and its mutant (pPst-) do not lead to 
an increase in LD50 with either in s.c. or respiratory challenge (SAMOILOVA et al. 1996). Another 
similar investigation showed that, six white mice and six guinea pigs challenged s.c. with the doses 
ranging from 10 to 104 cfu/per animal with Y. pestis 231 strain that harbor pesticin (pst+) and its 
mutant (pst-) did not show significant difference in both groups of animals, indicating that pesticin 
alone is not essential as factor of virulence in plague microbe. Similar studies on its 
immunogenicity showed no signs of protection (GREBTSOV. 1991 Some minor differences were 
observed in KIM and CO92 and some other strains. Although it was observed that Y. pestis strains 
which lost their capacity in producing P1 or the “switching-off” of pst gene had decreased the level 
of virulence i.e. increased the mean survival rates of the animals to two days longer than the wild 
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strain, significant level of protection was not observed when white mice and guinea pigs were s.c. 
inoculated. Some mutant (pst-) strains isolated from natural foci have been reported to be virulent 
(APARIN et al. 1987)  
 
Even though pesticin antigen alone is thought to be a weak immunogen, In Russian standard 
criterieum, like the live EV 76 NEIIG, the paternal vaccine strain, the forthcoming new vaccine 
strains candidates for the development of improved live attenuated vaccine must harbor pesticin 
(ANISIMOV et al. 2002). The reason might be, that pesticin may play some roles in concert with 
other immunogenic proteins like F1 and V-antigen in processes of inducing humoral or cellular 
immnuesystems that needs futher studies. 
 
4.1.5.6  pH 6 Antigen 
 
The pH 6 antigen (PsaA) is the only known putative adhesion antigen expressed on the surface of Y. 
pestis, when the bacterium is grown between pH 5 and pH 6.7 and between 35 °C and 41 °C 
encoded by the chromosomal psaA, while cells grown outside this parameter did not (PRICE et 
al.1995). The psaEFABC operon encodes a chaperone/usher pathway involved in the secretion and 
assembly of pH6 antigen as polymers on the surface of Y. pestis macrophages. These conditions are 
encountered in the phagolysosome and synthesised at this site in macrophages, which might 
facilitate the colonization of other cell types and contribute to the delivery of Yops into these cells 
by promoting bacterium-host cell contact (LINDLER et al. 1993, ZAVYALOV et al. 1996). The pH 6 
antigen was first identified as a virulent determinant factor when the derivatives of Y. pestis lacking 
the pH 6 antigen showed reduced virulence in mice (BEN-EFRAIM et al. 1961). Mutation of the psa 
locus results in a 200-fold increase in the LD50 of the mutant bacteria compared with the wild-type 
parent strain, when mice were challenged intravenous route of infection (LINDNER et al. 1990). pH 
6 antigen binds cerberosides containing ß1-linked galactosyl residues in glycosphingolipids of the 
host and are likely to be found on range of host cell types recognized by pH6 antigen. Thus a role of 
the pH6 antigen might be to maximize the colonization of the host cells (PAYNE. 1998). However, 
HUANG et al. (2004) demonstrates that pH6 antigen did not enhance adhesion of the bcateria to 
mouse macrophages but rather functioned as antiphagocytic factor independent of Yops and F1 
capsule. Therefore, pH6 antigen is unlikely to be adhesin that was previously thought to be 
responsible for the pathogen’s colonization of of host cells or the delivery of Yops to the host cells. 
 
The pH 6 antigen is induced inside macrophages under acidic environment a homopolymeric 
fibrillar structures on the bacterial surface (LINDLER et al. 1993). Production of the antiphagocytic 
of Y. pestis cells is reduced or not expressed under this condition, where the expressing of the pH 6 
(psaA) antigen is optimal (LINDNER et al. 1990). Suggesting that pH6 antigen might be the first 
antiphagocytic factor produced by the organisim after release from infected macrophages which is 
specific to pH6 antigen expressing organism, different from that of Yops (MAKOVEICHUK et al. 
2003). It was also found that pH6 aggultinate erythrocytes from a range of species and the pH 6 
antigen has been reported to bind to several human immunoglobulin G subclasses by acting as a 
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bacterial Fc receptor (ZAVYALOV et al. 1996). Intradermal injection of pH6 in guinea pigs isolated 
in immunosorption method induces inflammatory reaction and possesses hemagglutnating and 
cytotoxic activities in alveolar macrophages (STEPANSHINA et al. 1993). 
 
Immunological responses of 12 mice after aerosol challenge with approximately 100 LD50 of Y. 
pestis CO92 and subsequently treated with antibiotics starting 24 or 42 hrs post challenge showed 
no reaction. Thirty days post-challenge collected sera from survivors analysed for IgG by ELISA and 
immunoblotting methods specified that only one (1/12) animal responded to pH 6 antigen 
(BENNER et al. 1999) that indicates pH6 is a weak immunogen inductor to be considered as a 
candidate for subunit or recombinant vaccine production against Y. pestis alone.  
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4.2 Challenges of Vaccine Development against Glanders and Melioidosis 
 
In the last century the world had witnessed two world wars, where one of the oldest know 
pathogen that causes glanders, which is now known as B. mallei was used as biological weapon 
(GEISSER,1998). As a consequence, a number of states further intensified the research activities in 
quantities of microbes considered most suitable for weaponization during cold war era (BONDI 
and GOLDBERG 2008). The very majority of research activities of these pathogens were done with 
high security, secrecy in military centers and moreover these pathogens were genetically 
manipulated to enhance the resistance against any forms of antibiotic therapy or vaccines in some 
states (ALIBEK. 1999). 
B . mallei is an obligate parasite that typically infects solipeds and only occasionally infects humans, 
whereas B. pseudomallei is a widely distributed environmental saprophyte that cause a severe 
disease in human and animals in endemic regions (DANCE. 1991, WHITE. 2003). Because of high 
mortality rate in humans and the small number of organisms required to establish infection, if 
inhaled and furthermore, high MDR to most fortline antibiotics, relapses after complete therapy 
and intrinsic resistance (B. pseudomallei) in the environment, and lack of vaccine, they have been 
classified as category B potential candidates of biological warfare or bioterrorism agents (CDC, 
2000, KONDRIK et al. 2003), that enforces the development of effective prophylactic vaccine, to be 
the most realizable approach to the solution. Although infection with B. mallei and antibiotic 
therapy was raerly known, a single reported case know in human glanders, was laboratory related 
infection of a researcher n USA that showed the difficulty of the course of different antibiotics and 
its relapses (SIRINIVASAN. et al. 2001) indicating that, B. mallei might have similar characteristics 
of resistance to antibiotic therapy as its closely related MDR B. pseudomallei (BATANOV. 1997). 
The recently complete sequenced genomes of B.mallei strain ATCC 23344(NIERMAN et al. 2004 ) 
and B. pseudomallei K96243, a strain isolated in 1996 from a 34-year–old female diabetic patient in 
Khon Kaen hospital in Thailand (HOLDEN et al.2004) promoted research activities in determining 
virulence factors, pathogenesis, relationships and intraspecific diversity with in the strains and 
species. B. mallei is a clonally related organism to B. pseudomallei, as the genomes were compared, 
B. mallei is smaller with 5.8 Mb than B. pseudomallei with 7.5 Mb or B. thailandensis 
(environmental soil inhabitants) with 6.7Mb. Comparing the genome with one another, the authors 
found that 627 genes in chromosome 1 and 819 genes in chromosome 2, as one, 1446 genes of B. 
pseudomallei are either not present or variant in B. mallei. Whereas common genes to both species 
were highly homologous and organized similarly along the genome. Indicating the possibility of 
developing a single vaccine against both pathogens, most predictable an efficient melioidosis 
vaccine may provide protection against Glanders. Vaccine development will also profit from the 
current molecular tools, where by immunogenic substance can be screened and rationally 
designed and further studied in animal models.  
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Experimental Studies of vaccine development against glanders and melioidoise diseases includes, 
Syrian golden hamster, BALB/c mouse, C57B6/ mouse, CBA mouse, Guinea pigs, White rats, and 
monkeys, which are differently susceptible to the disease (KALACHEV et al. 1997, MANEZENYUK et 
al. 1999, ILYUKHIN. 1999, PIVEN. 2001). Syrian golden hamster are the most common animal 
model used for studies, but they are extremely sensitive to virulent strains of B.mallei and 
B.pseudomallei, (LD50 of 1-10 microorganisims when challenged s. c., and intraperitoneally with B. 
mallei C-5 and B. pseudomallei C-141), even a single cell can cause the disease which is 
characterized by acute septicemia just within an hour after infection. Guinea pigs, CBA mouse and 
Monkeys were found to mimic a chronic infection (MANEZENYUK et al. 1999). 
Experimental studies of BALB/c mice mimicking for acute Burkholderia infection made, showed 
acute clinical symptoms and succumb in only three days, while the C57B/6 mice showed 
heterogenic chronic symptoms with the same infection dose and can survive for two to six weeks 
post infection was reported, indicating CS7B/a shows a moderate resistance in comparison to 
BALB /C Mouse model (BRETT and WOODS 2000). It was reported that BALB/C mice are 
susceptible by a factor of 10 to 100-folds when compared to C57B/6 mice independent from the 
portal entry of infection (TAN et al. 2008) Similar clinical manifestations are also known in human 
infected especially with melioidosis. The question is not yet elucidated why some of the infection 
are acute where as others are sub acute or chronic and relapses were observed after 26 years of 
period in human. It seems, that next to the route of infection, the status of the immune system of 
the host must have some role to play as in the case of various mouse models. 
 
Although basic research activities on these pathogens have made progresses in the last decade, 
study of the immune responses against pathogenic Burkholderia species are complicated by the 
lack of animal models which survives long enough for the immune system to clear infection. The 
genomic plasticity of both pathogens, even within the type strain and the capability of residing in 
eukaryotic cells moreover cause difficulties  in vaccine research against both pathogens (HOLDEN 
et al. 2004,NIERMAN et al. 2004;PRUKSACHARTVUTHI et al.1990). However various forms of 
approaches were made in attempt to develop vaccines, that includes killed whole cell vaccines, live 
attenuated vaccines, heterologous vaccines, acellular vaccines, subunit /recombinant DNA vaccines 
in various species of animal models (DANNENBERG and SCOTT 1958, LEVINE and MAURER 1958, 
VASILEIV et al. 1993, MANEZENYUK et al. 1999, ILYUKHIN et al. 2002,AMEMIYA et al 2002, 
WHITLOCK et al. 2008). 
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4.2.1 Killed Whole Cell Vaccines 
 
The New York City board of health conducted an experimental immunization with a suspension of 
dried glanders bacilli, which was prepared in their laboratory in guinea pigs and horses in 1913 
(MOHLER and EICHHORN 1914). Guinea pigs received three weekly injection with the suspension 
containing 2mg/ml, subcutaneuosly. However none were resistance to the challenge. In the 
experiment conducted on 17 glanders-free, most of them aged, but in fair conditions, three or four 
injections with a dose escalating from 1ml to 12 ml were used. One week after the last vaccination, 
two horse were infected with B. mallei via nasal mucous membranes. Both contracted glanders and 
one died of acute form of the disease 21 after the infection. The rest of the animals were exposed to 
natural forms of infections, and four of the animals developed the diseases within 8 months. Nine 
out of 13 horse contracted glander diseases naturally. Thus the Authors concluded that control and 
eradication of glanders was dependent on elimination of infected horses and prevention of infected 
horses from entering stables that were free from diseases. Although these initial study and 
proposal of the Author is almost a century old, currently similar measures are used in areas where 
glanders disease outbreak is known. For instance, in spring 2007 outbreak of glanders in Russian 
auotomous Chita region remind us that 100 horses which were tested positive to glanders disease 
and all horses in-contact with infected animals were been killed, so far there is no vaccine. 
 
AMEMIYA et al. (2002) evaluated three nonviable cell preparations of B. mallei plus Alhydrogel in 
a, a heat-killed, an irradiation-inactivated and an irradiation-activated capsule mutant strain 
preparations BALB/c murine model of glanders. None of them provided protection against lethal 
challenge. It was reported that all three preparations yield similar immune responses when 
spelonocyte proliferation and sera immuno-globulin were analyzed and expressed various 
cytokines like IL-2, IFNγ, and small amounts of IL-4 and IL-5, and more IL-10. The author found 
higher level of IgG1 than Ig G2 subclasses production and, a mixed T-helper-cell like responses, 
demonstrated by Th1- and Th2-like cytokine and a Th2-like subclass Ig responses. Partial 
protection was observed when BALB/C mice were immunized s.c., with a mixture of nonviable B. 
mallei cell with IL-12 against i.p. challenged doses of (143 LD50s ) as independently. It also showed 
that the vaccine enhanced predominantly IgG2a isotype level and significantly increased the 
proliferation activities and IFNγ production by splenocytes. It was also reported that the spleen of 
vaccinated survivors were generally enlarged and heavily infected with B . mallei (AMEMIYA et al. 
2006). 
 
Attempts of passively transferred immunity with immune serum were unsuccessful (KOVALEV. 
1971). Passive transfer of monocolonal antibodies specific for B. mallei have also demonstrated 
early protection of mice infected with lethal aerosol challenged B. mallei (TREVINO et al. 2006). To 
determine the mechanisms involved in the development of protective immunity in a murine model 
of melioidosis BARENS and KEETHESAN (2007) reported that, C57BL/6 and BALB/c mice 
intravenous infection with B. pseudomallei, demonstrated delayed-type hypersensitivity (DTH) 
responses and the generation of B. pseudomallei-specific lymphocytes towards B. pseudomallei 
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antigens. No protection was observed when mice were subsequently challenged with lethal doses 
of highly virulent strain of B. pseudomallei. Subcutaneous immunization of BALB/c mice with live B. 
pseudomallei vaccine demonstrated significant protection compared with exposure to heat-killed 
B. pseudomallei culture filtrate. cell culture. In contrast SARKAR-TYSO (2009) recently reported 
that heat-inactivated Burkholderia thailandensis, B. mallei or B. pseudomallei cells as vaccines 
against murine melioidosis and glanders provided efficient protection against intraperitonial as in 
aerosol challenged with homologous strains and some cross protection were also observed when 
the mice were challeged with hetrologous strains. The Author explains the protection of heat killed 
vaccine in this study, might related to the much higher number of killed bacteria cells (108 cfu) 
used and differences in routes of administration. 
 
4.2.2 Live Attenuated Vaccines  
 
The resistance of mice and hamsters vaccinated with live avirulent strains of B. pseudomallei 
against aersol–initiated melioidosis with virulent B. pseudomallei strain 103–67 in comparison to 
non immunized mice were reported by DANNENBERG and SCOTT (1958, 1960), however the 
vaccine did not prevent the progress of the disease. Similar results were also reported by LEVINE 
and MAURER (1958). 
ILYUKHIN et al. (1999) investigated the efficiency of selected attenuated auxotrophic mutants of B. 
pseudomallei, purine dependent (Pur-) strains of B. pseudomallei (C141-206, 60806-10, 57576-25, 
60806-90) (Museum of Live culture Collection of Volgograd research Institute for plague control, 
Russia) (MERINOVA. 1997) and thermo-sensible (T s) strains of B. pseudomallei ( 57576-6, 57576-
7, 57576-9) vaccines in four species of animal models that includes Syrian golden hamsters, White 
rats, Guinea pigs and BALB/mice. Immunized animals showed significant resistance against s.c. 
challenged doses 1DLM (100 LD50 for Golden hamsters and 1000 LD50 for the rest of experimental 
animals) of highly virulent B. pseudomallei strains. The author found that, the best protective was 
obtained by the vaccine based on B. pseudomallei Pur - mutants (C141-206, 60806-90) and thermo-
sensible (Ts ) strain 57576-9 and the survival rates of immunized animals in average increased 
from 4 to 7 days in comparison to the control groups (tab. 4). But s.c. immunization of eight guinea 
pigs with B. pseudomallei strains C141-206, 60806-90 and Ts 57576-9 did not protect any of the 
animals from aerosol challenges, all animals died after aerosol infection of 1DCL with virulent B. 
pseudomallei 57576 strain. That in fact indicates the level of protection of the vaccines depends on 
the the route of infection induced. 
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Table 4. Survival of animals immunized with live attenuated vaccines of Pur-, 
Ts strains of B. pseudomallei against subcutaneous infection induced 
melioidosis 
Immunization Infection Animals Mtd Survivors /total % protection 
B. p. C141-206 B.p. C141 Golden hamster 2 4/16 25 
B. p. C141-206 B.p. C141 BALB/ mice 14 10/14 71 
B.p. C141-206 B.p. C141 Guinea pigs 7 3/10 30 
B.p. C141-206 B.p. C100 White rat 4 4/9 33 
B.p. C141-206 B.p. C141 White rats 17 4/9 33 
B.p. 60806-10 B.p. C41 BALB/mice 5 3/10 30 
B.p. 60806-90 B.p. C141 BALB/ mice 3 6/12 50 
B.p. 57576-25 B.p. C141 BALB/ mice 7 2/12 16 
B.p. 57576-9 Bp. C141 Guinea pigs 2 9/14 65 
B.p. 57576-9 B.p. C141 Hamster 1 1/9 11 
 
Notes. Immunization B.p- Burkholderia Pseudodomalle(Collection of the Museum of Live Culture of 
Volgograd, Russia), MTD-Mean date to death in days. Table compiled from Ilyukhin et al. 1999. 
 
 
Mice immunized with live attenuated B. pseudomallei purine auxotroph strain were also reported 
to be protective against the challenged wild-type of B. pseudomalli strain. But in light of the 
considerable antigenic variation present within B. pesudomallei strains (ATKINS et al. 2002). 
  
ULRICH et al. (2005) studied the ability of aerogenically vaccination with two live attenuated B. 
mallei strains, (a capsule mutant and a branched-chain amino acid auxotroph) to protect against 
high doses of (300 LD50) aerosol-initiated glanders in mice. Analysis of serum samples obtained 
from mice immunized with capsule mutant strain developed a Th2-like Ig subclass antibody 
response. It was found that the immune response did not provide protection, as no mice challenged 
with aerosolized B. mallei survived 5 days after infection survived. On the other hand mice 
immunized with auxotrophic mutant elicited a Th1-like Ig subclass antibody response that 
correlates with 50 % protection against a lower dose (5, 0x103: 5 times LD50) aerosolized 
challenges. It was also shown that serum IgG and IgM titers of mice were 20 and 60 fold higher 
than that of naive controls. However 105 cfu bacteria/ gm from organ homogenates i.e. spleen, lung 
and liver were counted. 
 
Previous studies showed that the immunological response that protects from pathogenic 
Burkholderia species were determined by the T- immune system (JONES. 1980). Further, studies in 
a murine model of melioidosis by KETHEESAN et al. (2001), also showed that the development of a 
T cell response in C57BL/6 mice infected with B. pseudomallei. In addition, in vitro a high 
proliferation response of purified splenic T cells from infected mice was observed in the presence 
of B. pseudomallei lysates. Similar studies carried out on 12 patients recovering from melioidosis 
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demonstrated the development of specific T cells responses and the involvement of both, CD4+ and 
CD8+ cells, in response to B. pseudomallei antigens. However, recent studies showed that both 
humoral and cell-mediated adaptive immune responses are required for whole protection against 
B. pseudomallei and B. mallei challenge and for bacterial clearance post-infection (HEALEY et al. 
2005). That indicates a vaccine which is protective against both pathogens must provoke both 
arms of the immune systems. For facultative intracellular organisms like Burkholderia, a live 
attenuated vaccine may be the best strategy of choice to induce both, cellular and humoral immune 
responses; they mimic natural infections and generate systemic and mucosal immune responses. 
They can often induce the production of cytokines that recruit the elements of the immune system 
that ordinarily do not responds to subunit and inactivated or killed vaccines (ULETT et al. 2000, 
KEETHESAN et al. 2002). 
 
Immunization based on avirulent strains of B. thailandensis (108Cfu) demonstrated more than 50 
% of protection in guinea pigs challenged s.c. with 200 LD50 of B. pseudomallei 100 virulent strain 
investigated for 60 days, where as all control groups died with in 2-3 weeks. Guinea pigs 
immunization based on B. cepacia strains did not show significant protection (ILYUKHIN et al. 
2002). That suggests vaccine based on B. thailandensis might be considered as an alternative 
prototype candidate. B. thailandensis is avirulent and is closely related to both pathogenic 
Burkholderia species, thus it is possible to say vaccine based on B. thailandensis (tab. 5) will be one 
of the prototype of vaccine candidate which needs further investigations for human use. 
 
Table 5. Protective efficacy of vaccine based on B. thailandensis against 
Melioidosis in guinea pigs 
 
 
 
 
 
 
Notes. B.p - B. pseudomallei, cfu- colony forming units, MTD- Mean time to death in days, compiled from 
ILYUKHIN et al. 2002). 
Strains № animals  
immunized 
% protection 
 
MTD 
(days) Immunization Infection with (cfu) 
B. thailandensis 251 B.p.100 ( 2x 103 ) 7 57 22 
B. thailandensis 265 B.p.100 ( 2x 103) 11 64 26 
B.cepacia 25416 B.p. 100 (5x103) 12 17 24 
Control B.p.100 (2x 103) 5 0 16 
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4.2.3 Heterologous Vaccines  
 
For instance immunization with Live Tularemia Vaccine (LTV) based on Francisella tularensis 15 
strain increased survival rate of guinea pigs to 1,5 fold in comparison to control groups were 
reported (ILYUKHIN et al. 2004). Other trails like live attenuated plague vaccine of Y. pestis EV76 
derivative of NIIEG line (LPEV), or live attenuated vaccine against tuberculosis (BCG) did not show 
protection. Mice immunized with vaccine against salmonellosis showed an increased survival rate 
of 2,4 fold longer in comparison to control groups against  B. pseudomallei infection, but less 
protection in animals tested when challenged subcutaneously with B. mallei C-5 strain 
(MANEZENYUK et al. 1999, ILYUKHIN. 1999). These results also showed that LTV expressed a 
better immunostimulating effect against the infection with virulent strain of B. mallei C-5, in golden 
hamster (TIKHONOV et al. 1995, VASILIEV et al. 1993). An efficient protection was also achieved 
after immunizing with tuberculosis BCG, tularemia LTV vaccines and a vaccine based on B. cepacia, 
when challenged with the virulent strain of B. pseudomallei C-141 to outbred white rats and mice 
(TIKHONOV. 1995). Yet, these are solo experimental studies published, which makes the issue of 
cross-over vaccine difficult to endorse further, as another possible option of vaccine development 
against pathogenic Burkholderia. 
 
Although different species of animals used in experiments, which were essentially differing by 
their sensibility to melioidosis and glanders responses vary, some of the heterologous vaccines 
were able to express immunostimulating effects, but their levels of protection indicated are very 
low, particularly when the pathogens are introduced to the respiratory systems, the most plausible 
route of dissemination in case of bioterrorism. As it was showed that white mice (moderately 
resistant to melioidosis) which were immunized twice with a virulent strain of B. mallei C-5, in a 
range of 1x106 to 3x1010 cfu doses followed by intrapulmonary infection with B. pseudomallei C-
141 in doses of 1-3x108 cfu, induced a weak protective response. The survival rate of individual 
experimental animals were in a range of 17 to 56 % (MANZENYUK et al. 1999). Although, the 
cross-protection provide by immunization of vaccine based on B. mallei against its closely related 
B. pseudomallei in this study is low, it is a possible indication to develop a vaccine against both 
pathogens based on single pathogen, which can be used as bivalent vaccine, which needs further 
investigation to enhance the level of protection achieved yet. 
The cross-over protections of vaccines of other intracellular pathogens like, live attenuated 
vaccines of Tularemia, BCG vaccine of Mycobacterium and the live plague vaccine of Yersinia EV76 
line NEIIG were studied in mice and guinea pigs as well as vaccine based another similar study by 
ILYUKHIN et al. (1999) indicated that BCG vaccine offered only 10 % of protection for white mice 
against a dose of 1 x 103 LD50 cf s.c. challenged with B. pseudomallei C-141 strain [Museum of Live 
culture of Volgograd Anti-plague Institute]. It did not offer any protection for Golden hamsters 
challenged with 1x 102 LD50 cfu of B. pseudomallei C-141. The Y. pestis EV NIIEG vaccine provided 8 
%, 12 % of protection of white mice and guinea pigs, respectively against s.c. infection with 1 x103 
LD50 cfu of the virulent strain of B. pseudomallei C-141. Similar immunization schedules in mice and 
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guinea pigs with a higher dose of 107and 108 respectively, showed also low protective efficacy in all 
experimental animals. 
 
Although much is known about the epidemiology, clinical manifestation and the courses of 
melioidosis and glanders, and to some extent their responses to antimicrobial agents, the 
knowledge of the host immune system towards the infections are just at the beginning. In order to 
understand the mechanism of the immune response during infection with B. pseudomallei 
CHENTHAMARKSHAN et al. (2001) investigated sera collected from septicemic patients and 
healthy groups indicated the presence of high levels of IgG and IgM in 85-100 % of the cases as 
compared to control groups. Highest antibody response was to IgG and lowest for IgM. IgG1 and 
IgG2 were the predominant subclasses produced against culture filtrate antigen of B. pseudomallei 
reflecting preferential responses to protein and carbohydrate epitopes.That indicates efficient 
vaccine must induce IgG subclasses. 
 
4.2.4 DNA /Subunit/Recombinant Vaccines  
 
The live vaccine strain of Tularemia, F. tularenisis 15, transformed to R-form that carried two DNA 
fragments with a size of 4.0 mD and 2 mD isolated from B. pseudomallei C-141 constucted by 
plasmid (pRM2) was studied as vaccine against virulent B. pseudomallei strains (ILYUKHIN et al. 
1999, 2002,2004, MANEZENYUK). Experimental animals were challenged subcutaneously with 
typical virulent strains of B. pseudomallei -C141, B. pseudomallei -57576, B. pseudomallei- 100, 
using a doses of 1x102 LD50 cfu for golden hamster and 1x103 LD50 cfu for other experimental 
animals like guinea pigs, white rats and white mice. Immunization was carried out with F. 
tularensis 15 (NIIEG Culture collection) and F. tularensis 15 RM2(tab 6) The survival rate of guinea 
pigs and rats immunized with F. tularensis RM2 recombinant vaccine challenged with the virulent 
strains of B. pseudomallei (tab. 4) increased the resistance of animals from 15 to 40 % except the 
Syrian golden hamster (ILYUKHIN et al. 1999, 2004). White rats and mice did survive slightly 
longer than golden hamsters, that indicates the vaccine provide no significant protection. Although 
tularemia vaccine strain was proposed as a potential vector in investigating the protective antigens 
of intracellualr pathogens for in recombinant antigens synthesis , it was assumed that the 
drawback of of F. tularensis as a vector for the production of recombinant vaccines against 
melioidosis and other recombinant vaccines is, that they are difficult to reproduce, instable and the 
inserted section of the targeted vaccine is not known and there are also concerns of safety and the 
high virulence of the vector itself.  
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Table 6: Protection eficacy of rF. tularensis RM2 and F. tularensis 15 immunization against 
virulent strains of B. pseudomallei against s.c. Infection 
 
Immunization Infection Animals MTD Survivors/total % Protection  
F. t. RM2 C-141 Golden hamster 1 0/5 0 
F. t.RM2 C-141 Guinea pigs 4 2/12 15 
F. t. RM2 100 Mice (CBA) 4 2/9 22 
F.  t. 15 C-141 Mice (CBA) 3 4/18 22 
F.t.15 100 White rats 5 9/20 40 
 
Notes. F.t. RM2- F. tularensis RM2, F.t 15-F. tularensis 15. C-141-B. pseudomallei C-141, MTD- Mean time to 
death in (days), compiled from Ilyukhin et al. 1999, 2004. 
 
 
The majority of recent studies concentrate on DNA-based vaccine strategies of selected isolates of 
immuogenic antigens as a novel approach for immunoprophylaxis against glanders and 
melioidosis. DNA vaccine is supposed to have more advantages as to that of classical types of killed 
or attenuated vaccines in that, DNA vaccine induces cellular immunity, which is indeed the most 
essential part of the immune system to protect and clear up disease cause by the intracellular 
pathogens like the agents of melioidosis and glanders from the host. The protective immunity 
results from the endogenous expression of foreign protein by host cells and the antigen is 
therefore presented to immune system in a manner that it mimicks the natural forms of infection. 
Those being the advantages of DNA vaccine, a recurring observation in clinical studies reported in 
in the literature so far are that antibody responses induced by DNA vaccination are relatively low 
in human as compared to laboratory animal models. In addition high doses are required to induce 
substantial T-cell immunity (DONNELLY et al. 2003, HANKE. 1999 ), and studies on safety concerns 
of DNA based vaccine are at the beginning phase. 
 
The plasmid DNA encoding the flagella protein (flagellin) vaccine was reported in induction of 
humoral and cellular immune response and provided a protection of Five out six (83%) 
BALB/mice immunized with flagellin-DNA vaccine against i.v. challenges with 105 cfu of B. 
pseudomallei was confirmed (CHEN. 2006). It was also shown that structural gene, artificially 
attenuated strains including B. pseudomallei bipD mutant, provided 50 % protection against 
challenge with wild type infection (STEVENS et al. 2004). 
 
Evaluation of the immunogenicity of selected proteins (LolC, PotF, and OppA) of the ATP-binding 
cassette systems of B. pseudomallei as a candidate vaccine antigen where non membrane regions of 
the B. pseudomallei proteins were expressed and purified from E. coli and then evaluated as vaccine 
candidates in an established mouse model of B. pseudomallei infection showed that the proteins 
were able to stimulate antigen-specific humoral and cellular immune responses. Immunization 
with LolC or PotF protein domains afforded significant protection against a subsequent challenge 
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with B. pseudomallei. The most promising vaccine candidate, LolC, provided a greater level of 
protection when it was administered with immune-stimulating complexes complexed with 
cytosine-guanine rich (CpG) oligodeoxynucleotide 10103. Immunization with LolC also protected 
against a subsequent challenge with a heterologous strain of B. pseudomallei, demonstrating the 
potential utility of this protein as a vaccine antigen for melioidosis (HARALAND et al. 2007). If it 
has the some effect against the causative agent of glanders is not known yet. 
 
B. pseudomallei is a resilient bacteria that can survive in variety of hostile conditions, Like many 
saprophytic organisms, including nutrient deficiency, acid and alkali pH disinfectant and antiseptic 
solutions, exposure to many antibiotics and extremes temperature. Whereas its closely related 
facultative intracelluar B. mallei is an obligate pathogens that does not exist in nature (WAAG and 
DESHAZER 2005, CHENG and CURRIE 2005), whose natural hosts are horse, donkeys and mules. 
However, many animal species ca be infected naturally including carnivores, like line and dogs 
eating infected meats (ALIBASOGUL et al. 1986). Indicating that both pathogens are well adapted 
to their many hosts and expressing an impressive array of both, secreted and cell-associated 
antigens, in order to adhere, invade, colonize, grow and develop a specific infectious process and 
combat the immune system of the host, able to survive and reproduce in the host cell. Direct cell-
to-cell spread has also been observed in human tissue, which was thought to occur by the 
induction of cellular protrusion and fusion of cell membranes and forms multinucleated giant cells 
(BRETT and WOODS 1996, BRYAN et al. 1994, CHENG and CURRIE 2005). The production of 
glycocalyx polysaccharide capsule by pathogenic Burkholderia species is probably thought to play 
an important virulence factor in protecting the microbe from unfavourable environment, host 
defense mechanisms and resistance to antibiotics (STEINMETZ et al. 1995). 
The completed genome of B. mallei ATCC23344 revealed putative gene products that were similar 
to virulence factors in other Gram-negative organisms, cell associated as well as secreted, including 
a type II, type III secretion systems, type IV pilli might have similar roles, which needs to be 
elucidated by creating defined mutation and examining their relative virulence in animal models of 
infection (FINLAY and FALKOW 1997, ZHU et al. 2002). Some of the studies showed that mutants 
in the general secretory pathway, resulting in failure to secrete protease, lipase or lecithinase, do 
not appear to result in a reduction of virulence in animal model (BRETT and WOODS, 2000), 
indicating that exotoxins don’t play a significant role in determining the outcome of the organism 
(WHITE. 2003), in contrast to, several studies in the 1950s reported that culture supernatant fluid 
of B. pseudomallei was toxic for both mice and hamsters (COLLING et al. 1958) and the level of 
production of toxin was strain-dependent (NIGG et al. 1955). 
 
A variety of animals have been used in experimental models to verify the mechanisms of virulence 
including inbred mouse strains (VELJANOV et al. 1996) chickens (VESSELINOVA et al. 1996) rats 
and guinea pigs (ILYUKHIN. 2004) and hamster (BRETT and WOODS 2000), which, showed 
different results. Thus, an attempt to identify virulence factors may be complicated by the fact the 
syndrome might be dependent on the strains studied and the choice of animal model and 
translation of the results to human. Although there are some conflicting results of innate immunity, 
the role of phagocytes, while the pathogen can survive and multiply within professional 
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macrophages, including, macrophage /monocytes and nuterophil cells, the induction of both arms 
of immune system is required for protection. 
 
4.2.5 Immunogenic Antigens against B. mallei and B. pseudomallei 
 
ILYUKHIN et al. (1997) studied, the level of protection of macromolecular fractions extracts 
obtained from broth cultures of Burkhoderia species that causes glanders and melioidosis, with 
less toxicity were examined. Based on the methods of extraction, such liquid forms or acetone 
dried extracts the Authors enumerated the fragments alpha- numeric such as as fragment C, 
fragment C1, fragment D, fragment H (AVOROROVA et al. 2004), fragment A, fragment D, fragment 
E, antigen fragment (Ag8) (KALACHEV et al. 1997, PIVEN. 1991). In addition he also studied some 
other components extracted from cellwall, cytoplasm, ribosome and murine-protein-complex. 
 
The author found that immunization with some of the combatants of the fractions induced the 
immune response and as a result the vaccine increased the resistance of the animals form 25-60 % 
against challenges of infection with virulent  B. pseudomallei strain in mice (PIVEN et al. 2001). 
One of the macromolecular fraction that demonstrated singnificant protection was known as 
antigen 8 (Ag8)an extract from the outer membrane of both species, It is also as known as one of 
the virulence factor of the pathogens (PIVEN. 1996). Ag8 is glycol-lipoprotein that consists of 70 % 
carbohydrate, 16 % protein and 14 % lipid, indicating, that the characteristics of biochemical 
composition of Ag8 can be considered as a good macromolecule of immunogenic properties. 
Experimental inoculation of laboratory animals with Ag8-mutant was reported in significant 
increases of the LD50 level and remarkably prolonged the dates of survival (PIVEN. 1991). That 
indicates Ag8 is capable of exhibiting  protection. 
 
In addition to Ag8, investigations of various series of common antigens isolated from the 
pathogens, using different biochemical and immunological methods and then recombined such as, 
three fragments designated A, D and E showed better protection as alone and significantly induced 
cellular immunity (KALACHEV et al. 1997). Moreover in combined form with Ag 8 fragment (A+ 
D+E+Ag8), demonstrated a better protection in comparison to single or partial combinations. It 
was reported that, immunization with four recombined fragments, increased the survival rate of 
immunized mice from 40-90 % when challenged with a dose of 30-100 LD50. And 66 % of rats 
survived against an infection with  virulent strain of B. pseudomallei of 13 LD50. Golden hamster 
immunized with recombinant antigens composed of another fragment know as D, E and F plus Ag8 
(D+E+F+Ag8) provided a protection of 40-50 % of against an infection with virulent B. mallei strain 
of 100 LD50 (PIVEN. 1991). Further reclassified extracts of immunogenic properties were also 
known in having protective substances. For instance the combination of three fractions, such as A9, 
D17 and E13 was also known in inducing protective immunity in white rats against an infection of 
highly virulent strains of B. pseudomallei (KALACHEV et al. 1997). At the mean time it was also 
reported that there are some know fragments purified such as B4 and B17 that showed 
immunosuppressive effects. A combination of three fragments (A9+D17+E13) was found to 
provide more pronounced protection against both causative agents and enhanced activation of the 
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cellular (T-cells) immune system, that plays a significant role in protection. Therefore, the 
recombinant fragments were proposed to be considered as a prototype of vaccine based on non-
cellualr components of the the cell. Synthetic vaccines based on immunogenic molecules as a 
vaccine against pathogenic Burkholderia species might overcome the drawbacks of traditional 
vaccine based on killed or attenuated vaccine, in concerns of safety, manufacture and reproduction. 
 
Another investigation of the immunogenic properties of the non-cellular virulence factors, like 
enzymes, was also made. The three forms of the exoproteases extracted from Burkholderia mallei 
and B. pseudomallei were designated as Protease I, II and III, showed that Protease I and III 
enhanced the survival rate of experimental animals against melioidosis to 2 – 5 folds i.e. 4 folds in 
comparison to control groups (PIVEN and ILUIKHIN 2000). 
 
A special attention was also given to the porine proteins of the membrane of Burkholderia to be 
used as vaccine. Immunization with a porine membrane protein protected 83 % of golden 
hamsters against a challenge of 20-50 Dcl ( where 1Dcl≈ 100 cfu) virulent strain of  B. mallei 
(SUPOTNIKII et al. 1993). In order to achieve a better synthetic peptide vaccine it is of value to 
consider antigen 8 (Ag8) protease I, III and porine protein (ZHUKOV et al. 1997). 
 
Clinical testing of a synthetic capsule-polysaccharide based vaccine against H. influenzae type B or 
Hib, was recently licenced for clinical use, a major cause of invasive bacterial infection, meningitis 
in children (VEREZ-BENCOMO. 2004). Native Hib capsule was shown to be protective in adults but 
was poorly immunogenic during infancy and requires the conjugation of Hib capsule to a protein 
carrier such cholera toxin or tetanus toxoid to provide protection (JACOB et al. 1985, SCIENCE. 
2004). Synthetic vaccines have the main advantages in production: higher quality, purer, 
affordable costs and safety. It will be the most realistic approach in developing vaccines for 
humans as opposed to a viable organism. They have been shown to elicit neutralizing antibodies in 
some viral infections of animals like FMD, Rabies and certain animals pathogen (MURPHY et al. 
1999) and some human bacterial pathogens, but in general this approach raises more questions, 
because peptides are linear aminoacids, lack any forms of conformation und could not induce both 
arms of the immunesystem which is required for protection against infections caused by 
pathogenic Burkholderia species. 
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4.2.5.1 Secretory and Cell associated Antigens 
 
B. pseudomallei produces several secretory and cell-associated antigens including, mucous 
endotoxin, exotoxin, protease, lecithinase, lipase, phosopholipase C (PLC), hemolysins, 
siderophores, and series of biopolymers (ASHDOWN et al. 1990, PIVEN and ILYUKHIN 2000, LEE 
and LIU, 2000, WAAG and DESHAZER 2005, COLLING et al. 1958). 
 
Studies conducted by SEXTON et al. (1994) have confirmed the presence of a 36 kDa antigen 
associated with protoelytic activities in B. pseudomallei culture supernatants. In particular, a 
protease expressed by B. pseudomallei 319a was found to be metalloenzyme requiring iron from 
maximal protease activity and demonstrated optimally activity at pH 8.0 and 60°C. GAUTHIER, et 
al. (2000) suggested that there is no correlation between virulence and the level of exoproteolytic 
activity of B. pseudomallei strain studied. 
 
Numerous gram-negative bacteria, including both animal and plant pathogens, encode specialized 
type III secretion system (T3SS), that deliver bacterial proteins (effector molecules) into the 
plasmamembrane and cytoplasm of eukaryotic cells (HUECK. 1998). Several investigations 
identified T3SS in B. pseudomalli, and B. mallei, that T3SS is found to be crucial for pathogenesis 
(RAINBOW et al. 2002, WINSTANLEY and HART, 2000). In B. pseudomallei mutation of the gene 
(bsaZ) showed a drastic reduction in intracellular replication within J774.2 murine macrophages, 
failure of endocytic vacuole escape and inhibition of actin polymerization (STEVENS et al. 2002, 
2004). This suggests T3SS plays an important role in B. pseudomallei virulence in all of its animal 
host (WARAWA and WOODS 2005). Virulence related investigation done on B. mallei T3SS, in two 
species of experimental animals i.e., Syrian hamster and the murine model showed that T3SS 
mutants were attenuated in hamsters model to LD50 values of greater than 106 cfu (the wild-type 
LD50 was less than13 cfu ) (ULRICH and DESHAZER  2004). This indicates that B. mallei is much 
more dependent upon the T3SS for its virulence in animals than B. pseudomallei (WARAWA and 
WOODS. 2005). Its role as protective antigen is not yet elucidated, however, vaccines based on 
mutants failed to elicit a protective immunity in BALB/C mouse and Syrian hamsters (ULRICH and 
DESHAZER 2004), that indicates T3SS possesses immunogenic characteristics. Further 
investigations are needed to determine the level of T3SS protection. 
 
Genomic analysis of B. mallei, indicates that genes encoding an exopolysaccharide capsule (EPS), a 
lipopolysaccharide (LPS), type IV pili, as well as type III and type VI secretion systems are 
associated with virulence of the pathogen (WHITLOCK et al. 2007). Although B. mallei contains less 
DNA than genomic comparison revealed significant homology, being ca. 99 % identical between 
conserved genes of B. pseudomallei (GODOY et al. 2003, NIERMAN et al. 2004). That indicates the  
potent of developing vaccine based on common protective antigens against both pathogenic 
Burkholderia species. 
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Cell-associated antigens include lipopolysaccharide (LPS), capsular polysaccharides (CPS), flagellin 
protein (BRETT and WOODS 1997, STEINMETZ. 2000). A number of cell-associated antigens have 
been demonstrated to be immunogenic in patients with melioidosis including CPS, LPS and 
flagellin protein (CHARUCHAIMONTRI et al. 1999, DESHAZER et al. 1998) and have been proposed 
to be used as vaccine components and serological diagnostic. Capsule from gram-negative and 
gram-positive bacteria are also known to be important virulence factors in the pathogenesis of 
invasive diseases (MOXON and KROLL 1990) because of their ability to protect the bacteria from 
the host defense system. They may play an antiphagocytic role, as they may induce cytokines for 
example TNF, IL8 and IL10 in various leukocytes population (GIBSON et al. 1996, POWELL et al. 
1997) and thereby, influence the type of immune response elicited by the host. Outer membrane 
proteins, such as protein tyrosine phosphatase, have been defined to play a role in invasion and 
virulence (KONDO et al. 1991), although Burkholderia do not contain substrates tyrosine 
phosphate, analogous enzymes in other bacteria such as Yersinia have alternative substrates that 
are believed to be important in signal transduction (KANAI and KONDO. 1994). However, acid 
phosphatase do not appear to be a major virulence determinate factor as strains with mutations of 
acpA, resulting in lose of phosphatase activity, retains their virulence (BURTNICK et al. 2001). 
 
4.2.5.1.1 Capsule 
 
Capsule production has been correlated with the virulence in many bacteria, particularly those 
causing serious invasive infections in humans (BOULNOIS and ROBERTS 1987, BOULNOIS. 1989). 
A number of functions have been suggested for polysaccharide capsules: prevention of desiccation 
for transmission and survival (KANAI and KONDO 1994) adherence for colonization, resistance to 
complement mediated phagocytosis and complement-mediated killing, and resistance to specific 
host immunity (PUTHUCH-EARY et al. 1996) due to a poor antibody response to the capsule Poly-
saccharide. Capsules are highly hydrated polymers that mediate the interaction of bacteria with 
their immediate surrounding (ROBERTS 1996). 
 
B. mallei was known as non capsule producer in old literature, on the other hand numerous studies 
prove that B. mallei does make a capsule, that is important for virulence (POPOVet al. 1991, 1995, 
2000, RECKSEIDLER et al. 2001, DESHAZER et al. 2001) Thus, the capsule of Burkhlderia species is 
suggested to protect in early the pathogen from being phagocytized and may block the 
microbicidal action of phagocytes after internalization (RECKSEILDER et al. 2001, POPOV et al. 
1991, 2000). It is possible the capsule may confers resistance of the bacteria to the hosts primary 
response to escape and able to replicate intracellular.  
 
A survey of phenotypic traits that are present in B. mallei and B. pseudomallei, but absent in B. 
thailandenssis, may allow the identification of new virulent determinants. A capsule-like 
exopolysaccharide is one of the candidates that fit these criteria. The exoploysaachride (EPS) 
produced by B. pseudomallei is an unbranched polymer of repeating tetra-saccharide units with the 
biochemical structure of•3)-2-O-acytel-β-D-Glap-(1-4)-α-D-Galp-(1-3)-β-D-Glap-(1-5)-β-D-KDOp-
(2-(NIMTZ et al. 1997, MASOUD et al. 1997). The genes encoding the EPS of both pathogens have 
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not been identified, and its role in pathogensis is currently unknown (WAAG and DESHAZER 
2005), but antibodies against EPS have been shown from melioidosis patient’s sera (STEINMETZ et 
al. 1995), that indicates EPS exhibits immunogenic properties, to be include in developing vaccine 
against Glanders and Melioidosis. 
 
The capsular polysaccharide of B. mallei is required for production of disease that was observed in 
in two animal models (hamsters and mice) of glanders infection and is a major virulence factor. 
Surprisingly the non-pathogenic Burkholderia thailandensis also harbores a portion of the capsular 
gene cluster (DESHAZER et al. 2001). The differences of virulent CPS of pathogenic strains versus 
non pathogenic strains of Burkholderia are not yet elucidated. 
 
4.2.5.1.2 Lipopolysacchride 
 
The LPS of B. pseudomallei has been reported to contain two types of O-poly-saccharide moieties 
termed type I O-PS (unbranched homopolymer of mannohepto-pyranosyl residues) and type II O-
PS (unbranched heteropolymer) (KNIREl et al. 1992, PERRY et al. 1995) which has been shown to 
be involved in serum resistance (DESHAZER et al. 1998). Mutants lacking type II O-PS were found 
to be sensitive to bactericidal activity of 30 % normal human serum (NHS) and also demonstrated 
reduced virulence in three animal models of infection. Thus, the type II O-PS is essential for B. 
pseudomallei serum resistance and virulence. Similarly, B. mallei strains that are deficient in LPS O-
antigen are killed by 30 % NHS (DESHAZER et al. 1998, BURTNICK et al. 2001)  
 
In previous studies, it was suggested that structure of LPS of B. mallei can be similar, possibly 
identical to B. pseudomallei. It was suggested, that it consists of a protein with molecular mass of 
20-60 kDa, a glucoprotein of 90-200 kDa and a lipoprotein with a molecular weight of 18-20 kDa 
(POPOV et al. 1991, 1995, 1997). The capsule formed by B. mallei was shown to be one of the 
factors facilitating its persistence in the body of the host (POPOV et al. 2000). Now there is a 
suggestion that describes the structure of B. mallei LPS, is as -3)-β-D-glucopyranose-(1,3)-6-deox-
α-L-talopyranose- (1- in which the talose residue contains 2-O-methyl or 2-O- acetyl substituent 
(BURTNICK et al. 2002, WAAG and DESHAZER 2005). B. mallei LPS O-antigens cross-react with 
polyclonal antibodies raised against B. pseudomallei LPS O-antigen (DESHAZER et al. 2001, 
BURTNICK et al. 2002). 
 
B. pseudomallei strains isolated from a variety of sources have homogeneous, highly conserved and 
constant LPS. LPS is a component of the outer cell membrane of gram-negative bacteria that is an 
important factor mediating the production and release of various mediators (such as NO) and 
cytokines from microphages through CD4. B. pseudomallei invaded and multiplied inside 
macrophages without substantial macrophage activation. The inducible nitric oxide synthase 
(iNOS) expression was not observed even when the cells were infected with B. pseudomallei at high 
multiplicity of infection (MOI). However, during these time intervals the macrophages did not 
produce sufficient quantity of nitricoxide (NO) to be detected in the supernatant by the Griess 
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method. Unlike B. pseudomallei, the cells infected with other gram-negative bacteria, such as E. col, 
or S. typhi, were able to express iNOS and released higher quantity of TNF-α at considerably lower 
MOI ratio (PONGSAK et al. 2001). These findings suggest that B. pseudomallei exhibits a unique 
mechanism for intracellular survival, most likely by interfering with normal cellular defense. Thus, 
the unique characteristic of both pathogens, their unusual structure of LPS, may facilitate its 
survival inside the cells which may in turn allow the bacteria to have a long latency state in the 
host.  
 
The O-PS side-chains of LPS are integral serum resistance determinants in some gram-negative 
bacteria (TAYLOR. 1983, JOINER. 1988). Performance of ELISA and mono-clonal antibody (mAb) 
specific for type II O-PS showed that serum-sensitive mutants lacking type II O-PS did not react 
with specific mAbs. That suggests a correlation between serum resistance and the presence of type 
II O-PS (BRAYN et al. 1994, DESHAZER et al. 1998). 
 
Comparative studies made between a serum-sensitive mutant named SRM117 and its parental 
strain 1026b in three animal models of B. pseudomallei infection, Golden hamster, (Mesocricetus 
auratus), Guinea pigs and infant diabetic rats showed, that the 50 % lethal doses (LD50s) for 1026b 
and the SRM117 in the hamster model of infection were <5 and 62 and in the guinea pig 2 x 103 
and 2 x 104, respectively. In case of the infant diabetic rat the LD50 s for 1026b and the SRM117 
were 2 x 104 cfu and >5 x 106cfu, respectively. Thus, the serum-sensitive mutant was 
approximately 10-fold less virulent than the parental strain 1026b in the hamster and guinea-pig 
and was more than 100-fold less virulent in infant diabetic rats model of melioidosis (DESHAZER 
et al. 1998, WAAG and DESHAZER et al. 2005, CHENG and CURRIE 2005). That also suggest the 
type II O-PS moiety of LPS is an important virulence determinant factor for pathogenic 
Burkholderia species. In recent publication the term LPS is used more often as II O-PS. B. mallei 
candidate conjugate vaccines, linking to the capsule and O-PS lipoploysaccharide-flagellin antigen 
were also demonstrated protecting of infant diabetic rats in passive immunization (BRETT. 2000), 
however, the conjugates are not tested in active immunization.  
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4.2.5.1.3 Flagella, Siderophore, and Pilli 
 
Flagella are commonly recognized as important virulence determinants expressed by bacterial 
pathogens since the motile phenotype imparted by these organelles often correlates with the 
ability of an organism to cause disease (PENN and LUKE 1992, MOENS and VANDERLEYDEN 
1996). Flagella are filamentous extracellular appendages that are employed by bacteria to move 
toward environments that promote their survival (WILSON and BEVERIDGE 1993) and are 
composed of 3 main elements: the flagellar cork-screw like propeller (filament), the universal joint 
(hook), and the transmission shaft, motor and bushing (basal body) which is embedded in the cell 
envelope. Flagellar filaments consist of one or two repeating subunits of identical polypeptide 
monomers called flagellin (HAKALEHTO et al. 1997). 
 
The flagella and motility, as well as the resistance of the organism to the bactericidal action of 
normal human serum, are believed to facilitate the dissemination from sites of localized infection, 
such as the lungs or skin, to virtually any other organ of the body via the blood circulatory system 
(DESHAZER et al. 1997, ISMAIL et al. 1998). In several bacterial pathogens such as S. enterica 
serovar Typhymurium and Vibrio cholerae, virulence has been correlated with flagella and 
bacterial motility, but it is not clear how flagella function as virulence factors (CARSIOTIS et al. 
1984, GARDEL and MEKALANOS 1996). Flagellar motility has been reported to enhance the 
invasion of the host cells by Campylobacter jejuni, Proteus mirabilis, Vibrio anguillarum, and other 
pathogenic species (MOBLEY et al. 1996, ORMONDE et al. 2000, YAO. 1994), whose role is 
attributed to the prospects of the filaments carrying adhesions for attachment to the intestinal 
mucosa, furthermore, may also assist bacteria in nutrient and waste exchange (WILSON and 
BEVERIDGE 1993). For example, a nonmotile mutant of B. cepacia with a defective component of 
the motor-switch complex of the flagellar basal body was found to be less invasive in lung 
epithelial cells. Flagellum-mediated motility has been implicated in the pathogenesis of B. cepacia 
because it facilitates penetration of the host epithelial cell barriers and contributes to the onset of 
systemic spread of the organism (TOMICH et al. 2002). 
 
Several genes are involved in the motility. They have been identified by transposon mutagenesis of 
B. pesudomallei. Among these is fliC, which encodes flagellin (DESHAZER. 1997). Antibodies rose 
against the B. pseudomallei flagellin markedly reduced the motility of the bacterium and provided 
passive protection against B. pseudomallei infection in animal models (BRETT et al. 1994). CHUA et 
al. (2003) found that the flagellum is an important virulent determinant factor in the pathogensis 
of B. pseudomallei based on the mouse model. In contrast, DESHAZER et al. (1997), showed that 
there were no significant difference between the virulence of the wild type and the virulence of the 
Tn5-OT182 disrupted fliC mutant when the pathogens were injected intraperitoneally into young 
diabetes rates and Syrian hamsters.The difference in the findings could have been due to the use of 
different animal models since the disease in diabetic rats and hamsters was more acute than in 
mice. 
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The causative agent of melioidosis, B. pseudomallei a motile gram-negative bacillus, that moves by 
means of polar tuft of two to four filamentous flagella, in comparison to the constructed non-motile 
mutant from virulent strain isolates of B. pseudomallei that lacks the flagellin (fliC) could also 
invade cells as effective as the wild-type bacteria, and showed no attenuation in virulence when 
tested on Caenorhabditis elegans as an alternative host. However, infection of mice through the 
intranasal route with the mutant did not cause disease whereas wild-type bacteria killed the mice 
within two weeks. Therefore, although flagella is not necessary for bacteria to invade cells in vitro 
and to infect C. elgans, it is important in the pathogenesis of B. pseudomallei in the mucosal 
infection of mice (FINKELSTEIN et al. 2000, CHENG and CURRIE 2005, GAN et al. 2001). 
 
The very closely related B. mallei, causative agent of glanders, is amotile. Surprisingly genes which 
are responsible for filament-forming flagellin (fliC) are found in B. mallei, where the only identified 
alteration of this gene in comparison to the motile B. pseudomallei is a shift from G to C at gene 
position 798 in all 7 B. mallei strains investigated (SPRAGUE et al. 2002). The reason why B. mallei 
lacks flagella remains obscure. 
 
Bacterial flagellin has been recognized as being an immuno-stimulator, capable of activating NF-
kB-signalling and subsequently induces the secretion of inflammatory mediators such as NO, TNF-
α, IL-1, IL-6 and IFN-γ, factors which amplify the overall immune performance of the host after an 
infection with flagellated bacteria (RUCKDESCHEL et al. 1998, EAVES-PYES et al. 2001, 
MCDERMOTT et al. 2000). Flagellin is also believed to present T-cell epitopes on antigen-
presenting cells (APC), and to induce maturation of APC, resulting in an expansion in the number of 
naive T cells (MCSORELY et al. 2002). These finding indicate that flagellin is an immunogenic 
substance that can be considered as a good candidate vaccine to be included in vaccine 
development against melioidosis. It is not known if flagellin will have the same effect against 
glanders. 
 
A conjugate molecule incorporating both, flagellin protein and O-polysaccharide antigens were 
proposed to be a reasonable vaccine candidate for use in active immunization against melioidosis, 
because both antigens have shown a high degree of conservation on structural and immunological 
levels. It is present in the majority of strains tested so far (BRETT et al. 1994, BRYAN. 1994, 
KNIREL et al. 1992, PERRY et al. 1995). Thus, a conjugate molecule incorporating both flagellin and 
the PS antigens would be a reasonable vaccine candidate for the use in active immunization against 
melioidosis and glanders. Flagellin gens are also proposed to be used as biomarker for detection of 
population genetics and epidemiologicaly analysis (WINSTANELY. 1997). An increase in IgG titers 
to LPS of strain 319a and flagellin protein was clearly demonstrated in the serum of vaccines after 
primary as well as two subsequent booster doses in rabbits (BRETT and WOODS 1996). Rabbit 
polyclonal antiserum raised against the glycoconjugate preparations was shown to react strongly 
with both proteins and is both, functional and specific (BRETT et al.1994). The purified 
immunoglobulin fraction utilized for passive immuno-protective studies in the animal model of 
diabetic rats showed that B. pseudomallei infection with LD50 of 8.89 x 105 for immunized group 
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and 7.54 x 103 for control group showed, that immunized groups displayed a 60 % survival rate 
over the same time; where as only 20 % of the animals of the control group were still alive after the 
eighth day of challenges (BRETT and WOODS 1996, BRYAN. 1994). 
The utilization of iron i.e. the ability to acquire iron from host sources is the prerequisite for the 
successful establishment and maintenance of most bacterial infections. YANG et al. (1991) have 
demonstrated that all 84 strains of B. pseudomallei examined during their studies tested positive 
for siderophore production. Further investigation to illustrate the structural and chemical analysis 
of the siderophore synthesis by B. pseudmallei U7 strain confirmed that the molecule was 
approximately 1,000 Da in size, water soluble with a yellow-green flourescence and that it 
belonged to the hydroxamate class and the name malleobactin has been proposed for this 
compound. Furthermore studies have also demonstrated the siderophore was capable of 
scavenging iron from both, lactoferrin and transferrin, in vitro (YANG et al. 1993). 
 
To asses the role of B. pseudomallei siderophore production in determining the level of virulence of 
the bacterium isolated from clinical or environmental samples studied by ULETT et al. (2001) in 
terms of virulence in BALB/c mice demonstrated that the level of virulence of B. pseudomallei in 
mice does not correlate with the level of siderophore production, although the production of 
siderophore was determined subsequently by each strains relatively. There was also no significant 
difference between the levels of siderophore production, by clinical as opposed to environmental 
B. pesudomallei strains. These results collectively indicate that siderophore production plays a 
limited role in the virulence of the pathogen. A high of the B. pseudomallei variability and within 
species lead to strong difficult in identification of the pathogen virulence as well as the 
immunogenic factors. 
 
Other cell-associated antigens include type I pili (encoded by fimA, fimC and fimD) and a putative 
type IV pilus are also mediated motility and pili are also known as virulent determinants of B. 
pseudomallei and it is proposed to be a protective antigen against the pathogen, but it is not clear 
how flagella and pilli functions as virulent factor and what level of protection it provides against 
melioidosis and glanders (CHEN. 2006). 
 
4.2.5.1.4 Antigen 8 
 
Antigen 8 is a glycoprotein of 289 kDa molecular weight, an extracelluar capsule–like substance 
found on the surface of both pathogenic Burkholderia species (PIVEN et al. 1996, SAMYGIN et al. 
2001, KHRAPOV et al. 1998, PIVEN. 2001). The scheme of the Burkholderia antigens have been 
porposed by Russian scientists on the bases of immuno-electrophoretic studies of aqueous-saline 
extracts from acetone-dried microbial cells belonging to 29 B. pseudomallei strains. The mixture 
consisted of 19 precipitates, whereby 13 of these showed to be common to all strains investigated, 
the rest been variable. The author designated the antigens alpha-numerically i.e. antigen A to 
antigen K and antigen 1 to 8 (PIVEN and ILYUKHIN 1981). Antigen 8 has an adhesive properties, 
supposed to be associated with surface capsule-like structure, which is linked with pronounced 
antiphagocytic and immuno-suppressive function that contributes to survival and maintenance of 
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the organisms in host cells (PIVEN et al. 1991, BROWN et al. 2002). One of its adhesive properties 
consists of the hydrophobic characteristic of its outer membrane, which in certain steps is required 
for the interaction of the bacterial cell with its environment (KAPLIEV. 1990). A comparative study 
of the adhesive properties of Ag8 of wild type virulent B. pseudomallei strain and its mutant defect 
of Ag8 showed a 34 % reduced adhesive activity in trachial epithelium (PIVEN and ILYUKHIN 
2000). This indicates that Ag 8 consists of adhesive properties comparable to that of fimbriae and 
pilli. Expression of Ag8 correlates with high virulence of B. pseudomallei and its absence for 
decreased virulence. This was confirmed by investigations of biological properties of subcultures 
which are unable to synthesis Ag8 isolated from highly virulent strains found in Asia and Australia, 
that showed the virulence of Ag 8- strains was reduced to 2 x104 and 1 x105 foldes, in white mice 
and golden hamster respectively (PIVEN et al. 1991). 
 
B. pseudomallei can persist in a dormant stage in macrophages for months or years and it has been 
found to survive and multiply in human phagocytes in vitro (HARELY et al. 1998, 
PRUKSACHARTVUTHI et al. 1990). The mechanism by which this organism survives within human 
phagocytes is still not fully known. It is assumed that B. pseudomallei might make use of host cell 
components, specifically micro-filaments, to invade eukaryotic cells as other invasive organisms 
like Yersina, Salmonella, Shigella do (PERRY and FETHERSTON 1997, MASTROENI et al. 2000). 
Intracellular pathogens have adapted various strategies to evade host defense mechanisms, 
including invasion of non-professional phagocytes, escape into the cytoplasmic compartment, 
interfere with reactive oxygen intermediates, inhibition of phagosome-lysosome fusion and 
phagosomal acidification, and resistance to lysosomal contents and cationic such as defensins 
(KAUFMANN. 1993). Pathogenic Burkholderia species can kill the host cells by inducing apoptosis 
in both, pahgocytic and nonphagocytic, cells (KESPICHAYAWATTAN et al. 2000). 
 
Inclusion of Ag8 to other non cellular components extracted from Burkholderia showed some 
extents of protection in experimental animals (ZHUKOV et al. 1997). That indicates Ag8 fraction 
can provide protection if used as a possible vaccine component of some other immunogenic 
fractions extracted from the pathogen as non cellualr/synthetic vaccine against Glanders and 
Melioidosis, that requires further investigations. 
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5 DISCUSSION 
 
Throughout the cold war, the causative agent of plague (Y. pestis), glanders (B. mallei) and 
melioidosis (B. pseudomallei) were considered as the main bacterial agents of military relevance 
and studied in depth in different states worldwide, genetically manipulated to enhance their 
potency virulence and drug resistance to the level of untreatable infection for instance in FSU 
(ALIBEKOV. 1999, DOMARADISKIJ. 1998, DOMARADISKI and ORENT, 2001). 
 
The possibility that an aerosolized form of thes agents could be used as a biological weapon, the 
capacity of dissemination from person-to-person, wide spread natural availability, higher fatality 
rate in cases of any sort of pulmonary infection, and furthermore the absence of stringent control 
system, MDR to chemotherapy and lack of prompt diagnostic methods makes them agents of high 
concerns of not only public health, but also security, social, economical and not less psychological 
impacts in human (CDC. 1999, KONDRIK et al. 2003, CFSPH. 2007). Thus, they are included in 
approved lists of of biological agents at global level.  
 
Just 24 days after the tragic events of 11th September 2001, in USA, the confirmed cases of letters 
sent to politicians and media offices containing deadly inhalational anthrax spore (Bacillus 
anthracis) was an intentional bioterrorism-related act “inside job” (CDC. 2001). and a suspected 
bioweapons scientist committed suicide reported in Los angeles times (2008) dictates us to live in 
world of fear. Currently, one can raise a question, how do the world act in response, if these 
pathogens are used to harm a human or suppose if this bio-attack was caused by plague agent 
instead of anthrax which is not a real respiratory disease, at present no body knows? Furthermore 
we also do not know from where the danger may come. 
 
Plague is an exceptionally virulent, vector-borne zoonotic disease transmitted from rodents, 
especially rats, through the bites of infected fleas, most often the rat flea, Xenopsylla cheopsis. At 
least over 200 species of mammals serves as reservoir that including rats, squirrels, mice, prairie 
dogs, gerbils, susliks, voles for the agent of plague, Y: pestis, which persists in the environment as 
the result of a stable and constant rodent-flea infection maintain the cycle in endemic regions 
worldwide except Australia (PERRY and FETHERSTON 1997, ANISIMOV et al. 2004). There are 
also reported cases, where plague was transmitted from non-traditionally associated animals like 
cats and dogs (GAG et al. 2000), or eating contaminated camel meats to human (ARBAJI et al. 
2005). 
 
The unique characteristic related to individual pathogens, highlights that arguably, the 
development of vaccine as the only appropriate steps to combat against such a disease of high 
calibre. And that the vaccines should be able to protect against pulmonary infection caused either 
by deliberate released weaponized strains, the most probable way bioterrorism may take, or 
undelibarte infection (HASSANI. 2004, CDC. 2005). 
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In the 20th century two classical forms of vaccines were used in immunization of human against 
plague worldwide. The first widely used plague vaccine was developed by Haffkine in 1897 using a 
heat-killed old broth culture of Y. pestis. administered s.c., (TAYLOR. 1933) It conferred significant 
protection against bubonic plague but induced severe adverse reactions including high fever in the 
majority of vaccines (WILLIAMS et al.1980, MEYER. 1974, ECHENBERG. 2001). Moreover, later 
studies in rodents and nonhuman primates showed that the vaccine was unable to elicit protection 
against pneumonic plague and do not provide protection against infectious caused by atypical 
strains (WILLIAMSON et al.1995, 2001). 
 
Varies modified series of a formalin-killed whole-cell vaccine known as USP, based on highly 
virulent strains like Shasta, Yerka and 195/P were developed in the mid-20th century in the USA. It 
was mainly used to protect US military personnel against bubonic plague during the Vietnam War 
(MEYER. 1964, MARSHALL et al 1974) but; it also caused severe adverse reactions and was unable 
to elicit protection against pneumonic plague. In the year 1999, the corporation stopped 
production and it is not more commercially available for human immunization (WILLIAMSON. 
2001). The demonstration of their low efficacy, high reactogenicty and their remarkably old 
technologies of killed vaccines preparations are fortunately, ‘antiquated’ is not necessarily 
synonymous with ‘bad’ some of the traditional vaccines are safe and effective as demonstrated by 
the recent eradication of smallpox and the expected eradication of poliovirus in a few years (WHO. 
2005). Indeed, some of the vaccines developed over the past century would not have met the 
standards of today and the only reason they are still on the market is that they have been used for 
many years to vaccinate humans and no new or improved vaccine is developed yet. They have 
been classified as safe and with a high benefit-to-risk ratio as it is in the case of live EV 76 line 
NIIEG vaccine against plague used in FSU and continued to be used in some members of CIS 
(FEDEROVA et al. 2007,2008). 
 
In retrospective survey of plague vaccine research publications data available in English language, 
It was found that the works of MEYER et al. (1974), MARSHALL et al. (1974), CAVANAUGH et al. 
(1974), as the final depth of research activities during the cold war era. Following two decades 
consistent research publications are not available, suggesting that it was easily forgotten. Where 
as, it was in this period that in FSU the novel achievements, what we today know about plague 
microbe was discovered and published in Russian scientific journals, dissertations and thesis were 
written, conferences, congresses were held. It was at this period that the API established  the 
“Biopreparte complex”, explored the notorious 43 autonomous natural foci which covers about 
10% of its territories, isolated highly intraspecifc diverse strains from various sources like soil, 
rodents, birds, insects, e.t.c., (NARKEVICH. 1991, ANISIMOV et al. 2004). It was also at this period 
that the API established its own taxonomy of plague microbe, which is currently used in the region 
and do not known or included in the taxonomy of International Code of Nomenclature of Bacteria 
(ICNB) (APARIN et al.1987).  
 
It was also in this period that earlier recognitions of the drawbacks of the killed plague vaccines, 
extacted fraction extracts of plague pathognes led to search and development other methods of  
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attenuation, such as heating the culture in presence of concentrated saccharose solution. In FSU 
studies on Live plague vaccine based on the strain of Y. pestis EV 76 proposed by Girard and Robic 
began in 1936 and the most common derivative strain  studied in depth and  used for human 
vaccination is the Y. pestis EV line NIIEG strain (ANISIMOV et al. 2002, FEODOROVA. et al. 
2007,2008). It is the national standard of plague vaccine strain used and manufactured in different 
forms and routes of administration, including, subcutaneous, cutaneous, inhalation, or 
intramuscular immunization. However, the highest level of specific immunity against plague was 
achieved either by scarifying the dermis followed by injection or after vaccination by inhalation 
(SALYTKOVA and FABICH 1975, ALEEXEVA et al. 1997, FEODEROVA. 2007). Other forms of 
vaccine preparations were also studied and used for a limited period of time such as a dry bivalent 
live vaccine called No 1-7 (KZOLOV et al. 1960). The Derivatives of EV 76 strain were the most 
widely used live palgue vaccine worldwide (GRASSET. 1942, 1946, MEYER, 1970, 1974, 
FEODEROVA et al. 2007, 2008). 
 
It was also at this period, that an aerosol immunization/inhalation, with dust plague vaccine based 
on live EV vaccine strain was developed studied in human (ALEXANDROV et al. 1962), that showed 
no significant post immunization clinical reaction. Field trails or this immunization method was 
proved to be simple, allowing mass (herd) immunization of the population to be carried out, such 
as in case of bioterrorism. Topical immunization via the respiratory tract would be highly 
beneficial against pathogens that case pneumonia as a primary target during lung infection, while 
it targets the bronchial and lung epithelium that comprises a large surface between host and 
environment. Aerosol vaccine has an advantage when compared to traditional routes of 
administrations, it potentially avoids needle injection and allow herd immunization in short 
period. Aerosol vaccine can be considered as an ideal emergency prevention measure against 
plague in case of bio-attack, if mass immunization is essential with in short period of time, if the 
vaccine is able to elicit rapid, robust and long-lasting protective immunity after vaccination and 
non-reactogenic. 
 
Other form of vaccine known as “chemical plague vaccine” according to the Author, that consists of 
capsule antigen and main somatic antigens of plague microbe was also tested in human. It was 
reported to be superior to live plague vaccine when used as booster immunization and proposed to 
be included in yearly plague vaccine calendar in the region (ALKESEEVA. 1997, DALVADYANTS. 
1997, 2005). 
 
Thus based on documents cited in this work, currently, what is known in English language research 
publications when compared to that of Russian language publications, it is possible to underscore 
the following major differences in plague microbe research in general and vaccine development in 
particular: 
1) Differences in new vaccine designs and strategies - After two decades of gaps, the renaissance of 
plague vaccine research activities in Western hemisphere, began in the mid of 90th, based on new 
molecular technology, like the development of vaccines based on recombination of of selected 
major immunogenic antigens of Y. pestis inserted in to gram negative pathogens such as 
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transformed E. coli (ANDREWS et al. 1996) or S. typhimurium aroA- (GARMORY et al. 2003) 
containing either F1 or V-antigen alone or in recombined form (WELKOS et al. 1995, MOTIN. 1994, 
LEARY. 1995, HEATH. 1997, 1998, WILLIAMSON. 2001) .The successes of these vaccines were 
mainly measured in comparision to USP (killed) vaccine. No comparative studies of recombinant 
antigens (F1+V) or Sub-unit (F1-V) to the live EV vaccine strain, more over of EV 76 line NIIEG, 
mostly used in CIS, are available either in animal models or human trails. Whereas, in FSU/CIS, the 
efficiency of various types of vaccines previously studied, and the forthcoming vaccine candidates, 
some new, some improved were/are measured in comparison to the paternal live plague vaccine 
of EV 76 line NIIEG (LEBEDENSKII. 1971, ANISIMOV et al. 2002, FEODOROVA et al. 2007).  
 
Plague vaccine studies predominantly concentrates on two major immunogenic proteins, F1, and 
V-antigen, which are currently, under trail phase, the rF1 + rV (Salsibury, UK) also known as 
recombinant plague vaccine, and F1-V (USAMRIID, Fort Detrick, USA) known as sub-unit vaccine. 
Although these vaccines are able to protect mice and non human primates but not guinea pigs from 
pneumonic plague and plague induced by atypical strains F1- are reported and tolerable in human 
trails (LEARY et al. 1995, TITIBALL and WILLIAMSOM 2001, WILLIAMSON et al. 2005). LcrV 
triggers the induction of IL-10 by host immune cells and suppresses proinflamatory cytokines as 
well as innate defence mechanisms required  to combat the pathogenesis of plague which may 
preclude the use of V-antigen as a human vaccine (NAKAJIMA. 1993). Y. pestis can bypass 
protective antibodies to LcrVand activation with IFN-gamma to survive and induce apoptosis in 
murine macrophages (NOEL et al. 2009). Vaccines based on selected antigens like F1-V in subunit 
or recombinant against plague might have a limitation in providing universal protection. It is not 
know if it can provide a protection against a number of atypical strains, isolated from different 
regions of the world for instance the highly diversified strains known in the FSU (ANISIMOV et al. 
2004) which might be more attractive to be used for intentional purpose in bioterrorism. There are 
also other emerging groups of Yops which are known to be protective in experimental animal 
models. Although some experimental studies made based on modified DNA derivatives of known 
major immunogenic antigens in prospects of new vaccine development against plague are 
available, they are irregular. 
 
Currently, researches activites of plague in FSU/CIS focuses on the improvements of live 
attenuated vaccine EV 76 strain line NIIEG. Currently, the new vaccine candidate, the Y. pestis lpxM- 
mutant live vaccine has been know in providing more protection, less toxicity, in three animal 
models studied and was reported in inducing enhanced immunity against bubonic plague and is 
under investigation for further development (FEODOROVA et al. 2007, 2008). Additionally a 
number of vaccine candidates of Y. pestis strains, with different contents of plague antigens are 
under investigation in comparison to live plague vaccine EV76 line NIIEG, to develop an improved 
live attenuated plague vaccine. 
2) National standard of instructions and methods of evaluating new strains for plague vaccine 
development- The major criteria of evaluating candidate strains of plague vaccine was used for 
more 7 decades and confirmed by the API experts and authorities like Ministry of Health of Russian 
Federation and implemented currently for plague vaccine research. These resolution includes the 
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guidelines and major criteria that a new candidates for new plague vaccine must fulfil i. e.: i) 
candidate vaccine must able to induce residual virulence in mice infected with higher dose, and in 
guinea pigs, indicates that the candidate strain must be able to replicate in experimental animals 
during the first two weeks after infection, ii) candidate must belong to group three security level, 
iii) must be pgm- (pgm mutant, iv) must harbor 3 plasmid DNA with corresponding molecular 
mass, pFra (60 MD), pCad (47 MD), and pPst (6 MD), v) candidate strain for plague vaccine 
production must protect against aerosol and s.c. challenged white mice with virulent strain and 
must induce efficient protection and sustain for longer period, vi) have typical cultural–
morphological characteristics. Another important properties of candidates vaccines immunology, 
like minimal and lethal doses, level of reactogenicity, methods of determining residual virulence, 
acceptable cellular alteration, routes of infection and immunization, methods of serological 
detection of the activities of immunological cells, were exactly predetermined in varies species of 
experimental animals and must be able to lysis by Y. pestis pahge L-413C based diagnosis (MoH. 
1970, ANISOMOV. 2002). 
3) Limited genotypic and phenotypic strains are known in Western hemisphere - The majority of 
studies of plague pathogen and plague vaccine, and what is known in the west (English 
publications) are based on limited Y. pestis strains predominantly the Y. pestis CO92 (HEATH. 1998,  
ANDREWS et al. 1996, 1999, ANDERSON. 1996) Y. pestis GB (DENG et al. 2002, JONES et al. 2003, 
WILLIASON. 2002, GRIFFIN et al. 2005), Y. pestis KIM (WANG et al. 2004), which are known to be 
genetically identical to the extent of over 98%. The first known strain in the west isolated from the 
former Soviet Union is, Y. pestis Pestoides F, sequenced by GARICA et al. (2007) which brought the 
classical methods of classification of plague pathogens used currently in Western hemisphere in 
question. Unlikely there are members of an atypical group of Y. pestis from Central Asia, Russia 
denominated as Y. pestis subspecies caucasica which varies from several classical Yersinia pestis 
strains still not well studied. These strains, are distinguished by a number of characteristics 
including their ability to ferment rhamnose and melibiose, their lack of the small plasmid encoding 
the plasminogen activator (pla) and pesticin, and their exceptionally large variants of the virulence 
plasmid pMT (encoding murine toxin and capsular antigen) and are proved to be virulent. For 
instance alone from Central Asian desert  natural foci region (UralEmba), 6,5 % of the isolate 
where atypical strains, 9,93  % of them were F1-, 7,14 % were LcrV- And 1,36 % of them were pst-. 
That indicates a high numbers of intraspecific genetic and phenotypic diversity among Y. pestis 
circulating in natural foci found in GUS alone, where consequent opportunity for genetic exchange 
and rapid growth of new phenotypes are to be seen. Recent observation made also showed that 
there are also differences between two isolates of the “classical” antiqa biovar, strains Antiqa and 
Y. pestis Nepal516 lineages DNA sequenced recently (CHAIN et al.2006). That indicates availability 
of high genomic diversity among Y. pestis isolates from different sources and regions of the world, 
that needs to be considered in order to develop a vaccine against plague with universal protection 
and global implication. The API of Russia possess the most diversified strains collection of plague 
pathogen in the world which are not yet known outside Russia. 
4) Preferences of Animal models in plague research- The most used Animal models in Western 
hemispheres relay on mice as model in studying plague vaccine for human use, such as Swiss 
Webster, BALB/C mice, e.t.c., (WORSHAM. 2004). Attaining the ultimate goal of vaccines that are 
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safe and efficacious in humans can be both advanced and hindered by studies in single animal 
systems. Guinea pigs are categorized as bad model for plague studies by western experts and are 
rarely used. In contrast in FSU/ CIS standard plague vaccine studies as a rule of law must includes 
at list three species of experimental animals with different level of sensitivity i.e. mice, guinea pigs 
and hamsters initially. Further studies include wild rodents, which are known as carrier in the 
natural foci, and primates and finally human. It is known that different species of experimental 
animals respond differently to the plague pathogen in their sensitivity, immunogenicity, and 
pathogenesis. Thus results of studies do also vary depending on the model animal used, and 
further more difficulty, when the ultimate goal of plague vaccine development is to protect human, 
including children and elders, eventually differs in the level of immunological status. Thus, 
translation of a successful vaccine results based on single species such as in breed or outbreed 
mice models of animal research might led to less efficient, less acceptance to global level, might not 
able to provide universal protection against the highly diversified strains known in different 
regions of the world. It is also crucial to take into consideration, that more than 200 species of 
animals and insects are known to harbor plague pathogens in natural foci. Thus, studies of plague 
in multiple animal models is more reasonable than studies based on single species to evaluate the 
efficacy of plague vaccines because human clinical trials that test new vaccines are not feasible. 
 
There are also a great concerns in regards to vaccine development based on live attenuated 
microorganism, a concern, that vaccine strain might be able to reverse to virulence, induces 
infection, that being the explanation why live attenuated EV strain was not licenced against plague 
in the last century in the west. At the mean time it is also known that vaccines based on live 
attenuated microoragnisms are superior to all forms of vaccines know today in inducing the 
appropriate immune responses. The licenced vaccine of EV 76 line NIIEG is known in inducing both 
arms of the immune system, which are crucial for protection of intracellular pathogens like Y. 
pestis. Unlike other EV 76 strains used as live vaccine worldwide, the derivative of line NEIIEG, 
showed no signs of revert and proofed to be stable. The humoral and cellular immune systems are 
both required in order to provide efficient protection against pneumonic plague, which any forms 
of forthcoming new vaccine must fulfil. 
5) Continuity and intensity- Further development of new or improved, live attenuated vaccine 
against plague in Russian is based on consistent monitoring of the maternal strain line EV NIIEG 
since 1936 that proofed to be stable, safe in all its physico-biochemical, immunological values. This 
consistent observation was made, after reinvestigation of a maternal strain stored for two decades 
in the laboratory and do not have characteristic for reversion to virulent strain (KUTYREV,2009, 
SALTYKOVA and FAIBICH 1975, ISTC. 2006; DOMARADISKIJI. 1998, ANISIMOV. 1999, 2002). 
Currently the live attenuated vaccine which is commercially available in Russain and some of the 
states of FSU is known with its trade name Vaccinum pestosum vivum siccum, registration 
93/160/21 and 93/132/20, for different routes of immunization included in regular vaccination 
calendar programs for the population living and working in enzootic regions (NIIEG. 2008, 
FEODOROVA et al. 2007,2008). 
6) Differences in taxonomy- Based on the current knowledge of sequences of plague microbe 
isolated from different regions of the world indicates that, the widely used classifications of plague 
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microbe in the Western hemisphere that was based on minor phenotypic and biochemical 
differences in three biovars is “aniquated”. It does not fulfil the current global know-how on plague 
bacilli. The Russian APS established system of classifying on plague microbe based on numerical 
analysis of 69 phenotypic features in national level  is used since 1987 plague research in the 
region that by far different from that of west is not included in International Code of Nomenclature 
of Bacteria, as  a consequence, research publications in Russian language were /are rarely known 
outside the region. Although no system of plague microbe classification might be 100 % perfect, 
standardization of the nomenclature of plague to global level will be required. Currently the 
numerical classifications of plague microbes taxonomy used in FSU/CIS is more inclusive as 
compared to what is used currently in west. 
 
Currently, there is no available animal or human vaccine trail against B. mallei and B. pseudomallei 
infection worldwide. Most of the available research publications on both pathogens are 
concentrated on pathogenesis, virulence factors, in elucidating the required immune systems for 
efficient protection, resistance to antibiotic therapy and route of transmission and distribution.  
However various forms of approaches were made in attempt to develop vaccines, that includes 
killed whole cell vaccines, live attenuated vaccines, heterologous vaccines, acellular vaccines, 
subunit /recombinant DNA vaccines in various species of animal models (DANNENBERG and 
SCOTT 1958, LEVINE and MAURER 1958, VASILEIV et al. 1993, MANEZENYUK et al. 1999, 
ILYUKHIN et al. 2002,AMEMIYA et al 2002, WHITLOCK et al. 2008). 
 
Based on cited publications, research strategies and attempts made to develop vaccines against 
Burkoholderia mallei and B. pseudomallei can be grouped in the following categories types: 
1) Killed whole cell preparations : Nonviable capsulated or non-encapsulated killed cells offered no 
protection from a parenteral live challenged virulent strain of B. mallei (AMEMIYA et al. 2002). 
Strong responses of inflammatory mediators like IFN-γ, IL-18, IL-12, IL-27 and IL-6 expressions 
were observed in BALB/c mice with in 24 hrs after intraperitonial infection with B. mallei ATCC 
2344 (ROWLAND et al. 2006). Immunization of BALB/c with IL-12 combined with non-viable B. 
mallei cells showed partial protection when compared vaccines based on killed cell. Indicating IL-
12 shows an immunosimulatory effect, much of the enhancement is thought to occur via increased 
production of IFN- γ and activation of macrophages. In contrast SARKAR-TYSO (2009) recently 
reported that heat-inactivated Burkholderia thailandensis, B. mallei or B. pseudomallei cells as 
vaccines against murine melioidosis and glanders provided efficient protection against 
intraperitonial as in aerosol challenged with homologous strains and some cross protection were 
also observed when the mice were challenged with hetrologous strains. The Author explains the 
protection of heat killed vaccine in this study, might related to the much higher number of killed 
bacteria cells (108 cfu) used and differences in routes of administration.  
2) Live attenuated virulent, mutant, low virulent or avirulent strains :-, Vaccines based seven 
selected auxotroph mutant strains of B. pseudomallei (Pur-, Ts) like B. pseudomallie C 141-206, 
provided over 70 % of protection for Balb/C mice, 30 % of protection for guinea pigs, 33 % of 
protection for white rats, and 25 % of protection for golden hamster against s.c. challenged doses 
of 1DLM (100 LD50 for Golden hamsters and 1000 LD50 for the rest of experimental animals) of 
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highly virulent B. pseudomallei strains. and the mean survival rates of immunized animals 
increased from 4 to 7 days in comparison to the control groups (ILYUKHIN et al. 1999 ). But no 
protection was provided against aerosol challenges That in fact indicates, besides to the species of 
animals, the level of protection of the vaccines depends on the the route of infection applied.  
 
An attenuated branched-chain amino acid auxotroph mutants of B. mallei was also known shown 
in providing to partially protect against aersol infection (ULRICH. et al. 2005). Immunization with 
live attenuated B. pseudomallei like organism, B. thailandensis, not virulent for guinea pigs and 
slightly virulent for golden hamster, provided more than 50 % of protection for guinea pigs s.c. 
challenged with 200 LD50 against virulent strain of B. pseudomallei 100 (ILYUKHIN et al. 2002). 
Suggests, that live attenuated vaccine based on B. thailandensis as a potential prototype vaccine 
against melioidosis. 
3) Non cellualr (surface) antigens and antigen complex:- Various surface antigens and antigen 
complexes extracted in different biochemical and Immunological methods studied examined in  
animal models showed. Among a number of fragments of antigens known in Burkholderia species,  
Immunization with 4 combined antigen complexes designated (A, D17, E13, and B4) showed some 
more protection (KALACHEV. 1997). Further studies are necessary, if vaccine based on surface 
antigens will be considered as another alternative of vaccine development against glnaders and 
melioidoisis, 4) DNA Vaccine:- Intramascularly adminstration of plasmid DNA enocoded flagellin 
protein against infection with B. pseudomallei in Balb-C/mice, was shown to elicit both, humoral 
and cellular immune responses, but in case of i.v challenges, a number of bacterial cells were 
detected in organs of the animals (CHEN et al. 2005). At the same time anti-flagella (flagellin) 
antibodies have been reported to be able to reduce bacterial motility in vitro, and thus provide 
some level of passive protection for diabetic rats infected with B. pesudomallei and can induce 
inflammatory mediators (BRETT et al. 1994). Suggests that vaccine based on flagellin protein 
alone, cannot protect melioidosis, but inclusion of flagellin protein in the development vaccine 
against melioidosis can enhance the efficacy of a vaccine in amplify the overall immune 
performance of the host after infection, 5) Subunit vaccines:-. From specific selected protein, 
categorized as subunit vaccine, the LolC - membrane protein, in adjuvant form, were found to be 
the most promising vaccine candidate against melioidosis. It was observed that five out of six Balb/ 
C mice immunized with LolC were protected against intra peritoneal infections with heterologous 
strains of B. pseudomallei (HARLAND et al. 2007). If the protein can also protect against pneumonic 
melioidosis or cross-protects against B. mallei infections is not known. . 
 
Bip proteins - are combinants of type III secretion system, critical for the virulence of the pathogen, 
but the author did not found that they are protective antigens because vaccinated mice with any of 
the Bip proteins (like BipB, Bip C or Bip D) did not result in protecting against experimental 
melioidosis (DRUAR et al. 2008). 
 
Although type IV pilin is known as highly immunogenic antigens and successfully used as subunit 
in prevention of several disease, vaccine trail in murine model failed to protect from lethal aerosol 
challenges of B. mallei. (FERNANDES et al. 2007), Currently, vaccinology will greatly benefit from 
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the emerging genomics technology such as bioinformatics, proteomics and DNA microarray. 
Information about the whole genome sequence of a pathogen, its’ molecular structure and its’ 
specific function will help us to better understand the organism and to identify possible targets for 
diagnosis, treatment and furthermore vaccine production. Thus new vaccine development against 
glanders and melioidosis can profit from it. 
 
 
Concluding remarks 
 
It was first in the year 1997 in Proceedings of the Scientific and Practical Conferences held in 
Saratov, Russia, dedicated to the centenary of the Russian Anti-Plague service, that experts from 
Western hemisphere get an opportunity, to participate in scientific conferences of this form after 
over six decades isolation of East and West blocs during cold war era. 
 
This meeting was remembered by some experts in the West, with high remarks like, “On the 
biological side we are very far behind, there is a whole of history of things we on this planet we 
don’t even know about” or in journal titled as “ to fight plague, look the Russian’s past” and in 
generalized form. The microbial science and research activities of the FSU /CIS on agents of 
bioweapon (military) and bioterrorism interest like plague and burkholderia species are 
continuous for decades as it is known “ the enclosed world of secret microbial science.” The agents 
belongs to the forefront research object of FSU, with high security, secrecy and intensity no state or 
institution is comparatively engaged with these agents in this level Worldwide. 
 
From Russian point of view some of the pioneer researchers expresses as ”The Soviets are born to 
research on Plague.” which was based on the capacity of the APS which recruited hundreds of 
highly qualified experts, worked in various research institutes located in the region. The APS has 
more than a century old, experiences, monitoring, preventing disease outbreaks and research 
activities. What is today known about this pathogens are found in Russian language, publications 
and in Russian scientific journals which are rarely known in western world. 
 
Yet, although changes have been seen in political-ideological arena, little moves are made to 
integrate these unique achievements of the API to the the global level. Misunderstandings 
misinterpretations, incorrectness of original research publications of Russian language are seen 
often in case cited in English language publications. The very majority of long year research 
published in Russian scientific journals are not known or unpublished literatures available in 
Russia still exists. For instance, in April, 2005 the U.S. Department of Defense announced a joint, 
multi-nation project arrangement between the U.S. Department of Defense (DoD), the Department 
of National Defence of Canada, and the Secretary of States for Defense of the United Kingdom of 
Great Britain and Northern Ireland was announced for the cooperative development of a vaccine to 
protect against plague. Under this agreement, the three nations will work together to develop and 
produce a plague vaccine that ultimately be licenced for human use. What every the reason might 
be Russia is not included. Exclusion of the immense knowledge available on the plague pathogen in 
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Russia in this particular case, may lead to a bottleneck to the global acceptance of the forthcoming 
plague vaccine based on the two immunogenic as well as virulence antigens F1 and V feasibility. 
 
As the current concern of bioterrorism with the use of agents like Plague and Bukholderia grows 
and it is of a global concern, full understanding of research achievements of the FSU/CIS on the 
subject is indispensible. Today more than ever, global threats requires much greater collaboration 
between governments, experts, institutions, in creating a global grass–roots of networks of 
research and discussion, to achieve global solutions in developing, an efficient, universal, 
acceptable vaccine most importantly against pneumonic plague-the most possible way 
bioterrorism may take, and pathogenic Burkhoderia species that can have not only public health 
concerns but also security at the global level. Thus, a long term sustainable schedules of congresses 
and partnership between Russia, and other leading states on the research activities of the 
pathogens in concerns in the world will be the best option for the solution, development of 
prophylactic measures against the pathogens, in creating a think-tank, comprising ranges of 
experts from different countries of interest, initiating dialogs’, enhancing transparency and better 
cooperation in both sides. 
 
Integration of a tremendous amount of knowledge available in Russia is very essential in order to 
find a global solution to counter the modern and real treat of bioterrorism. A number of variable 
virulent strains, which are available, only in Russian laboratories and not but known outside FSU, 
needs to be accessed for researcher purpose to the international researchers. Based on the extent 
of the natural foci in the region and the genotypic and phenotypic diversity of strains available in 
the ecosystem, one can say that alone the natural foci in the region in itself is a natural laboratory 
for plague research and researchers worldwide. More over understanding more than a century old 
research activities of API, on the pathogens, its high competence, unique practical experiences is 
critical important in an attempt of developing vaccines against plague, glanders and melioidosis 
diseases. 
122 
6 SUMMARY 
 
Taye Kissi Jimma  
 
VACCINE DEVELOPMENT AGAINST PLAGUE, GLANDERS AND MELIOIDOSIS IN THE FORMER 
SOVIET UNION IN COMPARISON TO THE CURRENT STATE OF GLOBAL KNOWLEDGE  
 
Institute of Animal Hygiene and Veterinary Public Health, Faculty of Veterinary Medicine, 
Leipzig University 
 
Submitted in January 2009  
 
(125 pages, 5 figures, 6 tables, 706 references) 
 
Keywords: plague, glanders, melioidosis, vaccine, biological weapon, antigens, immunity, Yersinia 
pestis, Burkholderia mallei, Burkholderia pseudomallei, Anti-Plague Institutes, Former Soviet Union 
 
The causative agents of plague (Y. pestis), glanders (B. mallei) and melioidosis (B. pseudomallei) are 
included in critical agents of bioterrorisim. They belong to the most intensively studied agents 
during cold war, specially in the former Soviet Union (FSU). Mostly what is known about these 
agents, particularly (Y. pestis ) is not available in English language publications. Many of the studies 
are written in Russian language and published in Russian scientific journals. Thus, the work is 
designed to evaluate, published and unpublished Russian language written data obtained, in 
comparisions to the current state of global knowledge on the pathogens in concern.  
 
The frame work of the dissertation is divided in to eight chapters: i) Introduction that includes 
historical backgrounds of the developments of biological weapon, vaccine development and 
peculiarities of the microbial science of FSU, ii) Challenging characteristics of the agents:  including 
global distribution, taxonomical differences, exceptionality of the distribution of natural foci in the 
FSU and intraspecific diversity, multidrug resistance, potential as biological weapon and the 
importance of the development of vaccines, iii) Materials and Methods: the items used for this 
study were based on through survey of data search on the topic, retrieved sources of information 
that can be grouped to the following categories: a) International congresses and conferences: 
delegate handbooks and abstracts, public- workshops, b) Web-based searching engines, c) 
Personal communications to the authors and institutions per-email or per-post, d) Traditional 
mode of subscription of articles, books, bulletins, journals, e.t.c. based on library loans. Critical 
evaluations of the material were made based on updated knowledge of a vaccine required to 
combat agents categorized as critical biological weapon groups like plague, glanders and 
melioidosis. That includes safety, efficacy, quality, cost, production, stability, easy handling of the 
vaccine and its efficiency in human immunization based WHO or UNICEF recommendation 
standards. iv) Development of vaccines – describing the historical backgrounds of the development 
of plague vaccine licenced for human use with special emphasis on Live dried plague vaccine of EV 
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76 line NEIIG, the most common derivativ strain used in USSR and continued to be used in the 
countries of Former Soviet Union. Currently, It is the only available vaccine for human use,  
licenced in Russia against plague prophylaxis, compared to the new vaccine candidate based on 
two major proteins, the F1 and the LcrV antigen (recombinant or subunit) studies known in 
experimental animals and human trails, which is curently found in process of licensing, Various 
forms of plague vaccine studies are known in experimental animals such as heterologous vaccines, 
DNA based vaccines, e.t.c., which are also throughly analysed in this part. This section also includes 
known virulence factors versus immunogenicity of plague microbe and critically evaluate the role 
of major protein extracts currently known in experimental animal studies.  
 
The second part of the vaccine section explores Several experimental studies made to develop 
vaccines against glander and melioidosis, for which currently ther is no vaccine avalaible. There 
are various forms vaccine trails known in experimental animal models that includes killed whole 
cell vaccines, live attenuated vaccines, heterologous vaccines, recombinant vaccines, acellular 
vaccines, DNA and subunit vaccines which are throughly evaluted in this part Although B. mallei 
and . pseudmallei are genetically very similar, there are remarkable genetic variations with in the 
type strains, posses high genomic plasticity that complicates vaccine development that can provide 
sterile immunity. However, there are some evidence that shows killed vaccines do provide some 
protection against glanders and melioidosis depending on the routes of infections, types of strains, 
concentrations of the bacterial cells used e.t.c., But there is no evidence that shows a full protection.  
 
Immunization based on avirulent strains of B. thailandensis demonstrated more than 50 % of 
protection in guinea pigs challenged s.c. with 200 LD50 of B. pseudomallei 100 virulent strain and 
which was proposed as a prototype against melioidosis. If similar protection can also provided 
against B. mallei is not yet known and further enhancements of its efficiency is required to achieve 
a sufficient protection. 
 
Vaccines based on live attenuated B. mallei also showed some protection in experimental animals, 
but this approach alone will not likely seems to provide sufficient protection, but adding IL-2 as 
adjuvant improved the level of protection. Live vaccine based on less virulent strains might be the 
preferable approach, because the can induce both humoral and cellular immune response, which 
are critical for complete protection against B. mallei and B. pseudomallei. This section also critically 
evaluates the role of individual antigen or recombinant extracts currently know and thier level of 
protection in different sepcies of experimental animals, v) Discussion, vi) Summary, viii) 
References.  
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Die Erreger, welche die Pest (Y. pestis), Rotz (B. mallei) und Melioidose (B. pseudomallei) 
verursachen, gehören zu den bekanntesten bakteriologischen Waffen. Sie gehören besonders in 
den Staaten der ehemaligen Sowjetunion zu den am meisten und am intensivsten untersuchten 
Agenzien während des Kalten Krieges. Demzufolge sind die meisten Informationen bezüglich 
dessen was über diese Agenzeien bekannt ist, in Russischer Sprache verfasst und in 
englischsprachigen Publikationen wenig bekannt. Dementsprechend wurden in dieser Arbeit die 
wissenschaftlichen Publikationen in russischer Sprache im Vergleich zu dem aktuellen globalen 
Wissensstand analysiert.  
 
Der Aufbau der Dissertation gliedert sich in acht Abschnitte: i) Einleitung, welche die historischen 
Hintergründe der Entwicklung von Biowaffen und Impfstoffen beinhaltet und Besonderheiten der 
sowjetischen mikrobiologischen Wissenschaften, ii) die Eigenschaften der Erreger, welche aktuell 
eine Herausforderung darstellen: die globale Verbreitung der Erreger, taxonomische Unterschiede, 
die spezielle Verbreitung der Naturherde in der ehemaligen Sowjetunion und deren 
intraspezifische Diversität, iii) Material und Methoden: das in dieser Arbeit verwendete 
Quellenmaterial wurde durch gründliche thematische Literaturrecherche gewonnen und kann den 
folgenden Kategorien zugeordnet werden: a) internationale Kongresse und Konferenzen: 
Handbücher, Abstracts, Veröffentlichungen von Workshops b) Web-basierte Suchmaschinen c) 
persönliche / direkte Kommunikation mit Autoren und Institutionen per Email oder Post d) 
traditionelle Bibliotheksausleihe (Artikel, Bücher, Bulletins, Journale, etc.). 
 
Die kritische Auswertung des Materials erfolgte auf Basis des aktuellen Wissensstandes im Bereich 
der Impfstoffe, die gegen Agenzien zum Einsatz kommen, welche als kritische biologische Waffen 
eingestuft werden, wie z.B. die Pest, Rotz und Melioidose. Die Anforderungen an die Impfstoffe sind 
Sicherheit, Effizienz, Qualität, Kosten, Produktion, Stabilität, leichte Handhabung und Effizienz bei 
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der Immunisierung von Menschen, welche auf Standards basieren, die von der WHO oder der 
UNICEF empfohlen werden. iv) Impfstoffentwicklung – Beschreibung der historischen 
Hintergründe der Entwicklung eines Impfstoffes gegen die Pest, der für den Einsatz am Menschen 
zugelassen ist. Besonders berücksichtigt wurde der lebend abgetrocknete Pest-Impfstoff EV76 
NIIEG Linie, der nur in Russland lizensiert ist im Vergleich zum Subunit /Rekombinanten Impfstoff 
in Versuchstieren. Der lebend abgetrocknete Pest Impfstoff, auf Basis von Y. pestis Linie NEIIG ist 
aktuell der einzig verfügbare Impfstoff, um die Pest in der Region zu bekämpfen. Er wird in den 
Ländern der ehemaligen Sowjetunion benutzt und ist bekannt für die Verminderung der 
Morbidität und Mortalität in Menschen bei der Pest. Zur Zeit gibt es in Russland Studien auf 
experimenteller Ebene mit einem verbesserten Impfstoff auf Basis des EV76 NEIIG Stammes mit 
geringer Toxizität und Reaktogenität. Im Westen befindet sich der rekombinante/subunit Impfstoff 
auf Basis von F1 und V Antigen im Prozess der Lizenzierung, aber es ist nicht bekannt, ob der 
Impfstoff in der Lage ist, einen universellen Schutz zu bieten und die Mortalität und Morbidität 
beim Menschen zu reduzieren.  
 
Im zweiten Teil des Abschnittes werden die Versuche der Entwicklung eines Impfstoffes gegen 
Rotz und Melioidose untersucht. Es gab verschiedene experimentelle Studien mit Tierversuchs-
Modellen zur Entwicklung von Impfstoffen gegen Rotz-und Melioidose-Erkrankungen, in welchen 
Impfstoffe mit ganzen getöteten Zellen, lebend attenuierten, heterologen, rekombinanten, 
azellulären, DNA und Subunit getestet wurden. Es gibt zwar einige Hinweise, die zeigen, dass diese 
Impfstoffe einen gewissen Schutz gegen Rotz und Melioidose bieten, jedoch ist dieser vom 
Infektionsweg abhängig, von den Typen der Stämme, der Konzentration der bakteriellen Zellen 
u.s.w.. Es gibt keine Nachweise, die auf einen vollständigen Schutz hindeuten. Obwohl B. mallei und 
B. pseudomallei genetisch sehr ähnlich sind, gibt es bemerkenswerte genetische Variationen 
innerhalb der Typen der Stämme, eine breite genomische Plastizität. Es sind intrazelluläre 
Bakterien, welche Impfstoffentwicklung erschweren. Impfstoffe müssen in der Lage sein, beide 
Zweige des Immunysytems zu induzieren, welche wichtig für einen kompletten und universellen 
Schutz sind. 
 
Eine Immunisierung, die auf avirulenten B. thailandensis-Stämmen basiert, zeigte mehr als 50% 
Schutz bei Meerschweinen gegen subkutane Infektion mit 200LD50 virulente B. pseudomallei 100. 
Dies wurde als Prototyp für einen Impfstoff gegen Melioidose vorgeschlagen. Es ist noch nicht 
bekannt, ob der Impfstoff einen vergleichbaren Schutz gegen B. mallei bietet und es sind weitere 
Steigerungen seiner Effizienz nötig, um einen belastbaren Schutz zu erreichen. 
 
Impfstoffe, die auf attenuierten B. mallei basieren, zeigen partiellen Schutz bei Versuchstieren, aber 
diese Vorgehensweise allein wird wahrscheinlich nicht genügen, um ausreichenden Schutz zu 
gewährleisten. Jedoch erhöhte die Zugabe von IL-2 als Adjuvans die Wirksamkeit. Lebend-
Impfstoffe, die auf weniger virulenten Stämmen basieren, mögen der zu bevorzugende Ansatz sein, 
weil sie sowohl eine humorale als auch eine zelluläre Immunantwort auslösen welche wichtig sind 
für einen kompletten Schutz gegen  B. mallei und B. pseudomallei. Aktuell ist gegen Rotz und 
Melioidose kein Impfstoff verfügbar. v) Diskussion, vii) Zusammenfassung, viii) Literatur-
verzeichnis. 
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